Patch graft compositions for cell engraftment
The novel patch graft composition for cell transplantation into solid organs addresses the challenges of low engraftment efficiency by using early lineage stage cells and biomaterials to facilitate rapid integration and maturation into functional cells, enhancing therapeutic outcomes.
Patent Information
- Application Number
- JP2024135195
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-04-30
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-19
AI Technical Summary
Current methods for cell transplantation into solid organs, such as the liver and pancreas, face challenges due to mechanical forces and complex microenvironments, leading to low engraftment efficiency and ectopic tissue formation, with existing strategies like vascular delivery and direct injection resulting in low survival and integration of transplanted cells.
A novel patch graft composition is developed, comprising a mixture of early lineage stage mesenchymal cells and epithelial cells, embedded in a biomaterial with specific mechanical properties, which is applied directly to the target organ surface, utilizing membrane-bound and secreted matrix metalloproteinases to facilitate engraftment and integration.
The patch graft composition significantly enhances cell engraftment and integration into solid organs, maintaining cells in an immature state, allowing for rapid migration and maturation into functional adult cells, thereby improving therapeutic efficacy.
Smart Images

Figure 2024161469000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a joint venture of U.S. Pat. No. 6,351,431 filed on June 12, 2017 under 35 U.S.C. § 119(e). Application No. 62 / 518,380, and U.S. application Ser. No. 62, filed April 30, 2018. / 664,694, the contents of which are incorporated herein by reference in their entirety. is incorporated herein by reference.
[0002] The present invention relates generally to the field of cell transplantation or tissue engraftment. More specifically, The present invention relates to a method for the preparation of a solid organ or tissue, particularly a visceral organ or tissue. to treat a disease or condition of a particular cell or tissue, or to establish a model system for the disease. Compositions that provide strategies for rapid transplantation, engraftment and integration of cells into organs and tissues Representative of this potential are cell therapy for the treatment of liver or pancreatic disease. It is law. [Background technology]
[0003] Transplantation strategies for cells from solid organs, hematopoietic cell transplants or mesenchymal stem / progenitor transplants are used A different strategy than the one used to be used has long been needed. Turner, R., et al. .Transplantation 90,807-810(2010);Gattin oni,L.et al.Nature Medicine 23,18-27(201 7);Trounson A.et al.Cell Stem Cell 17,11 -22(2015);Sun BKet al.Science 346,941- 945(2014);Lainas,P.et al.J Hepatol 49,35 4-362(2008). Transplantation of hematopoietic and mesenchymal cells is a cell transplantation method through vascular channels. This is routinely achieved by delivery of microenvironment signals, a process known as "homing." Null signaling relies on the activation of adhesion molecules on the transplanted cells when they are in the relevant target site. The method for use on the skin (similar to ocular targeting) involves applying a microparticle directly to the target area. Sun BK et al. Science 346 , 941-945 (2014). Many transplantation methods for skin use cells from solid internal organs. Although available for use in vivo, they require substantial modification to accommodate the microenvironment of these visceral organs. The implant must counteract the mechanical forces generated by tissue and organ interactions. For example, the effect of the lungs during breathing, the pressure of the liver against the diaphragm, or during food processing The temporary effect of mechanical forces on adjacent tissues caused by the intestine. in relation to the size, shape, and complexity of organ structures in addition to dynamic mechanical forces. Concerns make design difficult.
[0004] For decades, cell therapy with cells from solid organs other than the skin has been conducted via the vascular route. Most transplanted cells have been When delivered by any of these strategies, they either die or are transported to ectopic sites. There, they can survive for several months and produce tissue in inappropriate locations, potentially resulting in adverse clinical outcomes. Turner, R., et al. Transplantation 90, 8 07-810(2010);Lanzoni,G.et al.Stem Cells 31, 2047-2060 (2013). Engraftment in the liver was achieved by coating the cells with hyaluronan. The efficiency of engraftment can be improved by providing blood vessels to the liver. The above is due to the natural process of hepatic hyaluronan removal. Nevi et al. Stem Cell Research & Therapy 8,68,2017. However, However, this improvement is still less efficient than with the transplantation strategy, and importantly In particular, it still allows for the delivery of cells to ectopic sites.
[0005] There remains a need for improved methods of cell engraftment into solid organs. The present disclosure addresses this need. and provide related benefits. Summary of the Invention
[0006] There has long been a need for transplantation strategies for cells from solid organs (Turner, R., et al., Transplantation of Cells from Solid Organs, vol. 133, no. 1). t al.Transplantation 90,807-810(2010), Strategy are different from those used for transplantation of hematopoietic cells, mesenchymal stem cells, or skin. Transplantation of cells and mesenchymal cells is routinely performed via vascular channels, a process known as "homing." Microenvironment signaling, a process that mediates adhesion molecules at relevant target sites, increases their activity. The method used for the skin is a transplantation method using cells applied directly to the target site. To hire.
[0007] Transplantation of cells from solid organs other than the skin has long used vascular delivery. Adhesion molecules on the cytoplasm are constantly activated, resulting in rapid (second-to-second) proliferation that can generate life-threatening emboli. ) This is not logical as it would result in cell clumping. Even when the plug is well managed, the efficiency of cell engraftment is low, at approximately 20% for adult cells and 20% for stem / progenitor cells. The percentage is even lower in the human body (<5%). Most transplanted cells die or are transplanted to ectopic sites. They are transported to a nearby location, where they can survive for several months, produce tissue in inappropriate locations, and cause adverse clinical outcomes. A small percentage of cells that engraft at the target site may become a significant part of the tissue. It takes several weeks to several months for the cells to become hyaluronan-rich and slowly integrates. coated with hyaluronan and delivered to the blood vessels for removal from tissues (e.g., liver) When the stem cell line is used in combination with the erythrocyte-derived stem cells, the engraftment in the liver is improved. (Nevi et al. Stem Cell Research&Therapy 8,68,2017).
[0008] Applicants have demonstrated a fundamentally different approach that has been more successful than coating cells with hyaluronan. We propose a novel approach: placing the graft directly on the surface of the target site and placing the graft on the surface of the target site. When transplantation is performed, the unique phenotypic properties of the transplant biomaterial and specific cells can be used to promote engraftment. This corresponds to some aspects of the cell therapy strategy for the skin, but it is not without mechanical effects, Wear or compression of the organ, and the unique fluid microenvironment of a particular organ, as well as the size of the organ ,Given the structure and complexity, it requires significant ,modification for internal organs.
[0009] Described herein are novel patch graft compositions for the transplantation of cells into tissues and solid organs. In some embodiments, the methods and implants are The design features are based on the maturity level of the cells, whether they are stem cells or mature cells. In some embodiments, the donor cells of the patch graft (optionally The cells may be any of the following: Id morphology, epithelial stem cells and their native aggregates, lineage stage appropriate mesenchymal cells Cellular partners, e.g., mesenchymal stem / progenitor cells such as early lineage stage mesenchymal cells (ELSMCs) In some embodiments, the donor cells are incorporated into the graft biomaterial as The cells are incorporated into the graft material as a suspension of endothelial cells and express membrane-bound and / or secreted matrix in ratios designed to optimize expression of mesenchymal metalloproteinases (MMPs). Stem / progenitor cells, optionally adult cells associated with ELSMC. In some embodiments, Other important variables are the implant biomaterial and backing material, both of which are highly sensitive to donor cell distribution. The effect on the
[0010] Aspects of the present disclosure include a patch for sustaining and maintaining a single or mixed cell population. Regarding the graft, the patch graft may be: (a) a patch having a single cell type or two or more cell types; A mixed population of IgG1-associated and / or IgG2-associated proteins, at least one of which is a membrane-bound and / or secreted macrophage. At an early lineage stage capable of expressing myelolytic metalloproteinases (MMPs) or Contains MMPs from various sources (e.g., purified or recombinant MMPs) and hydrogels. The cell population or mixed population supported by the medium present in the matrix is optionally The mixed population is transferred into or out of the hydrogel and / or into or out of the patch graft. (b) a single cell type or mixed population with sufficient viscoelasticity to allow for cell movement; a biocompatible, biodegradable material having sufficient viscoelasticity to inhibit the movement of the mixed population in the direction of the and optionally (c) a lining overlying the serosal (i.e., outer) surface of the lining. a hydrogel, which is opposite to the one in contact with the mixed population, In embodiments where the tip is tethered to the target site, the tip is on the side opposite the side in contact with the target site. In some embodiments, the hydrogel comprises a hydrogel that is inserted into the tissue (e.g., an organ or tissue). The layer prevents or prevents adhesions by or from other tissues or organs. In some embodiments, the patch graft sustains and maintains the mixed population. while the at least one early lineage stage cell type is membrane-bound and / or secretory. to inhibit differentiation or further maturation to later lineage stages that can no longer express MMPs The patch graft may be a single layer plus a backing layer or multiple layers. do.
[0011] In some embodiments, the backing is porous or non-porous. In some embodiments, the backing comprises a porous mesh, a scaffold, or a membrane. In form, the lining may be made of silk, synthetic fibers, or aminion, placenta or In some embodiments, the backing comprises a natural material such as a mesh, or a combination thereof. The implant comprises a porous mesh infused with a hydrogel. The injection prevents migration of the cells out of the target organ or tissue. , the backing comprises a solid material.
[0012] In some embodiments, one or more of the hydrogels comprises hyaluronan. include.
[0013] In some embodiments, the medium is a Kubota medium or a medium that supports stem cells and The present invention includes a separate medium capable of maintaining the above-mentioned.
[0014] In some embodiments, the mixed population comprises mesenchymal and epithelial cells. In embodiments, the epithelial cells may be ectodermal, endodermal, or mesodermal. In some embodiments, the mesenchymal cells comprise early lineage stage mesenchymal cells (ELSMCs). In some embodiments, the ELSMCs are hemangioblasts, precursors of vascular endothelium, astrocyte precursors, or In some embodiments, the inflammatory bowel disease may include one or more of: In some embodiments, the epithelial cells comprise epithelial stem cells. In some embodiments, the epithelial cells comprise biliary stem cells. In some embodiments, the epithelial cells include committed (committed) cells (BTSCs). In some embodiments, the comitrized and / or mature epithelial cells. The transplanted and / or mature epithelial cells include mature parenchymal cells. In the present invention, the mature parenchymal cells are one or more of hepatocytes, bile duct cells, and pancreatic islet cells. In some embodiments, the mesenchymal and epithelial cells both comprise stem cells.
[0015] In some embodiments, the mixed population comprises autologous and / or allogeneic cells.
[0016] In some embodiments, one or more of the cell types are genetically modified.
[0017] Further aspects relate to methods of using the disclosed patch graft compositions. Thus, provided herein is a method for treating a target tissue with a patch graft as disclosed herein above. contacting a cell with a target tissue, comprising, consisting of, or consisting essentially of This is a method of allowing the tissue to take root.
[0018] In some embodiments of this method, the target tissue is the liver, pancreas, bile duct, thyroid, thymus, Gastrointestinal, lungs, prostate, breasts, brain, bladder, spinal cord, skin and subcutaneous tissue, uterus, kidneys, muscles, blood In some embodiments, the tissue is selected from the group consisting of vascular, cardiac, cartilage, tendon, and bone tissue. In embodiments, the target tissue is liver tissue. In some embodiments of this method, the target tissue In some embodiments of this method, the target tissue is bile duct tissue. In some embodiments of the method, the target tissue is gastrointestinal tissue. In some implementations of this method, the tissue is diseased, damaged, or impaired. In one embodiment, the target tissue is kidney tissue.
[0019] In some embodiments of this method, the target tissue is an organ. In an embodiment, the organ is a musculoskeletal system, a digestive system, a respiratory system, a urinary system, a female reproductive system, a male reproductive system, The organs are the reproductive system, the endocrine system, the circulatory system, the lymphatic system, the nervous system, or the integumentary system. In some embodiments, the organ is a liver, pancreas, bile duct, thyroid, thymus, stomach, intestine, lung, prostate, or lung. prostate, breast, brain, bladder, spinal cord, skin and subcutaneous tissue, uterus, kidneys, muscles, blood vessels, heart, soft tissue In some embodiments, the organ is selected from the group consisting of bone, tendon, and bone. is damaged or impaired.
[0020] Also provided herein is a method of treating a subject having a liver disease or disorder, comprising: The method includes contacting the liver of a subject with a patch graft as disclosed hereinabove. In some embodiments of this method, the method comprises, consists of, or consists essentially of Liver disease or disorders include liver fibrosis, cirrhosis, hemochromatosis, liver cancer, biliary atresia nonalcoholic fatty liver disease, hepatitis, viral hepatitis, autoimmune hepatitis, fascioliasis, Alcoholic liver disease, α1-antitrypsin deficiency, glycogen storage disease type II, transthyretin Related hereditary amyloidosis, Gilbert syndrome, primary In biliary cirrhosis, primary sclerosing cholangitis, Budd-Chiari syndrome, liver trauma, or Wilson's disease be.
[0021] In another aspect, provided herein is a method of treating a subject having a pancreatic disease or disorder. The method includes contacting the pancreas of the subject with a patch graft as disclosed hereinabove. The method includes, consists of, or consists essentially of In embodiments, the disease or disorder of the pancreas is diabetes, exocrine pancreatic insufficiency, pancreatitis, pancreatic cancer, opioid Sphincter of Diploicmia insufficiency, cystic fibrosis, pancreatic duct nonfusion, annular pancreas, pancreatic trauma, or pancreatic duct bleeding (hemosuccus pancreaticus).
[0022] In another aspect, provided herein is a method of treating a subject having a gastrointestinal disease or disorder. The method includes administering to one or more subjects an intestine a patch as disclosed hereinabove. comprising, consisting of, or consisting essentially of a graft. In some embodiments, the gastrointestinal disease or disorder is gastroenteritis, gastrointestinal cancer, ileitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, peptic ulcer, celiac disease, fibrosis, vascular dysplasia, Hirschsprung's disease, pseudomembranous colitis, or gastrointestinal trauma.
[0023] In some embodiments, provided herein are methods for treating a subject having a renal disease or disorder. The method comprises administering to one or more subjects kidneys the method as disclosed hereinabove. Comprising, consisting of, or consisting essentially of a patch graft in contact with the patch graft. In some embodiments of this method, the kidney disease or disorder is nephritis, nephrosis, renal inflammation syndrome, nephrotic syndrome, chronic kidney disease, acute kidney injury, kidney trauma, cystic kidney disease, multiple Cystic kidney disease, glomerulonephritis, IgA nephropathy, lupus nephropathy, kidney cancer, Alport syndrome, myloidosis, Goodpasture's syndrome, or Wegener's granulomatosis. [Brief description of the drawings]
[0024] [Figure 1-1]Figure 1A-1C provide information about the porcine donor cells for patch grafts. Figure 1A is a schematic of the process and predicts the time required to prepare the organoids, assemble the patch graft, and perform the surgery. In Figure 1B, donor cells for stem cell patch grafts were isolated from a cell suspension of bile duct tissue from transgenic pigs, and the cells were prepared as organoids in serum-free Kubota medium and on low-attachment culture dishes. Organoids of bile duct stem cells (BTSCs), as well as their early lineage stage mesenchymal cell (ELSM) partners, hemangioblasts, and precursors of vascular endothelium and stellate cells. They are shown in phase micrographs showing expression of the transgene, green fluorescent protein (GFP). All cells in the aggregates are green because the transgene is in both epithelial and mesenchymal cells. The transgene was bound to the histone (H-2B) locus. Histology of stem cell organoids embedded in paraffin, sectioned, and stained with hematoxylin / eosin. (d) Close-up images of BTSC and ELSMC organoids. Figure 1C shows immunohistochemistry (IHC) showing expression of stem cell, hepatic and pancreatic markers indicating that these cells are precursors of both the liver and pancreas. The IHC assay shows an outer layer with intermediate stage stem cell markers such as EpCAM, and inner cells expressing very primitive genes such as pluripotency genes and endodermal transcription factors (e.g., SOX17, SOX9, PDX1). [Figure 1-2] Figure 1D provides information about the porcine donor cells for patch grafts. Figure 1D is a representative qRT-PCR assay evaluating the expression of various genes within the organoids and showing that the cells are stem cells or early precursors. The control was mature hepatocytes from piglet liver. [Figure 2-1]Figures 2A-2B provide information about the main components of the patch graft. Figure 2A is a schematic diagram of a patch graft affixed to a pig liver, and on the right is the composition of the graft. Early lineage stage cells, both epithelial and mesenchymal cells, are the source of production of matrix metalloproteinases (MMPs), which are the main regulators of engraftment. The matrix component of the graft biomaterial, on which the donor cells are placed, is soft (approximately 100 Pa) without (or with minimal) sulfation, such as hyaluronan hydrogel. The structure of the graft consists of a layer of biomaterial and cells tethered to the target site. The media components should be devoid of serum, growth factors and cytokines that affect donor cell differentiation, and tailored to the survival and proliferation of early lineage stage cells, such as stem cells / progenitors. The backing should have sufficient tensile strength to be used in surgical procedures, but be neutral in its effect on donor cell differentiation (e.g., those with type I collagen should be avoided). The backing is impregnated or coated with a more rigid 10X hydrogel (approximately 700 Pa) to act as a barrier to direct donor cell migration towards the target tissue and minimize adhesions. After attachment to the target site, 2X HA hydrogel, which is fluid enough to coat or paint onto the serosal surface, is added and used to further minimize adhesions. Figure 2B shows the graft affixed to the host liver or pancreas. [Figure 2-2] Figures 2C-2E provide information about the major components of the patch graft. Figure 2C is a schematic of the graft showing the layers that make up the graft composition. Figure 2D shows the results of an assay to empirically evaluate the rheological or viscoelastic properties (shear and compressive mechanical forces) of a particular hydrogel layer. Figure 2E provides a blend of the viscoelastic properties of the three layers of hydrogel. [Figure 2-3] Figure 2F provides information about the main components of the patch graft. Figure 2F is a close-up image of the patch graft sutured to the surface of the pig liver. [Figure 3-1]Figures 3A-3B show the results of immunohistochemistry (IHC) and histology of the liver patch graft. Figure 3A shows the results of trichrome staining of the patch graft after one week. Trichrome was used to identify collagen (blue), cytoplasm (red) and nuclei (black) and to identify Glisson's capsule (usually adjacent to the surface of the liver lobule) and adhesions (on the serosal surface of the graft). The serosal surface layer had high levels of blue staining, suggesting adhesions to the graft. Grafts were also frequently found to separate from the host tissue at the interface between the lining and the host, as more MMPs are produced at this interface. Areas of remodeling provide evidence of loss of the classic lobular structure of the liver, and they result in areas where donor cells migrate into the tissue and simultaneously alter the host tissue architecture. In the low magnification image (a), trichrome staining of the graft placed in the liver confirmed that extensive remodeling of the Glisson's capsule has occurred, and that the graft and host liver are often separated. Higher magnification (b) shows that the area of remodeling is remarkably extensive, consisting of (c) areas close to the graft that are completely devoid of hepatic lobule structure, and (d) areas within the remaining hepatic lobule that are undergoing degradation in the remodeling process. Figure 3B shows trichrome staining of the patch graft after three weeks. Hyaluronan within the graft has been resorbed leaving only the lining (a). Upon resorption of hyaluronan, Glisson's capsule reappears, and (b) the hepatic lobule adjacent to the graft has re-stabilized into the typical histological pattern of liver lobules and acini. The arrow in (b) indicates the reappearance of collagen in the remodeling Glisson's capsule. [Figure 3-2]Figures 3C-3D show the results of immunohistochemistry (IHC) and histology of liver patch grafts. Figures 3C and 3D show the results of hematoxylin / eosin staining of sections from grafts one week after implantation (C) and two weeks after implantation (D). The upper figures are at 40x magnification. The areas in figures (a, b, c) are magnified at 100x magnification, and the rectangular images below each of these are at 200x magnification. Three areas of the graft are shown: (a) a site within the lining and associated graft biomaterial, (b) a site at the interface between the graft and the host tissue, and (c) a site within the liver lobule. Hematoxylin / eosin staining gives images that contribute to the evaluation of the engraftment and migration process that incorporate features of the inflammatory process. [Figure 4]Figures 4A-4C show engraftment, migration, and rapid maturation to an adult fate within one week. Figure 4A is a low magnification image of a patch graft on the surface of a pig liver after one week. The dashed line indicates the interface of the graft and host liver. Donor GFP+ cells (with pink nuclei, white arrow indicates an area with numerous donor GFP+ stem cells) were visualized by labeling with an antibody against GFP and secondary labeling with Novo Red, a red fluorescent probe. Staining the nuclei blue with 4,6-diamidino-2-phenylindole (DAPI) allowed recognition of host cells with only blue nuclei and donor cells with pink nuclei (mix of DAPI and Novo Red). The host tissue (a) extends within the hyaluronan (HA, black background) of the graft, the tissue from the lining contains occasional organoids (inserts), but many donor cells are dispersed into single cells, and numerous dispersed donor GFP+ stem cells (b) are seen throughout the host tissue. There is no evidence of Glisson's capsule in this region constituting a zone of remodeling. Figure 4B shows that donor cell engraftment and migration was rapid, and within a week, all donor cells were within the host liver, with donor cells both near the transplant site and on the opposite side of the liver lobe (estimated distance at least 1.5 cm from the graft). In ongoing studies, regions of the piglet liver are analyzed at larger distances (i.e., other lobes of the liver) to more precisely define how far donor cells can migrate in a given time. Shown are donor cells (pink nuclei) near a lobule of host mature hepatocytes (forest green from lipofuscin autofluorescence) on the distal side of the liver lobe from the transplant site. Figure 4C shows that donor cell maturation triggers adult fate in parallel with HA resorption. Magnified image of a region containing donor GFP+ cells (single cells with pink nuclei) near forest green (autofluorescence of lipofuscin) host hepatocytes (a) and easily identified from mature donor derived hepatocytes (b) in lavender (mixture of pink GFP, blue-DAPI, and green lipofuscin), i.e., that are lineage restricted from donor GFP+ stem cells.In other IHC assays (data not shown), the bright new green cells in the plates of both host and donor hepatocytes proved to be vascular endothelial and stellate cells. [Figure 5-1]Figure 5A-B compare the engraftment and maturation of cells in liver patch grafts one and two weeks after transplantation. Figure 5A is an examination of a pig liver one week after patch grafting. Immunohistochemistry and immunofluorescence (IF) staining for pancytokeratin (pCK) and Sox9 were performed on consecutive 3-μm sections using Sirius Red staining, an azo dye that stains collagen. At the patch graft site, transplanted donor cells have fused with the liver lobule. In the top panel (original magnification = 5x), the patch graft is composed of mesenchymal and epithelial pCK+ cells (arrows). In the middle panel, a higher magnification is provided (20x). The epithelial cells display a typical biliary stem cell (BTSC) immunophenotype, expressing biliary cytokeratin (pCK) and the endodermal stem cell marker Sox9. BTSCs within the patch graft are arranged in cell columns that reconstitute bile ductules (arrows) and are in direct continuity with the hepatocyte plate in the adjacent liver lobule (arrowheads). Host hepatocytes in the lobule are pCK and Sox9 negative. In the lower panel (original magnification = 20x), immunofluorescence for GFP allows identifying individual transplanted cells and their progeny. Hepatocytes in the lobule adjacent to the patch graft are GFP positive, indicating that they were derived from donor cells that had fused to the host liver parenchyma. At the interface between the patch graft and the liver lobule, pCK+ / GFP+ ductules (donor-derived bile duct cells) are in direct continuity with GFP+ / pCK- cells (donor-derived hepatocytes) in the lobule (arrowheads), suggesting maturation of transplanted cells to a hepatocyte fate. Figure 5B is an examination of a pig liver 2 weeks after patch grafting. IF staining reveals that GFP+ cells are present within the lobule remote from the transplant site. They are homogenously distributed and therefore a mix of host cells (cells with blue nuclei due to DAPI) and donor cells (pink / purple nuclei due to fusion of blue DAPI and red GFP label). They co-express mature hepatocyte markers such as Hepatocyte Nuclear Factor (HNF) 4α (mixture of green and pink / purple nuclei) and albumin (green cytoplasm and pink / purple nuclei). Separate or fused channels were included. Nuclei are shown in blue (DAPI). Original magnification: 40x. [Figure 5-2]Figure 5C compares the engraftment and maturation of cells in liver patch grafts one and two weeks after implantation. Figure 5C is an evaluation of the porcine liver one week after patch grafting, showing extensive areas of remodeling occurring at the interface between the patch graft and the host tissue. The low magnification image and portions of the enlarged image in 1 are hematoxylin / eosin (lightly stained), 2 are stained with Vector-SG, providing blue / grey, and 3 are stained for alpha-fetoprotein in a hematoxylin / eosin background. Specific sites within 5C are numbered and correlated with the enlarged photographs showing the changes occurring within the lobule. The host liver lobule and acini are disrupted as large amounts of MMP invade this area along with the donor cells. Donor cells are observed in the border areas of the lobule, and sites showing hepatic specific markers such as HNF4-α and alpha-fetoprotein also imply that the cells are maturing to a hepatic fate. These properties were not expressed by BTSC, indicating that the donor cells had undergone maturation towards a hepatic fate. [Figure 6-1]Figures 6A-6B provide information regarding patch grafting of stem cell organoids tethered to the pancreas. Figure 6A is a low magnification (panoramic scan) image of GFP+ donor cells engrafted in most of the pancreas and in the submucosa of the duodenum (the region containing Brunner's glands). Immunofluorescent staining of the porcine pancreas, liver, and duodenum at the site of the patch graft. GFP (green), insulin (red), DAPI (blue). Donor-derived GFP+ cells arise near the site where the patch graft was positioned and appear to be integrated within the pancreatic parenchymal tissue. The silk mesh of the SERI surgical scaffold is observed sandwiched between the pancreas, liver, and duodenum. Figure 6B shows that donor cells mature into functional islets. At higher magnification, donor-derived GFP+ / insulin+ beta cells (yellow from merging GFP and red from staining for insulin) are observed intermingled with host GFP- / insulin+ (red) beta cells within the pancreatic parenchymal tissue. Surrounding the islet cells are numerous GFP+ cells that display a morphology consistent with that of exocrine pancreatic cells, including acinar and ductal cells. Supporting this interpretation is the finding in C and D that these cells do in fact produce amylase, a classical acinar marker. [Figure 6-2] Figures 6C-6D provide information regarding patch grafting of stem cell organoids tethered to the pancreas. Figures 6C and 6D show evidence of functional acinar cells derived from donor stem cells. Immunofluorescent staining of consecutive sections from the same tissue block at the patch graft site, focusing on the area of engrafted GFP+ donor cells. Amylase (green), insulin (red), glucagon (white - not visible in panoramic scan in C, but visible at higher magnification in D), DAPI (blue). Amylase+ acinar cells are the majority of the exocrine tissue of the pancreas. By comparing the staining shown in consecutive sections at low and high magnification, it is inferred that most of the donor-derived GFP+ cells in the pancreas have acquired an amylase+ acinar fate. [Figure 7-1]Figures 7A-7D provide characterization of matrix metalloproteinases (MMPs). MMPs consist of a large gene family of calcium-dependent zinc-containing enzymes that dissolve extracellular matrix components. There are at least 24 isoforms known in pigs of which a subset are secreted factors (e.g., MMP1, MMP2, MMP7, MMP9) and a subset are membrane-bound (e.g., MMP14, MMP15). MMP1 was identified by IHC, especially in areas of remodeling, but not by RNA-seq, as there are no annotated forms of porcine MMP1 available for RNA-seq analysis yet. Figures 7A, 7B, 7C, and 7D show that isoforms in the secreted and membrane-bound categories were expressed by both stem / progenitor and mature cells. Quantification of expression levels showed that the membrane-bound forms were similar for both stem / progenitor and mature cells (see comparison in Figure 7D). In contrast, the secreted forms were expressed at very high levels in stem / progenitor and low or negligible levels in mature cell types. The analyzed cell populations of adult cells were isolated from suspensions of piglet liver and bile duct tissue and consisted of CD45+ cells (hematopoietic cells), CD146+ cells (stellate cells), CD31+ cells (vascular endothelium), EpCAM+ / CD45- cells (adult diploid hepatocytes and cholangiocytes). These EpCAM+ / CD45- cells are mature parenchymal cells found in piglet liver. BTSCs were isolated from the bile ducts by the protocol given in the examples. [Figure 7-2]Figures 7E-7H provide characterization of matrix metalloproteinases (MMPs). Figure 7E shows representative MMP expression in areas of remodeling with BTSC / ELSMC grafts. Sections adjacent to the BTSC / ELSMC patch grafts were stained with Trichrome showing areas of remodeling (brackets). The areas appear as linear stripes of red and blue, cells and matrix components that dissolve into a "sea" of MMPs. The stripes end at the edges of the lobules, which are still mostly intact, but begin to "fray" at their borders from the effects of MMPs originating from invading cells. Figure 7F shows a representative image of an IHC assay for MMP1 (Novo-red+). Methyl green is the background stain. The liver lobule / acinar structure dissolves into undulating whorls of cells and is characterized by strong expression of MMP1, the secreted isoform of MMPs. Figure 7G shows a section stained for MMP2 (Novo-red+). Hematoxylin is the background stain. The lobule / acinar structure of the liver disappeared and was replaced by a mixture of cells that stained strongly for MMP2 (rust brown). Figure 7H shows the ongoing remodeling process within the liver lobule. The liver lobule is reduced to cellular debris interspersed with invading cells, and MMP2+ expression (rust brown) is very high, contributing to the disappearance of the lobule / acinar structure. When hyaluronan was removed (2-3 weeks), the lobule structure reappeared. [Figure 8] FIG. 8 is a schematic demonstration of the engraftment and integration phenomenon in the liver and pancreas. [Figure 9-1]Figures 9A-9C provide information on patch grafts of mature (adult) hepatocytes combined with mature mesenchymal cells (MMCs), such as vascular endothelium or stellate cells. These patch grafts failed to engraft. When hepatocytes were combined with early lineage stage mesenchymal cells (ELSMCs), here porcine mesenchymal stem cells (MSCs), engraftment was achievable. When ELSMCs were presented, engraftment occurred but was restricted to the area near the graft. Figure 9A shows trichrome staining of a normal porcine liver. Bars are 200 μm for low magnification image (a) and 50 μm for high magnification image (b). Note the collagen of the Glisson's capsule and the boundaries between the hepatic acini. Figure 9B shows trichrome staining of a patch graft of normal adult hepatocytes combined with mature mesenchymal cells (MMCs), vascular endothelium, and stellate cells failed to engraft. Note in the low magnification image (a) that the Glisson's capsule is intact and that cells remain on top of the capsule. (b) At higher magnification, there is evidence of remodeling (plasticity phenomenon) of cells (mottled red within hepatocytes) in the lobule next to the graft. This plasticity is hypothesized to result from membrane-bound MMPs, known to be present in both stem cells and adult cells. Figure 9C shows an IHC assay on a patch graft of normal adult hepatocytes combined with mature mesenchymal cells (MMCs). Sections were stained with an antibody against RBMY-1 and with hematoxylin as a counterstain. The Glisson's capsule is intact, as is the border zone between the lobules. At higher magnification (b), it is clear that no engraftment has occurred. (d) Negative control (staining without primary antibody) to show non-specific staining. [Figure 9-2]Figures 9D-9E provide information regarding patch grafts of mature (adult) hepatocytes combined with mature mesenchymal cells (MMCs) such as vascular endothelial or stellate cells. Figure 9D shows trichrome staining of a patch graft of normal adult hepatocytes combined with ELSMCs, here porcine mesenchymal stem cells (MSCs) served as the cellular source of MMPs. The graft is separated at the interface between the graft and the host tissue. The brackets indicate areas of remodeling. Note that the hepatic lobules have lost the matrix that normally constitutes the border zone between them and appear frayed at the edges. At higher magnification (a), donor cells (light red compared to the dark red ones in the center of the lobule) can be seen throughout the image, while in (b) and (c) are close-ups of areas showing that the Glisson's capsule has thinned considerably underneath the patch (compared to the area to the left of the box). Extensive remodeling was evident in cells adjacent to the graft (c). Figure 9E shows a patch graft after one week of hepatocytes combined with ELSMCs (porcine MSCs). Section (a) was stained with an antibody against RBMY-1 (brown) and methyl green as a counterstain. The donor cells engrafted (rust-red areas) and matured into adult parenchymal cells in the acini near the graft. Section (b) shows a close-up of the image of a remnant of the thinned Glisson's capsule, showing that the donor cells (dark brown nuclei) were uniformly interspersed among the host cells (nuclei were methyl green). Section (c) is a negative control for (b). Section (d) was stained with an antibody against GFP (which binds with Novus red, resulting in a rust-brown color) and methyl green as a counterstain. Most of the cells engrafted and formed a band of dark red donor (mature) hepatocytes within the host liver acini. The Glisson's capsule remained but was reduced in thickness. No migration much beyond the area of the liver near the graft was observed within the three week time frame of the experiment. [Figure 10] FIG. 10 is a schematic comparing stem cell and adult cell engraftment. [Figure 11]Figure 11 provides evidence that the engraftment process involves migration of cells to substantial distances within the host tissue. In a BTSC / ELSMC graft, organoids are shown one week after transplantation. A schematic diagram of the liver divided into eight different zones is used to show the areas assessed for the presence of donor cells. Sections are prepared from areas 1-8 and then stained to allow identification of donor cells. A table summarizes the results showing the distance between the graft and each area, and the percentage of GFP+ cells found. Images to the left of the table are scans of representative sections for each zone. The dark brown staining is strongest in zone 6 close to the graft and becomes lighter with increasing distance from the graft, being lightest in zone 1. [Figure 12-1] Figure 12A provides evidence of donor cell migration throughout the host liver. GFP+ cells were stained with Novo-red (rust brown) and host cells were stained with methyl green. Figure 12A is a low magnification image of the interface between the graft and the host liver. Separation of the graft from the host liver was frequently seen (also note this in Figure 3) and was shown to correlate with very high levels of secreted MMPs. Magnified photographs of areas (a) and (b) are shown below. Note the areas in the low magnification image, and in the magnified photograph of (b), with areas that are patchy in staining and show a washed-out appearance that is evidenced to be due to tissue hyaluronan levels. [Figure 12-2] Figures 12B-12E provide evidence of donor cell migration throughout the host liver. GFP+ cells were stained with Novo-red (rust brown) and host cells were stained with methyl green. Figure 12B shows the intermediate zone where cells migrate. Donor cells are present throughout the tissue in both the bile ducts and the parenchyma of the acini. Figure 12C shows the distance zone where cells migrate. Note that only the bile ducts are stained. Figure 12D provides a close-up showing donor cells in the bile ducts. Figures 12E and 12F provide a close-up within the parenchyma showing that donor cells have GFP labeling in the nuclei. [Figure 13]Figure 13 shows the adverse conditions obtained with patch grafts with certain backings (see also Tables 1 and 2). These included sites of cholestasis, which was found to occur when the graft was placed too close to some ducts such that necrosis, adhesions, and swelling caused ductal obstruction. [Figure 14] FIG. 14 shows charts of the lineage stages and corresponding biomarker profiles for both epithelial (FIG. 14A) and mesenchymal (FIG. 14B) cells. [Figure 15] FIG. 15 shows H2B-GFP+BTSC / ELSMC organoids patch grafted into the kidney. Evaluation was performed 1 week after transplantation. Panel A shows trichrome staining of the transplanted kidney. The kidney was prepared in section to expose the deeper layers that form a "V" shape with the graft. The lower half of the "V", stained in light blue, is the graft side of the kidney, and the upper side of the "V" in the figure is the deeper layer that was grafted. Panel B shows H&E staining of the same section of the transplanted kidney. Panel C is a higher magnification of the patch grafted kidney. The kidney capsule under the graft was loosened in a similar manner to the liver (from dissolution by MMPs). Panel D shows IHC staining of GFP+ cells (dark red) engrafted into the kidney in the layer under the patch. Panel E shows engraftment of GFP+ cells (dark red) in the deeper layers of the kidney. Autopsy reports showed that no necrosis was observed within the transplanted kidney or elsewhere in the animals that received the patch graft.
[0025] Brief explanation of the table Table 1 provides a summary of surgical or other procedures for patch grafts.
[0026] Table 2 provides a comparison of the backings tested against the exemplary patch grafts.
[0027] Table 3 provides an overview of the antibodies used for IHC and IF in the Examples.
[0028] Table 4 provides an overview of the primers used in the qRT-PCR assay. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] Embodiments according to the present disclosure are described more fully below. However, aspects of the present disclosure The present invention may be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments should not be construed as limiting the present disclosure so that this disclosure will be thorough and complete. These and other aspects of the present invention are provided in order to fully convey the scope of the present invention to those skilled in the art. The terminology used is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. All publications, patent applications, patents and other documents mentioned herein are not to be construed as a substitute for the express written consent of the present invention. References are incorporated by reference in their entirety.
[0030] Unless otherwise defined, all terms used herein (including technical and scientific terms) (including) have the same meaning as commonly understood by a person skilled in the art to which the present invention pertains. Terms, such as those defined in commonly used dictionaries, are used throughout this application and the related art. The term "common" should be interpreted to have a meaning consistent with the context of the art and is used herein. Unless explicitly defined, they should not be interpreted in an idealized or overly formal sense. It is further understood that such use is not permitted. Words should be interpreted in accordance with their common meaning.
[0031] The practice of the present techniques is within the skill of the art in tissue culture, immunology, and the like, unless otherwise indicated. Employing conventional techniques in molecular biology, microbiology, cell biology, and recombinant DNA. For example, Sambrook and Russell eds. (2012) Molecul ar Cloning:A Laboratory Manual,4rd editi on;the series Ausubel et al.eds.(2012)Cu rrent Protocols in Molecular Biology;the series Methods in Enzymology(Academic P ress,Inc.,N.Y.);MacPherson et al.(1991)P CR 1:A Practical Approach(IRL Press at O xford University Press);MacPherson et al .(1995)PCR 2:A Practical Approach;Harlow and Lane eds.(2014)Antibodies,A Laborat ory Manual,2d edition;Freshney(2011)Cult ure of Animal Cells:A Manual of Basic Te chnique,6th edition;Gait ed.(1984)Oligon ucleotide Synthesis;U.S.Patent No.4,683, 195;Hames and Higgins eds.(1985)Nucleic Acid Hybridization;Anderson(1999)Nucleic Acid Hybridization;Hames and Higgins ed s.(1984)Transcription and Translation;Im mobilized Cells and Enzymes(IRL Press(19 86));Perbal(1984)A Practical Guide to Mo lecular Cloning;Miller and Calos eds.(19 87)Gene Transfer Vectors for Mammalian C ells(Cold Spring Harbor Laboratory);Makr ides ed. (2003) Gene Transfer and Expressi on in Mammalian Cells;Mayer and Walker e ds.(1987) Immunochemical Methods in Cell and Molecular Biology(Academic Press,London) and Herzenberg et al. eds(1996)Weir' See Handbook of Experimental Immunology This is what I mean.
[0032] Unless the context indicates otherwise, the various features of the invention described herein may be combined in any combination. It is specifically contemplated that the present disclosure may be used in combination with other embodiments. It also means that any feature or combination of features described herein may be excluded or omitted. For purposes of illustration, the specification states that a complex comprises components A, B, and C. In this case, A, B or C, or any combination of them, may be used alone or in any combination. It is specifically intended that these provisions may be omitted and waived in their entirety.
[0033] For example, all numerical indications such as pH, temperature, time, concentration, and molecular weight including ranges are , in increments of 1.0 or 0.1 as appropriate, or + / - 15%, or 10%, or It is an approximation that changes (+) or (-) with a fluctuation of 5% or 2%. However, although not always expressly stated, all numerical designations are preceded by the word "about." Also, of course, although not necessarily explicitly stated, The reagents described herein are merely exemplary and equivalents thereof are known in the art. .
[0034] definition As used in the description of this invention and the appended claims, the singular forms "a," " "An" and "the" include the plural unless the context clearly indicates otherwise. It is intended.
[0035] As used herein, the term "about" refers to an amount or concentration (e.g., a biomatrix In some cases, this refers to a measurable value such as the percentage of collagen in the total protein in the scaffold. In some cases, this may include variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of a particular amount. It means to include.
[0036] Used to describe the selection of any ingredient, range, dosage form, etc. disclosed herein The terms "acceptable," "effective," or "sufficient" are used to describe the components, ranges, dosage forms, etc. is intended to be suitable for its intended purpose.
[0037] Also, as used herein, "and / or" refers to one or more associated Any and all possible combinations and alternatives of the listed items. ("or") means and includes the absence of a combination.
[0038] As used herein, the term "comprising" refers to compositions and methods that include recited elements. As used herein, the term "substance" is intended to mean inclusive of, but not exclusive of, others. In this case, the transitional phrase "consisting essentially of" (and grammatical variations) refers to the listed materials or or steps and "that do not materially affect the basic and novel characteristics" of the recited embodiment. In re Herz, 537 F. 2d 549,551-52,190 USPQ461,463(CCPA 1 976)(emphasis in the original);MPEP § 21 See 11.03. Accordingly, as used herein, "consisting essentially of" The term "comprises" should not be construed as equivalent to "comprises." "Consists" means that other components and a substantial method for administering the compositions disclosed herein. Each of these transition terms is defined as excluding the Such embodiments are within the scope of this disclosure.
[0039] As used herein, the term "patch graft" refers to the transfer of donor cells (allogeneic or The cells are embedded in or contained within a suitable biomaterial that allows for the transplantation of the cells (autologous) into the host. In some embodiments, the term refers to the composition of cells transplanted into a host. refers to a composition of cells embedded or contained in a suitable biomaterial that allows The biomaterial is prepared under defined conditions (e.g., in an optionally supplemented basal medium). and / or nutritional factors, vitamins, amino acids, carbohydrates, minerals, insulin, tra Insulin / Fe, and / or lipid media (purified albumin and high density lipoprotein Purified free fatty acids in complex with lipoprotein carrier molecules such as lipids, optionally and contained in a soft gel (less than 200 Pa, optionally about 100 Pa) to allow surgical attachment. have sufficient tensile strength to be able to be otherwise tethered to host tissue or organs; The donor cells may then be covered with a chemical backing that has minimal effect on their differentiation. What we want to avoid are factors that may promote cell differentiation, especially early lineage stage mesenchymal cells. (ELSMC)-containing supplements, which include serum, Growth factors and cytokines, as well as mature matrix components (e.g., type I collagen ) are included.
[0040] The term "backing" as used herein refers to a material that connects the implant to the target site and and / or facilitate the migration of cells therein to the target site and / or toward the lining. A lining or a surface of the patch graft that can prevent or inhibit cell migration. The backing refers to a material that functions as a barrier. "synthetic, biodegradable material" or any variation thereof referring to the material and (ii) the material is biocompatible with the subject into which it is to be implanted. It exhibits mechanical resilience that allows it to withstand compressive and shear forces occurring inside the material (especially the internal ones), thereby (iii) the material is in contact with the tissue, allowing the material to function as a surgical tissue; In some embodiments, patch cloning has a neutral or minimal effect on the differentiation state of cells. The raft backing comprises such a material. In such an embodiment, (ii) mechanical elasticity The backing should be such that it can tether the graft to the target site. In such an embodiment, the backing may, for example, be a viscoelastic material that moves away from the target site. by affecting the differentiation of these cells or by physically blocking their migration. In this regard, suitable materials include cereals, Silk (Seri-silk), optionally contoured Seri-silk, or its derivatives, its amini aminion or an extract thereof (e.g., fetus-facing side and / or PG A and / or PLLA) Non-limiting examples of suitable patches of synthetic materials include 91% PGA-co-9% PLLA. a woven patch made of 91% PGA-co-9% PLLA, a knit patch made of 91% PGA-co-9% PLLA, or More commonly, suitable backings include nonwoven patches made of Se ri R Surgical Silk Scaffold(Sofregen, New The silkworm silk morphology, such as that of silkworm moth (New York, NY), other derivatives of silkworm silk, and poly Synthetic fibers, such as poly(glycolic acid)-co-poly(L-lactic acid) (PGA / PLLA), are included. It can be rare.
[0041] In some embodiments, the backing is also bioabsorbable. "Bioabsorbable" means that the implant cannot be broken down by the host or recipient's body. In some embodiments, a bioabsorbable backing is a material that does not require mechanical removal. About 2 to 10 weeks, about 2 to 20 weeks, about 2 to 52 weeks, about 4 to 16 weeks, about 4 In some embodiments, the composition is bioabsorbable within an interval of about 4 to about 8 weeks. The bioabsorbable backing is for about 4 to about 8 weeks, about 4 to about 12 weeks, about 4 to about 16 weeks, or about 4 to about 20 weeks, and is bioabsorbable at intervals of about 4 to about 52 weeks.
[0042] As used herein, the biomaterial of the implant includes any of the following: The term "gel" includes anything that can form a gel, ranging from soft and weak to hard and It refers to a solid, jelly-like material that can have a variety of properties, from hard to tough. A polymer is defined as a substantially dilute cross-linked system that does not exhibit flow when in steady state. By weight, gels are mostly liquid, but they form three-dimensional cross-linked networks within the liquid. It behaves more like a solid. The gel has a structure (hardness, stiffness, mechanical properties or viscoelasticity) that It is the cross-links within the fluid that give it its adhesive properties. A dispersion of liquid molecules within a solid, where the solid is the continuous phase and the liquid is the discontinuous phase. The "hydrogel," also referred to herein as the "hydrogel matrix," is a polymer chain. A non-limiting example of a gel made up of a polymeric polymer gel made up of a network of Hydrogels can undergo network formation by either chain or step growth. , are synthesized from hydrophilic monomers or hydrophilic dimers (eg, in the case of hyaluronan). The net-like structure together with void defects enhances the hydrogel's ability to absorb large amounts of water through hydrogen bonds. As a result, hydrogels have a characteristic firm, yet elastic, mechanical Develops mechanical properties. New bonds form naturally when old bonds are broken within the material. The structure of the hydrogel, together with the electrostatic adhesion, is governed by non-covalent hydrogen bonds. Promotes new bond formation.
[0043] The biomaterials used in the implants are mechanically modified, which can be more strictly defined as the viscoelastic properties of the biomaterial. It has excellent mechanical properties and rigidity. https: / / en.wikipedia.org / wiki / DeepL / Viscoelasticity. Graft biomaterials that lead to engraftment are non- It is always soft (e.g., about 100 Pa) and the donor cells remain immature (Lozoya et al.Biomaterials 2011;32(30):7389-740 2) Conditions must be such that membrane-bound and / or secreted MMPs can be produced.
[0044] As used herein, the term "viscoelastic" refers to a material that exhibits viscous and elastic properties when subjected to deformation. The term refers to the property of a material that exhibits both shear and viscosity. Viscous materials, such as honey, are resistant to shear flow. Elastic materials resist deformation and distort linearly with time when stress is applied. When the stress is removed, they quickly return to their original state. Viscoelastic materials possess both of these properties. Elasticity is usually governed by the crystalline structure of ordered solids. The viscosity is the result of bonds extending along geometric planes, whereas the viscosity is the result of the bonds between atoms or molecules within an amorphous material. There are numerous instruments available to test the mechanical and viscoelastic response of materials. Can be used above and below ambient temperature to test elastic behavior and to test viscoelastic properties Broadband viscoelastic spectroscopy (BVS) and resonant ultrasound spectroscopy (RU S) is more commonly used. These two instruments appeal to the superposition of time and temperature. The damping mechanism is employed at various frequencies and time ranges without considering the BVS and RUS. Using the technique to study the mechanical properties of materials provides insight into how viscoelastic materials behave. This is important to understand how
[0045] As used herein, the term "hyaluronan" or "hyaluronic acid" refers to Glucosamine and glucuronides linked by β1-4, β1-3 bonds and their salts It means a polymer of disaccharide units consisting of saccharide units [1-3]. Hence, the name hyaluronan. The term refers to both natural and synthetic forms of hyaluronan. (HA), D-glucuronic acid (GlcUA) and N-acetyl-D-glucosamine (G Water-soluble polysaccharides containing disaccharide units of lcNAc are linked alternately to form linear polymers. High molecular weight HA can contain 100-10,000 disaccharide units. HA is often It occurs naturally as the sodium salt, sodium hyaluronate. Preparations of either sodium hyaluronate and HA or sodium hyaluronate are Non-limiting examples of acceptable hyaluronic acids include hyaluronan. Examples include potassium hyaluronate, magnesium hyaluronate, and calcium hyaluronate. can be done.
[0046] Other glycosaminoglycans (GAGs) can also be used in the hydrogel. These include chondroitin sulfate (CS) and dermatan sulfate (DS), glucuronic acid and galactosyl sulfate. Polymers of heparan sulfate (HS) and heparin (HP), glucuronic acid and glucosamine The sulfation patterns are consistent across multiple protein families (e.g. Determines the formation of complexes with proteins (e.g., coagulation proteins, growth factors, cytokines, neutrophil enzymes) Therefore, the degree and pattern of sulfation of these GAGs is important. ll AK, Yates EA, Fernig DG, Turnbull JE. Int eractions of heparin / heparan sulfate wit hproteins:appraisal of structural facts rs and experimental approaches.Glycobiol ogy.2004 Apr;14(4):17R-30R]. To optimize engraftment, suitable patch grafts include hyaluronan, non-sulfated GAGs, including those that are minimally sulfated such as chondroitin sulfate found in the niches of hepatocytes be caught. Karumbaiah L, et al.Chondroitin Sulfa te Glycosaminoglycan Hydrogels Create En dogenous Niches for Neural Stem Cells.Bi oconjug Chem.2015 Dec 16;26(12):2336-49 and Hayes AJ,et al.Chondroitin sulfate s sulfation motifs as putative biomarkers f or isolation of articular cartilage prog enitor cells.J Histochem Cytochem.2008 F eb;56(2):125-38 (hereby incorporated by reference).
[0047] As used herein, the term "cell" refers to one or more cells in a graft. The cells of the present disclosure are eukaryotic. In some embodiments, the cells are optionally Derived from animals derived from human organs, stem cells, mature somatic cells, progenitor cells, or mature somatic cells from stem cells The term "population of cells" or "cell" refers to a lineage intermediate between a cell and a lineage. Refers to a group of one or more cells of the same or different cell type, of the same or different origin. This term is used interchangeably herein with the term "donor cells" and refers to autologous or In some embodiments, the population of cells is freshly isolated. The cells may be derived from a cell line from an isolated cell, or in some embodiments, The population of cells may optionally be derived from a portion of an organ or tissue from a donor or recipient. good.
[0048] The term "stem cell" refers to a cell that is capable of self-renewal (producing daughter cells identical to the parent cell) and A cell population that is pluripotent, i.e., capable of giving rise to multiple types of adult cells, As used herein, the term "progenitor cell" or "precursor" refers to a stem cell. A progeny of a cell, including the offspring of the cell and its progeny, may be a pluripotent, bipotent, or A population of cells that can be either unipotent or unipotent but have minimal (if any) self-renewal capacity. The mitochondria are unipotent and differentiate into a specific lineage to give rise to only one mature cell type. Non-limiting examples of stem cells include embryonic stem (ES) cells, induced pluripotent stem cells, and Stem (iPS) cells, endoderm stem cells, committed stem cells (ectodermal, mesodermal, or endodermal sex), perinatal stem cells, amniotic fluid-derived stem cells, mesenchymal stem cells (MSCs), hemangioblasts, and umbilical cord , Wharton's jelly, and / or placenta. Intermediates between stem cells and committed progenitors include hepatoblasts and pancreatic ductal precursors. Which cell populations, and which are pluripotent, have extensive proliferative potential and self-renewal capabilities (if any)? Other forms of TA cells are included that are more specific (if applicable).
[0049] The term "mesenchymal cells" refers to hemangioblasts, endothelial progenitors, astrocyte progenitors, endothelial cells, , astrocytes, stromal cells, various subpopulations of mature and progenitor cells, as well as multipotent stromal cells. These include mesenchymal stem cells (MSCs), which are a subpopulation of mature and precursor mesenchymal cells. MSCs refer to cells of mesenchymal origin, including, but not limited to, cells derived from tissues through a culture selection process. The cell population was prepared by Stem Cell Processing (Cathery et al. ls 2018;PMID:29732653;Graceb et al.Bioch imie 2018:PMID 29698670;Caplan AI.Stem C ells Int.2015;PMID:26273305. Mature mesenchymal cells have few There are at least two main categories: (a) fibrillar collagen (e.g., types I, III, and V) ) and associated matrix components (fibronectin, chondroitin sulfate proteoglycans, glycans, dermatan sulfate proteoglycans), and binding signals that form complexes (e.g. growth factors, cytokines) and associated with what are usually linear (string-like) cell populations. Extracellular molecules that contain binding signals (e.g., growth factors, cytokines) that form complexes that interact with the The mature mesenchymal cells (stellate / stromal cells) that generate the morphology of the trichomes and are surrounded by them Non-limiting examples of such cells include astrocytes, tendon, interstitial, and myofibroblasts. (b) network collagen (e.g., types IV, VI, VIII, X) and Associated matrix molecules (laminin, heparan sulfate proteoglycans, heparin proteinases) oglycan), and associated with cells with a more flattened, cuboidal, or cobblestone morphology. Generates extracellular matrix morphology that contains integration signals (e.g., growth factors, cytokines) and are surrounded by mature mesenchymal cells, such as vascular endothelium. Examples include vascular endothelium, and myoepithelium.
[0050] The precursors of these mesenchymal cell types include the multipotent and vascular endothelial (this later stage is known as fenestrated vascular This later stage can differentiate into myofibroblast (stromal) lineages. Progenitors include, but are not limited to, hemangioblasts, which are pluripotent cells that can Fibroblasts (stromal cells), osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) , and mesenchymal stem cells (MSCs), which can also differentiate into adipocytes (fat cells). can be optionally prepared by culture selection methods (Cathery et al. Cells 2018;PMID:29732653;Graceb et al.B iochimie 2018:PMID 29698670;Caplan AI.St em Cells Int.2015;PMID:26273305.
[0051] The term "epithelial cell proliferation" refers to colonies that typically have a cuboidal or cobblestone morphology. An estimate of growth that is a combination of the diameter of the epithelial cell colonies that form and the diameter of the cells in the colonies In contrast, mesenchymal cells are more migratory and motile, and colony density correlates with colony density. This reflects the net sum of cells remaining within the knee boundary, and therefore is an estimate of mesenchymal cell colony growth. correlates with colony density.
[0052] The term "epithelial cells" refers to cells that provide diverse functions to the tissue and / or systemic needs of the host. They refer to cells derived from the epithelium, which are specialized cells that act as precursors or immature cells. They are recognized by their ability to move as apical, basal and subapical structures. They form layers of flat, cobblestone-like, or columnar polarized cells with various junctions. They are connected to each other by junctions (connexins, tight junctions, adhesions). Ronnie's diameter (not density). Mature epithelial cells produce specialized secretion or metabolism (hepatocytes, bile duct cells), detoxification (hepatocytes), production of enzymes (acinar cells), Production of endocrine factors (e.g., pancreatic islets or other endocrine cells), electrical activity (neurons), and They serve diverse functions such as contributing to endothelial function (endothelial cells) and absorption (enterocytes).
[0053] The term "bile duct stem cells" (BTSCs) refers to cells found throughout the bile duct and peribiliary glands (PBGs). Epithelial stem cells located in the Brunner's glands, both extramural and intramural, and in the crypts of the gallbladder villi. These are cells that have the capacity to transition into committed hepatic and / or pancreatic progenitor cells. Hepatic progeny enter the sinusoids of the liver via the ducts of Hering. Pancreatic precursors enter the pancreas via the ducts of Hering. It is found within the pancreatic ductal gland (PDG), the region in which the bile duct is located.
[0054] So far, at least seven subpopulations of stem cells have been identified with overlapping characteristics. , from extremely primitive BTSCs to stem cell populations that can be defined as hepatic or pancreatic stem cells. Below is a description of what is known about these. The most primitive are the extramural Peribiliary glands - those attached to the surface of the bile duct; intramural peribiliary glands - those found within the bile duct wall Intramural peribiliary glands (PBGs) near the fibromuscular layer in the center of the bile duct wall were They can also be considered as crypts, niches in which the most primitive stem cell populations are found (as in intestinal crypts). The greatest number of PBG in the bile duct network is in the common duct of the hepatopancreas and in the large intrahepatic bile ducts. PBG does not occur in the gallbladder, but instead, stem cell niches within the gallbladder are found in the hepatic stem cells. The fundus of the gallbladder villi contains a population of mid- to late-stage stem cells that are the precursors of BTSCs. are progenitors of both the liver and pancreas. They are hepatic stem cells, hepatic progenitors, and pancreatic They give rise to pancreatic stem cells, precursors of the pancreas, which are found throughout the bile duct but are more numerous in the liver. Therefore, the small number of pancreatic stem cells and the large number of hepatic stem cells are affected by how close they are to the pancreas. Pancreatic stem cells are located in the PBG of the large intrahepatic bile ducts, while a small number of liver stem cells and a large number of pancreatic Stem cells are located in the PBG of the hepatopancreatic common duct.
[0055] An overview of the gene signatures is shown in the figure. In general, all subpopulations of BTSCs were found to be involved in the development of liver and Endodermal transcription factors in both the pluripotent and pancreatic stem cells (e.g., SOX9, SOX17, PDX1), Sex genes (e.g., OCT4, SOX2, NANOG, SALL4, KLF4 / KLF5 , BMI-1); one or more hyaluronan receptor isoforms of CD44 (standard and / or variant isoforms); CXCR4; and cytokeratin 8 and and 18. Stem cells in the bile duct and PBG The subpopulations include: (1) those that express CK7, TRA-160 and 181 and are also expressed in the intestinal stem Brunner's gland cells in the submucosa of the duodenum, which have different properties from iodine cells. (2) The sodium ion transporter (NIS) and CXCR4, OCT4, SOX2, and NANOG expressing LGR5 or EpCAM, but not LGR5 or EpCAM, C) (3) An intermediate stage in which NIS expression is low but LGR5 expression is obtained instead of EpCAM expression. (4) Intrastallular BTSCs, also seen in large numbers in the large intrahepatic bile ducts and the common duct of the hepatopancreas, at a later stage Intramural BTSCs (the only BTSCs found in the gallbladder). These express both LGR5 and EpCAM. These are hepatic stem cells (located in the liver and expressing SOX17, but not PDX1). (which do not express PDX1) and pancreatic stem cells (located in the common hepatopancreatic duct, which express PDX1 but not SOX1 (5) Hepatic stem cells are the precursors of the canals of Hering, the large intrahepatic bile ducts. It can be found in the PBG, the extrahepatic bile duct PBG, and the hepatopancreatic common duct PBG, but is most commonly Hepatic stem cells are most commonly found in intrahepatic sites. Hepatic stem cells retain the capacity for self-renewal and pluripotency. Biomarkers for these cells include SOX9, SOX17, and HNF-4α. α, ITGB1(CD29), ONECUT2, SALL4, LGR5, CD44, cell Epithelial cell adhesion molecule (EpCAM), neural cell adhesion molecule (NCCAM), found in the interstitium and on the cell membrane AM), CD133 (prominin), negligible (or absent) levels of albumin , complete absence of alpha-fetoprotein (AFP), absence of P450 A7, and secretin Hepatic stem cells and hepatoblasts lack the cytokine 8, 1 (6) Pancreatic stem cells are found in small numbers throughout the bile duct ( They are also found in large numbers in the PBG of the large intrahepatic bile ducts, and in the PBG of the common duct of the hepatopancreas. They have expression of the ability genes and other genes found in all stem cell populations, but not SOX17. A subpopulation that is lineage-restricted to pancreatic islets expresses NGN3, whereas a subpopulation that is lineage-restricted to pancreatic islets expresses NGN3 They express EpCAM throughout the cell and on the cell membrane, and express low insulin (and Their maturation is accompanied by increased expression of insulin, as well as other islet hormones ( For example, glucagon expression correlates with the expression of MUC6 and acinar cells. It expresses amylase.
[0056] Hepatic and pancreatic stem cells can also be found in their respective source organs early during development. Any of these cells disclosed herein can be induced to Note that iPSCs can alternatively be generated as iPSCs (i.e., "iPSCs").
[0057] As used herein, the term "support" refers to the propagation of cells from another lineage stage. Support or influence on neighboring cells in terms of survival, expansion, migration, differentiation, and maturation They can provide support to neighboring cells through the production of "paracrine signals," which are factors that are actively involved in their functioning. For example, supporting mesenchymal cells can affect epithelial cells. and optionally a matrix metalloproteinase (MMP) and / or one or These may be defined through multiple paracrine signals or secretion of growth factors. (Cathery et al. Stem Cells 2018;PMID:29732653;Graceb et al.Biochim ie 2018:PMID 29698670;Caplan AI.Stem Cel ls Int.2015;PMID:26273305.
[0058] The term "lineage stage partner" as used herein refers to a cell that supports engraftment. Refers to mesenchymal and / or epithelial cells that are at the appropriate lineage stage to differentiate into hepatic or biliary stem cells. Regarding the cells, hemangioblasts (CD117+, CD133+, VEGFr+, CD31-negative) ) and their direct progeny, vascular endothelial precursors (CD133+, VEGFr+, CD31 +, von Willebrand factor (vWF+)) as well as astrocyte precursors (CD146 +, ICAM-1+, smooth muscle α-actin+ (ASMA), vitamin A negative). These include, but are not limited to, mesenchymal stem cells (MSCs), such as those derived from bone marrow or adipose tissue. It can be imitated in part and / or to some extent by using Without being bound by the present invention, such cells may be cultured immediately after isolation from tissue or ideally in vitro. Generally, these should be used after a minimum of passage under serum-free conditions. The cells are collectively referred to herein as early lineage stage mesenchymal cells (ELSMCs).
[0059] Intermediates within the lineage network, called "TA cells," are bipotent (or pluripotent) Cells that can reproduce have considerable proliferative capacity but little (if any) true self-renewal. However, they have low to moderate (or absent) pluripotency gene expression and are highly expressed in the liver (e.g., alveoli). bumin, alpha-fetoprotein) or pancreatic (e.g., insulin, MUC6, amyloid These include hepatoblasts (hepatocytes), which express characteristics that indicate commitment to a hepatocellular fate. pancreatic duct precursors (the network that gives rise to the pancreas) and pancreatic duct precursors (the network that gives rise to the pancreas) .
[0060] As used herein, the term "pancreatic ductal progenitor" refers to the pancreatic ductal glands (P This refers to bipotent cells found in the DG (dimer-derived glomerulus) that give rise to acinar cells and pancreatic islets. These include SOX9, PDX1, PTF1a, HNF1β, EpCAM, LGR5, and ICA M-1, expressing CD44, with subpopulations expressing NGN3, MUC6, or amylase They have been extensively characterized by others. For example, Re zanejad H,Ouziel-Yahalom L,Keyzer CA,Sul livan BA,Hollister-Lock J,Li WC,Guo L,De ng S, Lei J, Markmann J, Bonner-Weir S. Hete rogeneity of SOX9 and HNF1β is dynamic.S tem Cell Reports.2018 Mar 13;10(3):725-7 See reference 38.
[0061] As used herein, the term "hepatoblast" refers to hepatocytes and cholangiocytes. lineages can arise within or adjacent to the canal of Hering, or in large These are bipotent liver cells found in the PBG of the intrahepatic bile ducts. have an extraordinary ability to proliferate (i.e., expand) compared to that observed in BTSCs. These cells are the hepatic stem cells or bile duct stem cells. Characterized by biomarker profiles that overlap but are distinct from stem cells These include SOX9, low (or negligible) levels of SOX17, and high levels of LGR 5, HNF4-α, and EpCAM, and are found primarily at the plasma membrane, and express P450A7, Sarcopenia Itokeratin 7, a secretin receptor, is expressed and albumin is expressed consistently in all hepatoblasts. It expresses high levels of alpha-fetoprotein (AFP), intercellular adhesion molecule (ICAM-1 ), but not NCAM, and pluripotency genes are expressed at negligible levels or not at all. (e.g., SALL4, KL4 / KLF5, OCT4, SOX2, NANOG). In addition, markers of mature liver parenchyma are not expressed (eg, P450 such as P4503A).
[0062] As used herein, the term "committed progenitor" refers to a single cell type, e.g. For example, it refers to unipotent precursors that give rise to committed hepatocyte precursor cells. In morphology, they do not express pluripotency genes. Committed hepatocellular precursors are Min, AFP, glycogen, ICAM-1, various enzymes involved in glycogen synthesis, and the expression of the gap junction gene, connexin 28. These are recognized by hepatocyte Committed bile duct (or cholangiocyte) precursors give rise to cholangiocytes, E pCAM, cytokeratin 7 and 19, aquaporins, CFTR (cystic fibrosis membrane complex) ductance regulator), and membrane pumps involved in bile production. In some embodiments, committed islet precursors express insulin, glucagon, and They express low levels of pancreatic islet hormones and other islet hormones, and upon maturation, they increase the expression of pancreatic islet hormones. Although levels increase, certain cells preferentially express certain hormones.
[0063] As used herein, the term "aggregate" refers to multiple cells that are grouped together. The aggregates may vary in both size and shape, or may be of substantially uniform size. As used herein, a cell aggregate may be any shape and / or form, e.g., a sphere. The shape may vary, such as cylindrical (preferably with equal height and diameter), or rod-shaped, among others. Although other shapes of aggregates can be used, the present disclosure In one embodiment, it is generally preferred that the cell aggregates are spherical or cylindrical. The term "aggregate" refers to an individual or single cell, stem and / or progenitor cell, or mature cell. In some embodiments, the compositions provided herein comprise substantially aggregated cells. , substantially non-aggregated cells, or a mixture thereof.
[0064] As used herein, the term "organoid" refers to a simple panning method as described herein. Mean specific cell aggregates of donor epithelial cells with mesenchymal cells self-organized by the method In some embodiments, the mesenchymal cells are supportive mesenchymal cells. In this study, organoids were cultured in low-attachment dishes and then adapted to lineage stages of aggregated cells in suspension. Others have been developed using specific matrigel substrates such as Matrigel. Organoids are prepared using extracts of cerebrospinal fluid (C-C-F) from the cerebrospinal fluid (C-F) of ... It is known that. Hindley et al. Dev. Biology 201 6;420:251-261. See PMID:27364469. The described conditions under which ganoids are maintained are consistent with those described in the patch grafts of the present invention. Factors such as those found in Matrigel do not work well for use with organoids. These cells are required for successful patch grafting and MMP production is stopped or substantially reduced. Additionally, Matrigel is a biocompatible material that can be used to culture cells for clinical human and veterinary purposes. It cannot be a component of the conditions for
[0065] The term "culture" or "cell culture" refers to the maintenance of cells in an artificial in vitro environment. "Cell culture system" as used herein means a system in which a population of cells is cultured ex vivo ( This refers to culture conditions in which cells can grow outside of a living organism.
[0066] As used herein, "culture medium" refers to a nutrient solution for the cultivation, growth, or proliferation of cells. Culture media refers to, but is not limited to, cells that are cultured in a particular state (e.g., a pluripotent state). the ability to maintain cells in a state (proliferative, quiescent, etc.), to mature cells, and in some cases Specifically, functional properties such as the ability to promote differentiation of precursor cells into cells of a specific lineage are Non-limiting examples of culture media may be characterized by their characteristics. Serum supplemented medium (SSM) is any basal medium supplemented with serum at a level of approximately 20%. Serum can be autologous (same species as the cells) or, more commonly, for commercial purposes (e.g., Serum from animals that are routinely slaughtered for animal welfare (such as chickens, cattle, pigs, etc.) can be used. In particular, the present embodiments involving stem cells include serum and / or serum components that drive differentiation. Use a medium that avoids the incorporation of endodermal stem / progenitors. Serum-free medium designed for endodermal stem / progenitors The Kubota medium is copper-free, low calcium (<0.5mM), and low in selenium, zinc, Supplemented with insulin, transferrin, lipids, but no cytokines or growth factors It consists of a basal medium, which is a medium that does not contain any nutrients (nutrients, amino acids, vitamins, salts, carbohydrates). Other media that support stem cells may also be used, but the maturation process must be membrane-bound. This will attenuate the production of endothelial and / or secretory MMPs, and therefore any The causes need to be avoided.
[0067] Basal media is a buffer used in cell culture that contains amino acids, sugars, lipids, vitamins, minerals, and Contains various nutrients, salts, trace elements, and other compounds in a composition that mimics the chemical composition of the interstitial fluid surrounding cells. In addition, cell culture media usually contain a small percentage of blood (typically 2-10%). The transplantation techniques described herein consist of a basal medium supplemented with supernatant. Maintain cells as stem cells or early precursor cells, and commit cells to a mature cell fate Avoid serum or any typical supplements that may be harmful to cells. In addition, various nutritional supplements, lipids (complexed with carrier molecules such as albumin and high density lipoproteins) (a mixture of free fatty acids combined with carbohydrates). Only two hormones / growth factors are added: insulin, which is required for synthesis, and transferrin, which is required as an Fe carrier for the polymerase Kubota's medium, a serum-free medium designed for endodermal stem / progenitors, is low in copper and phosphorus. Contains no calcium (<0.5mM), no zinc, no selenium, no insulin, no transferrin, It consists of a basal medium supplemented with lipids but without cytokines or growth factors. Other growth factors and cytokines, and especially serum, induce differentiation of donor cells, which should be avoided to minimize the production of MMPs required for the engraftment and migration process. be.
[0068] As used herein, "Kubota's medium" refers to a medium supplemented with copper, calcium (<0.5 mM), Selenium, zinc, insulin, transferrin / Fe, free lipids bound to purified albumin Any medium that does not contain a mixture of fatty acids and, optionally, high density lipoproteins (HDL). In some embodiments, the Kubota medium is copper- and calcium-free (e.g., 0.3 mM), about 10-9M selenium, about 0.1% bovine serum albumin or human serum albumin (highly purified and fatty acid free), nicotinamide at about 4.5 mM, sulfate at about 0.1 nM Lead heptahydrate, approximately 10-8 M hydrocortisone (used for hepatic precursors but not pancreatic precursors) (optional components not used in the study), approximately 5 μg / ml transferrin / Fe, approximately 5 μg / 1 ml of insulin, approximately 10 μg / ml of high density lipoprotein, and purified serum albumin. Any medium (e.g., The free fatty acid mixtures were each approximately 100mM palmitic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, and stearic acid. A non-limiting exemplary method for the preparation of this medium has been described elsewhere. For example, Kubota H, Reid LM, Proc. Nat. Acad. Sci. (USA) 2000;97:12132-12137, the disclosure of which is , the entirety of which is incorporated herein by reference.
[0069] In some embodiments, therefore, these patch graft conditions are This is contrary to the routine use of media supplemented with serum (typically 2-10%). Essential signaling molecules required to promote biological processes (e.g., proliferation, differentiation) Hormones, growth factors, and cytokines) have long been added to the diet. In some embodiments, to avoid differentiation of cells and / or to inhibit the production of secreted MMPs in particular No serum was included to avoid inactivation or inhibition.
[0070] As used herein, the term "effective amount" or "effective amount" refers to a disease condition or An effective amount refers to an amount sufficient to treat a disease or condition (e.g., liver or pancreatic disease). Such delivery may be in one or more administrations, applications or doses. Many variables, including the period for which the different dosage units are used, the bioavailability of the composition, the route of administration, etc. However, the specific amount of the composition for any particular patient will depend on the number of doses used. The activity of the specific drug being administered, the patient's age, weight, health, sex, and diet, time of administration, excretion Depending on the amount of excretion, the combination of compositions, the specific disease being treated (e.g., liver or pancreatic disease), It is understood that this will depend on a variety of factors, including severity, and mode of administration.
[0071] The terms "equivalent" or "bioequivalent" refer to a specific molecular, biological, or cellular Used interchangeably when referring to materials, the materials that are Intended to be of the same sex.
[0072] As used herein, the term "expression" refers to the transcription of a polynucleotide into mRNA. The process by which the transcribed mRNA is subsequently produced into peptides, polypeptides, The process by which a polynucleotide is encoded in genomic DNA and translated into a protein. If derived, expression may include splicing of the mRNA in eukaryotic cells. Expression levels are determined by measuring the amount of mRNA or protein in a cell or tissue sample. Further, the expression levels of the genes may be determined by the expression profile of a particular sample. It may be decided to establish a file.
[0073] As used herein, the term "functional" means to achieve a particular, specific effect. may be used to modify any molecular, biological, or cellular material in order to obtain.
[0074] As used herein, the term "gene" refers to a gene that encodes an RNA (e.g., an mRNA). RNA molecules, whether coding (e.g., ncRNA) or non-coding (e.g., ncRNA) The term "nucleotide sequence" is meant to broadly include any nucleic acid sequence transcribed into a nucleic acid molecule.
[0075] As used herein, the term "generate" and its synonyms (e.g., generating "produced," "produced," "produced," etc.," when referring to the method steps that result in the organoids of the present disclosure , "produce" and their synonyms.
[0076] The term "isolated" as used herein means substantially free of other materials. The term refers to any molecule or biological or cellular material not containing
[0077] The terms "nucleic acid," "polynucleotide," and "oligonucleotide" are used interchangeably. It is used in the synthesis of either deoxyribonucleotides or ribonucleotides or their analogues. A polynucleotide refers to any polymeric form of nucleotides of any length. They can have original (3D) structure and can perform any function, known or unknown. Non-limiting examples of polynucleotides include: genes or gene fragments (e.g., promoters, promoter sequences, and promoter sequences). lobe, primer, EST or SAGE tag), exon, intron, message mRNA, transfer RNA, ribosomal RNA, RNAi, ribozyme, cD NA, recombinant polynucleotide, branched polynucleotide, plasmid, vector, any isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers.
[0078] Polynucleotides may contain modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, it may be used prior to or after assembly of the polynucleotide. Modifications to the nucleotide structure can be added later. The sequence of nucleotides is The polynucleotide may be interrupted by non-nucleotide components. The term can also refer to a double-stranded molecule, which can be further modified after polymerization, such as by attachment of Unless otherwise specified or required, the term "polynucleotide" refers to both single-stranded and non-polynucleotide molecules. Any embodiment of this technology may comprise a double-stranded form and a double-stranded form known or predicted to be composed of The term encompasses both the two complementary single-stranded forms of each of which is shown in FIG.
[0079] The terms "protein," "peptide," and "polypeptide" refer to two or more subunits. To mean a compound of the unit amino acid, amino acid analog, or peptidomimetic, Used interchangeably in the broadest sense, the subunits are linked by peptide bonds. In another embodiment, the subunits may have other linkages, e.g., esters, ethers, etc. A protein or peptide may be linked by a linker. This limits the maximum number of amino acids that may make up a protein or peptide sequence. As used herein, the term "amino acid" includes glycine and D and Natural and / or synthetic derivatives, including both optical isomers, amino acid analogs, and peptidomimetics. The term refers to either unnatural or synthetic amino acids.
[0080] As used herein, the terms "subject" and "patient" are used interchangeably. is intended to mean any animal. In some embodiments, the subject is a mammal. In some embodiments, the mammal may be a bovine, equine, porcine, canine, feline, In some embodiments, the subject is a human. .
[0081] As used herein, the term "tissue" refers to any tissue from a living or dead organism. derived from or designed to mimic bodily tissue or living or dead organisms Any tissue designed to be healthy, ill, or injured by trauma. The terms "natural tissue" or "biological tissue" and Modification, as used herein, refers to anything that has not been altered since its natural state or origin in an organism. "Micro-organs" refer to living tissues that exist in a modified state. This refers to the "engineering organization" segment.
[0082] A biological tissue is any single tissue (e.g., a collection of cells that may be interconnected) or a part of an organism. It may include a group of tissues that make up an organ or part or region of the body. The material may include, for example, lung tissue, skeletal tissue, and / or muscle tissue. The tissue may be a composite structure such as that found in areas of the body including the breast. These include the liver, pancreas, bile duct, lungs, intestines, thyroid gland, thymus gland, bladder, kidneys, prostate, uterus, and breast. Atrium, skin and subcutaneous tissue, brain, spinal cord, blood vessels (e.g., aorta, iliac vein), heart, muscle, and any combination thereof.
[0083] As used herein, "treating" a disease in a subject or "treatment" of a disease refers to ) The onset of symptoms or disease in a subject who is predisposed to a disease or who has not yet exhibited symptoms of the disease (2) to inhibit or arrest the onset of a disease; (3) to prevent the onset of a disease. "Ameliorating or reversing the symptoms of a disease or disorder" as understood in the art. As used herein, "treatment" means any procedure for obtaining a beneficial or desired result, including a clinical result. The beneficial or desired outcome for the purposes of this technique may be detectable or undetectable. Alleviation or improvement of one or more symptoms, or a decrease in the severity of a condition (including a disease) stabilization (i.e., not worsening) of a condition (including a disease); delay or slowing of a condition (including disease), progression, improvement, or alleviation of a condition (including disease), status, and remission (partial The term "therapeutic agent" may include, but is not limited to, one or more of the following:
[0084] Abbreviation AFP, alpha-fetoprotein; ALB, albumin; BTSC, biliary stem cell; CD, Common determinant; CD44, hyaluronan receptor; CD133, prominin; CFTR, cystic Fibrosis transmembrane conductance regulator; CK, cytokeratin protein; CXCR4, CX C-chemokine receptor 4 (also called fusin or CD184; also called platelet factor 4) EGF, epidermal growth factor; ELSMC, hemangioblasts and their progeny, vascular endothelium Early lineage stage mesenchymal cells consisting of precursors of epithelial and astrocytes; EpCAM, epithelial cell adhesion Molecules; FGF, fibroblast growth factor; HB, hepatoblast; HGF, hepatocyte growth factor; HpS C, hepatic stem cells; KM, Kubota's medium, a serum-free medium designed for endodermal stem cells; KRT, cytokeratin gene; LGR5, leucine-rich ribonucleotide that binds to R-spondin pEt-containing G-protein-coupled receptor 5; MMP, extracellular matrix dissolution, cell migration Matrix metalloproteinases, a large family of proteinases involved in migration and regeneration reactions NANOG, a transcription factor critically involved in self-renewal; NCAM, a transcription factor involved in the repair of damaged cells Transcellular adhesion molecule; NIS, sodium / iodide symporter; OCT4, (octamer binding Transcription factor 4) a gene expressed by stem cells, also called POU5F1 (PO U domain, class 5, transcription factor 1); PDX1, a transcription factor important in pancreatic development; Pancreatic and duodenal homeobox 1;PBG, stem cell niche of bile duct stem cells, bile duct Peripheral gland; SALL4, a Sal-like protein found to be important for stem cell self-renewal protein 4; SOX, Sry-related HMG box; SOX2, embryonic stem cell and A transcription factor essential for the self-renewal or maintenance of pluripotency of stem cells. SOX9, endodermal tissue ( Transcription factors associated with liver, intestine, and pancreas; SOX17, a transcription factor essential for hepatic differentiation VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
[0085] Methods of carrying out the present disclosure In the examples provided herein, Applicants have demonstrated that cells are either stem cells or mature cells. Patching, a novel method for transplanting cells into organs with engineered features, Applicants establish a raft of bile duct stem cells, which are the precursors of both the liver and pancreas. We demonstrate these methods herein by using grafts of BTSCs to transplant into the liver or pancreas. The host used to develop these methods is the porcine species, Sus scrofa These are exploratory medicine, surgical models, and procedural training. It is the primary animal species used in the study and is increasingly being used as an alternative to monkeys in preclinical studies. .
[0086] An exemplary success has been the organogenesis of biliary stem cells (BTSCs), the precursors of the liver and pancreas. The implant is combined with early lineage stage mesenchymal cells (ELSMCs) and placed in a soft (approximately 100 Pa) hyaluronic acid bath. This was achieved by including the organoids in an HA hydrogel. The serosal side of the HA hydrogel was impregnated with a more rigid HA hydrogel (approximately 700 Pa). The grafts are placed on a silk lining (mesh material) and surgically attached to the surface of the liver or pancreas. Within a week, the grafts had grown to the organ capsule and adjacent tissue, and optionally inducing reconstitution of distal parenchymal tissue, followed by donor and host cell combination. By two weeks, the donor cells were producing either hepatocytes (albumin) or pancreatic islets (β-cells). After three weeks, hyaluronan was removed and The histology of the organ capsule and normal tissue was restored. The engraftment / migration / integration process was The mechanism is dependent on multiple membrane-associated and secreted matrix metalloproteinases expressed by the It was found to exist.
[0087] The results of these examples contrast with previous efforts to transplant cells from solid organs into internal organs. In contrast, transplantation is achieved by either direct injection or delivery of cells via vascular routes. (Bhatia et al., Lanzoni et al., Weber et al. (See reviews by Fischer et al.) Previous implantation methods have been associated with potentially life-threatening embolic events. A small number of cells engrafted with significant levels of ectopic cell distribution, at risk of glaucoma. These issues have led to minimal or no use of cell therapy for internal solid organs. do not have.
[0088] The patch graft strategy offers an alternative method for cell therapy, allowing the delivery of adequate cell numbers and tissue The present invention provides a method for the preparation of a medicament for the treatment of cancer, the use of which is disclosed in Japanese Patent Application Laid-Open No. 2003-2004. The biomaterials and linings used maintain some or all of the donor cells in an immature state. This supports the idea that the relevant repertoire of MMPs can be generated and demonstrates safety. A common cause of failure was any factor that led to differentiation of the donor cells. Although not intended to be limiting, the present invention provides a method for providing the graft with cells that naturally produce the required MMPs. Instead, purified MMPs can be produced using recombinant expression systems or other genetic modification techniques. Implant biomaterials can be incorporated and / or cells can be transformed to express MMPs. In such an embodiment, the polypeptide may be integrated via the construct and secreted. The combination of engineered or transduced MMPs includes the expression profiles provided in the Examples below. should include those specified in the profile.
[0089] Composition of patch graft The embodiments disclosed herein involve the use of a single population of cells or two or more populations (e.g., autologous or donor cells, which may be allogeneic) and a source of MMPs, and a layer containing the graft at the target site. and a backing comprising a biocompatible, biodegradable material that can be used to connect the In some embodiments, the population or cell population is a population of epithelial cells and and a population of mesenchymal cells. In some embodiments, the population of cells is These must be maintained in a particular state or "lineage stage" by This means that the cells will not differentiate or mature further until they reach the target cell type. This can be achieved by balancing variables related to the medium used and the quality of the substrate. Each of these aspects is described in more detail below.
[0090] Without wishing to be bound by theory, patch grafts are made by: (1) providing supportive mesenchymal stem / progenitor cells; In media and hydrogels containing appropriate MMPs, which do not lead to differentiation of the subpopulation Optimal cell population or mixture of cells - e.g., cells that produce membrane-bound and / or secreted MMPs (2) transplantation into the target site Suitable for connecting the pieces and preventing cells within the graft from migrating away from the target site into the lining It is believed that success can be achieved by using backing and.
[0091] Exemplary Cells Without wishing to be bound by theory, the cells may be embryonic stem (ES) cells, induced pluripotent stem (iP) cells, S) cells, including committed stem cells, committed progenitors, TA cells, or mature cells. However, in certain embodiments, the MMP source is a pacing Therefore, what is intended in this specification is that A cellular source of MMPs for use in Tigraft. Such cellular sources include membrane-bound and and / or early lineage stages capable of expressing secreted matrix metalloproteinases Non-limiting examples of such early lineage stages include early lineage stage mesenchymal stem cells. The cells are endoscopy-specific lymphocytes (ESMLCs).
[0092] In some embodiments, the transplanted cells are epithelial cells in combination with mesenchymal cells. In some embodiments, the epithelial cells comprise epithelial stem cells. Epithelial cells include committed and / or mature epithelial cells. In some embodiments Committed and / or mature epithelial cells include mature parenchymal cells. In one embodiment, the mature parenchymal cells are one or more of hepatocytes, bile duct cells, or pancreatic islet cells. In some embodiments, the mesenchymal cells comprise ELSMCs. Morphologically, ELSMCs are classified as hemangioblasts, precursors of vascular endothelium, precursors of astrocytes, and M In some embodiments, the epithelial cells and mesenchymal cells include one or more of the following: , are lineage stage partners of each other. In some embodiments, epithelial cells and mesenchymal cells are not lineage-stage partners of each other. For example, In some embodiments, the epithelial cells are mature cells. In this state, the mesenchymal cells are ELSMCs.
[0093] In some embodiments, at least one of the epithelial cells and the mesenchymal cells is a donor cell. In some embodiments, the donor is a subject in need of a tissue transplant. In some embodiments, the donor is a healthy cell source for tissue transplantation. In terms of morphology, at least one of the epithelial cells and the mesenchymal cells is intended for patch grafting. In some embodiments, all cells (i.e. , epithelium and mesenchyme) are autologous to the intended recipient of the graft. In this embodiment, the donor of the cells may be other than the recipient (allograft). or a subject with a diseased or dysfunctional organ (self), The cells are then extracted from parts of the organ that are not diseased or dysfunctional and / or are then transplanted to restore function. It is obtained from cells that have been genetically modified to
[0094] In another embodiment, the mesenchymal cell is a lineage stage partner of the donor cell, e.g., or a corresponding lineage stage. In another embodiment, the mesenchymal cells are at the appropriate lineage stage of the donor cells. Mesenchymal lineage-stage cells are not the only potential partners. Hemangioblasts, endothelial cells, and / or stellate early lineage stage precursors of cells, mesenchymal stem cells, vascular endothelial or astrocytes, or any of these cells It may be a derivative of the population.
[0095] For stem cell transplantation, epithelial cells are transplanted into the host cell network by transferring them to their original lineage-stage partner mesenchymal cells (angioblasts). and / or endothelial or astrocyte precursors). For epithelial cells, suitable partners are hemangioblasts and / or astrocytes and vascular The present invention relates to a method for the treatment of endothelial cell-derived endothelial cells (ECs) comprising the steps of: We have demonstrated that stem cell (MSC) preparations can be used in combination with adult cells to achieve engraftment. In some embodiments, certain MSCs may be preferred over other MSCs. Without wishing to be bound by theory, it is possible that cell culture can be minimized and cell differentiation promoted. By choosing cell combinations that avoid potential serum and matrix components It is believed that the graft can be optimized by using the paracrine model. The epithelial-mesenchymal relationship is important because IL-1 signaling supports the production of MMPs. It is further understood, however, that mature epithelial cells in combination with mature vascular endothelium may be They survive and become functional cells within the endothelium, but do not engraft. Thus, mature epithelial cells are not associated with mature stroma. When combined to form a graft, the resulting graft may become fibrotic. expensive.
[0096] For the treatment of diseased or dysfunctional organs, cells are derived from a non-recipient donor (allogeneic may be derived from a human (human) organ (transplant) or may be autologous, and thus may be a disease or function-specific Cells from a subject with a dysfunctional organ may be cultured in a manner similar to that used for cultures of organs that are not diseased or dysfunctional. from parts of the genome and / or from cells that have been genetically modified to restore function It is obtained.
[0097] To establish a model system to study disease, cells are grown in a diseased, experimental host. It may be implanted onto / into normal tissue.
[0098] In some embodiments, the epithelial cells are combined with supporting mesenchymal cells, optionally ELSMCs. These organoids are stem cells that are optionally self-organizing. The ganoids may be embedded in or contained within a hyaluronan hydrogel. Stem and / or progenitor cells of the present disclosure include, for example, embryonic stem cells (ESCs), embryonic germ cells (EGCs), (EGC), induced pluripotent stem cells (iPSC), pancreatic stem cells (PSC), hepatic stem cells (Hp SC), bile duct stem cells (BTSC), hepatoblasts, pancreatic ductal precursors, committed pancreatic progenitor cells, or any stem and / or progenitor cells known in the art, including committed liver progenitor cells. In some embodiments, the cell population may include pancreatic stem cells, hepatic stem cells, or progenitor cells. cells, bile duct stem cells (BTSCs) or Brunner's gland stem cells. In embodiments, the cells include only multipotent progenitor subpopulations, such as hepatoblasts or pancreatic ductal progenitor cells. Alternatively, the graft may generate committed, unipotent precursors (e.g., hepatocellular or bile ductal). In another embodiment, the cells can include islet or acinar committed progenitor cells. The cells include a mixture of stem cells and progenitors.
[0099] When adult epithelial cells are used, they are mixed with ELSMCs in an appropriate ratio to form the biomaterial. The ratio of the cell mixture may be determined to mimic the target tissue. Alternatively, or additionally, the ratio can be determined through self-organization of the organoids. The organoids or cell mixtures are then placed in a soft graft medium such as a soft hyaluronan hydrogel. In the case of stem cell grafts, the stem and / or progenitor cells of the present disclosure are embedded in a body material. For example, embryonic stem cells (ESCs), embryonic germ cells (EGCs), induced pluripotent stem cells (iPSCs), ), Brunner gland stem cells (BGSC), biliary stem cells (BTSC), pancreatic stem cells (PSC) , hepatic stem cells (HpSCs), TA cells (e.g., hepatoblasts or pancreatic ductal precursors), and Committed, unipotent precursors (e.g., committed pancreatic precursors or hepatocytes or bile duct The present invention may include any stem and / or progenitor cells known in the art, including stem and / or progenitor cells (cell precursors). In some embodiments, the cell population comprises only stem cells. In other embodiments, the cells comprise a mixture of stem cells and progenitors, or Alternatively, the cells may contain a mixture of stem / progenitor cells and more mature cells. (e.g., hepatocytes, cholangiocytes, intestinal cells, pancreatic islets) and ELSMCs.
[0100] Stem and / or progenitor cells may be identified by any method known to those of skill in the art. Non-limiting examples include assays that define self-renewal capacity, morphological analysis, genetic Assays for pluripotency, including gene and / or protein expression and cell surface markers In some embodiments, stem and / or progenitor cells are used in combination. , which express genes encoding early stage hepatocyte lineage cells (e.g., SOX17, HNF-4 alpha, HNF6, HES1, CK19) and at least one marker indicative of early stage pancreatic cell lineage (e.g. At least one marker indicating a gene expression level (e.g., PDX1, PROX1, NGN3, HNFβ1) For example, stem and / or progenitor cells, particularly BTSCs, express SOX9, SOX17, PDX1, CD133, NCAM, Sonic Hedgehog (SHH), sodium iodide Various isoforms of the neurotransmitter symporter (NIS), LGR5, LGR6, EpCAM, and CD44 form, CXCR4, and various pluripotency genes (e.g., OCT4, SOX2, NANOG, KLF4, KLF5, SALL4, BMi-1), or any combination thereof The proteins can be identified by their combined expression.
[0101] In some embodiments, stem and / or progenitor cells are derived from parental lineages of the liver and pancreas, etc. Thus, the hepatocytes express at least one marker indicative of the early parental cell lineage. Both lineages and pancreatic lineages (e.g., SOX9, LGR5 / LGR6, EpCAM, C D133, CK19), and those shared by liver lineages (e.g., SOX17, HNF-4-alpha, HNF6, HES1), and one for early stage pancreatic cell line Express one for each lineage (e.g., PDX1, PROX1, NGN3, HNFβ1). For example, stem and / or progenitor cells, particularly BTSCs, express SOX9, SOX17, PDX1 , CD133, NCAM, Sonic hedgehog (SHH), sodium-iodide symporter NIS, LGR5, LGR6, EpCAM, and various pluripotency genes (e.g. (e.g., OCT4, SOX2, NANOG, KLF4, KLF5, SALL4, BMi-1) or any combination thereof.
[0102] Generation of mature cell types Stem and / or progenitor cells can also be differentiated into more mature cell types, if desired. This can be accomplished in vitro by spontaneous and / or directed differentiation. Directed differentiation can be achieved by using defined media, genetically modifying stem and / or progenitor cells, The method may include expressing a gene of interest by a gene encoding a target gene, or a combination thereof.
[0103] Non-limiting examples of defined media for differentiating cells include those for differentiation of endodermal stem cells to an adult fate. One example is hormone-defined medium (HDM), which is used for differentiation of . Adding an inhibitor to promote the differentiation of normal hepatic or biliary stem cells to specific adult fates Hormone-defined media (HDM) can be generated that contain at least 0.6 mM serum. Top concentration: 1 nM triiodothyronine (T3), 10 -12M copper, 10 nM hydrochloride lutizone, and 20ng / ml basic fibroblast growth factor (bFGF) Hepatocytes (HDM-H) vs. Cholangiocellular (HDM-C) vs. Pancreatic Additional medium conditions required for selective production of islets (HDM-P) are as follows: Cage: 1) HDM-H: 7 μg / L glucagon, 2 g / L galactose, 10 ng / ml supplemented with 20ng / ml epidermal growth factor (EGF) and 20ng / ml hepatocyte growth factor (HGF); 2) HDM-C: 20ng / ml vascular endothelial growth factor (VEGF) and 10n Further supplementation with 300 mg / ml HGF; and 3) HDM-P: Prepared without glucocorticoids, containing 1% B27, 0.1 mM adenosine Scorbic acid, 0.25 μM cyclopamine, 1 μM retinoic acid, 20 ng / ml Further supplementation with FGF-7 for 4 days followed by 50 ng / ml of exendin-4, and The medium was then supplemented with 20 ng / ml HGF and induction continued for an additional 6 days.
[0104] The HDM provided herein includes a combination of Wnt signaling, epidermal growth factor (EGF), fibroblast Growth factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), Transforming growth factors (TGFs), nerve growth factors (NGFs), neurotrophic factors, various insulins, Tarleukin, leukemia inhibitory factor (LIF), vascular endothelial growth factor (VEGF), platelets derived growth factor (PDGF), stem cell factor (SCF), colony stimulating factor (CSF), GM -CSF, erythropoietin, thrombopoietin, heparin-binding growth factor, IGF-binding factor Examples of suitable therapeutic agents include, but are not limited to, ribozymes, ribozymes, and / or placenta growth factor.
[0105] The HDMs provided herein include interleukins, lymphokines, monokines, cytokines, and inflammatory cytokines. These include knee stimulating factors, chemokines, interferons, and tumor necrosis factors (TNFs). The antibodies can be supplemented with cytokines, including but not limited to cytokines.
[0106] Applicants believe that hyaluronan may affect stem and / or progenitor cells, and may mediate cell attachment and They express factors that regulate important cell adhesion molecules required for cell-cell interactions and are involved in stem and / or Progenitor cells internalize these attachment factors following cell suspension preparation, cryopreservation, or transplantation. Non-limiting examples of such adhesion factors include integrins. Integrins bind cells to extracellular matrix proteins in the basement membrane and to other cell surfaces. Ligands and heterodimeric transmembrane glycoproteins that function to attach soluble ligands Integrins are a large family of proteins. They are classified into two groups: large and small, called α and β. The subunits form an αβ heterodimer, which is found in humans at low At least 18 α and 8 β subunits are known, forming 24 heterodimers. In some embodiments, stem and / or progenitor cells produce higher levels of insulin. Tegrin subunits, such as ITGα1, ITGα2, ITGα2B, ITGα3, I TGα4, ITGα5, ITGα6, ITGα7, ITGα8, ITGα9, ITGα1 0, ITGα11, ITGαD, ITGαE, ITGαL, ITGαM, ITGαV, I TGαX, ITGβ1, ITGβ2, ITGβ3, ITGβ4, ITGβ5, ITGβ6 In one preferred embodiment, the stem and / or stem / stem cells express ITGβ, ITGβ7, and ITGβ8. Alternatively, progenitor cells express higher levels of integrin subunit beta 1 (ITGβ1). and / or express integrin subunit beta 4 (ITGβ4). da Y. et al. (2007) Genome Biol. 8(5):215.
[0107] In some embodiments, the stem and / or progenitor cells of the present disclosure are naturally occurring stem and progenitor cells. and / or progenitor cells, unmodified stem and / or progenitor cell integrin subunits At least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% %, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95 %, 100%, or 200% greater expression of integrin subunits. Increased integrin subunits may be required for stem and / or allows progenitor cells to attach, form cell-cell interactions, and differentiate stem and / or progenitor cells. It is intended to help prevent internalization.
[0108] MMP MMPs are one of the major factors promoting engraftment and integration. isoforms (at least 28, 24 known in pigs) Some of these are secreted (e.g., MMP1, MMP2, MMP7, MMP9), and some are associated with the cell membrane (e.g., MMP14, MMP15). Without wishing to be bound by theory, However, it is believed that the mixture of these is necessary for engraftment, especially for the mixture of secretory types. All cells produced both secreted and membrane-bound forms in varying amounts, but stem / progenitor The body produces very high levels of secreted MMPs. Engraftment is achieved by the secretion of these MMPs (and membrane-bound These cell sources rely on As an alternative, applicants may refine the MMP. Incorporating recombinant DNA into the graft biomaterial and / or genetically engineering cells within the graft , is intended to produce the necessary MMPs.
[0109] Cells are a source of multiple matrix metalloproteinases (MMPs), ideally cellular As long as there is a cellular source, optionally either secreted or membrane-bound, successful engraftment can be achieved. MMPs are produced by all cell types, both immature and mature. However, it remains to be seen which isoforms are produced and at what levels of specific MMPs they occur. The representative secreted forms are MMP1, MMP2, MMP7 and MMP9. Representative membrane-bound forms include MMP14 and MMP15. The highest production of secreted MMPs was by early lineage stage cells, stem cells and early progenitors. The graft biomaterial has been shown to be a potent source of both epithelial and mesenchymal cells. Supporting forces dissolve the encapsulation around the organ or tissue, releasing multiple extracellular matrix components. These multi-form matrix metastases allow cell migration by lytic means of multiple forms. It produces MMPs (maltodextrinsic proteinases).
[0110] More generally, matrix metalloproteinases (MMPSs) act on the extracellular matrix. Involved in the degradation and regulation of cellular components, as well as in transplantation, invasion, and endothelial cell proliferation during normal and pathogenic processes. , a large family of zinc-dependent proteinases involved in angiogenesis, vasculogenesis, and migration. Matrixin, Adamalaisin, Astasin, Seralisin There are at least 28 isoforms, including scin, which play a role in placental implantation. It is characterized by normal processes such as cancer progression, as well as pathogenic processes such as cancer invasion and metastasis. It has come.
[0111] The studies described herein demonstrate that MM contributes to the engraftment, migration and integration of transplanted cells. We provide evidence for an entirely new role for P. cerevisiae in both epithelial and mesenchymal stem / progenitor They express multiple MMP isoforms that are particularly potent in these roles. The expression of one or more potent stem / progenitor cell-associated MMPs was attenuated, slowing down the invasion and migration processes. Adult cells also express MMPs, primarily membrane-bound (MT-MMPs), which The MMPs are involved in plasticity processes, but are not involved in the large-scale engraftment and integration of cells into tissues. However, there is some synergy between MT-MMPs and secreted forms. The net result of this realization is that the implant biomaterial, backing and other conditions, among other properties, In particular, we have optimized the expression of various MMPs, including secretory MMPs, to enhance the transplantation and migration process. Therefore, the transition must be able to occur. Factors that promote differentiation of transplanted cells also attenuate the complex MMP response. Factors to be avoided include serum (which promotes differentiation), soluble signals that promote differentiation (e.g. e.g., certain growth factors, cytokines, and hormones; extracellular matrices that promote differentiation; The proteins are composed of collagen, adhesion molecules, highly sulfated glycosaminoglycans / proteins, and proteoglycans); and mechanical forces that contribute to graft stiffness (viscoelastic properties that promote differentiation) This means that the following is included:
[0112] In some embodiments, one or more cells in the mixture are secretory and / or The secreted MMPs are optionally secreted from one or more epithelial cells or MMPs can be naturally produced by mesenchymal cells or, optionally, engineered for MMP production. Transformation of one or more epithelial or mesenchymal cells with expression vectors or gene editing In some embodiments, stem / progenitor MMPs that naturally secrete MMPs may be produced by conversion. Variables that attenuate MMP expression, including but not limited to cell populations, optionally membrane-bound and / or secreted MMP expression is regulated within the patch graft. Typical examples include serum supplementation to culture media or graft biomaterials, addition of epithelial and / or mesenchymal cells, Hormones or other soluble signals that affect cell differentiation, oxygen levels (anaerobic conditions) (because higher oxygen levels promote differentiation while keeping the cells immature) and graft material stiffness (as stiffness, or mechanical forces such as shear and compression, may promote differentiation) Variables that result in stem / progenitor cell maturation include, but are not limited to:
[0113] For stem cell grafts, both the epithelial and mesenchymal cell partners are optimal stem cells or precursors, as both provide contributions of multiple types of MMPs. For engraftment of adult cells, either epithelial or mesenchymal cells may be membrane-bound and / or should optimally provide a cellular source of secreted MMPs. For example, if desired, membrane-bound MMPs and / or use ELSMCs as a cellular source of secreted MMPs. Grafts in which both endothelial and mesenchymal cells are mature cell types have not been successful. In the latter case, epithelial cells are likely to survive, proliferate and function, but do not engraft. In cases of poor vascularity, the graft is more likely to become fibrotic.
[0114] In summary, both epithelial-mesenchymal cell partners are stem / progenitor or epithelial cells. Alternatively, engraftment will occur if at least one of the mesenchymal cells is a stem cell. For example, optionally, matrix-bound and / or matrix metalloproteinases (MM We used ELSMCs as a source of secreted isoforms of P or their When purified / recombinant forms of MMPs are delivered to the graft biomaterial, they are suitable for patch grafts. Early lineage stage mesenchymal cells (ELSMCs) are precursors of hemangioblasts, endothelial cells, and early lineage stage the vascular endothelium of the first stage, astrocyte precursors, early stage astrocytes, or mesenchymal stem cells (MSCs), Or it could be a mixture of these.
[0115] Thus, what is contemplated herein is at least one cell population (e.g., For use as a patch graft containing a source of epithelial and mesenchymal cells and MMPs (i.e., optionally supported by the conditions of the medium and / or hydrogel) Membrane-bound and / or secreted matrix metalloproteinases (MMPs) (an early lineage stage cell population with the capacity to express
[0116] Media components For use in combination with the sources of cells and MMPs disclosed herein, any in culture medium (containing nutrients, vitamins, salts, etc.) for stem / progenitor proliferation and / or Insulin, transferrin / Fe and lipids, known to be beneficial for survival Important soluble factors such as MMPs can be used. Maturation is characterized by the decreased or attenuated expression of MMPs. It is necessary to avoid all factors that cause cells to mature. These factors include serum, soluble signals that promote differentiation, extracellular matrix components that promote differentiation, and and stiffness or mechanical force (compression, abrasion). Non-limiting examples of such media include Kubo It is a culture medium for the growth of bacteria.
[0117] Thus, contemplated herein is at least one cell population and an MMP. and a composition for use as a patch graft that contains a source of Supported by the results, membrane-bound and / or secreted matrix metalloproteinases (MM P), or an early lineage stage cell population capable of expressing purified MMPs). A non-limiting example of a suitable medium is Kubota's medium. Other stem cell media, such as those used for iPS cells, contain cells that are the source of MMPs. Unless they contain soluble or matrix signals that promote differentiation of To the extent that it exists or is included from another source, it may be appropriate as well.
[0118] Hydrogel The patch graft comprises one or more hydrogel components. Biomaterials capable of forming hydrogels, or similar insoluble complexes (e.g., non- Collagenous gelatin) is a type of collagen that is made up of hyaluronan, thiol-modified hyaluronan, and other glycosaminoglycans. The trigger for coagulation is the matrix Any factor that induces cross-linking or gelation of the components of the gelatinous composition. The crosslinker can be poly(ethylene glycol) (PEG) or PEG-diacrylate. PEG-2-(D-aspartate) hydrogel, or a disulfide-containing derivative thereof. In particular, biomaterials contained in hydrogels are used in patch graphs such as ELSMC. The ability of one or more of the disclosed cell populations to support stemness for use in The selection should be made according to the criteria.
[0119] Matrix components that support the maintenance of stemness can be used, but components that promote differentiation cannot. Non-limiting examples of supporting components include hyaluronan or non-sulfated (or minimally sulfated) These include oxidized glycosaminoglycans, which have various levels of stiffness (optional viscosity). These are particularly useful because they can be modified and "tuned" to have different elastic properties (measured as elasticity). Thus, in some embodiments, the cell population, which is optionally an isolated cell of a visceral organ, comprises cells hosting Typically, the biomaterial is allowed to solidify ex vivo prior to introduction, or alternatively, the biomaterial is allowed to solidify ex vivo prior to introduction. It can be injected as a body material and allowed to clot in vivo.
[0120] Very soft versions of the hydrogel (e.g., about 100 Pa) allow the donor cells to grow undifferentiated. Ideal for keeping the product in a ripe state. Use a more rigid version (e.g. >500 Pa). This allows cells to mature sufficiently to shut off MMP production and block migration. In addition, the stiffer version can also minimize adhesions from adjacent tissue. In certain embodiments, the population of cells and the source of MMPs, optionally in combination with another cell population (i.e. They express membrane-bound and / or secreted matrix metalloproteinases (MMPs). a population of cells at an early lineage stage that has the ability to
[0121] Without wishing to be bound by theory, the morphology of the extracellular matrix found in the amniotic membrane is Therefore, amniotic membrane is a hydrogel that can keep donor cells immature. and, optionally, as an alternative biocompatible, biodegradable material. It has been done.
[0122] In particular, materials known to induce maturation include, but are not limited to, type I collagen. These materials include certain components derived from the mature extracellular matrix, such as collagen. comprises cells, hydrogel, medium, backing, and / or any further components, All elements of the patch graft, including but not limited to, should be excluded.
[0123] Thus, contemplated herein is at least one cell population and an MMP. A composition for use in a patch graft that contains a source of Membrane-bound and / or secreted matrices supported and contained in hydrogels an early lineage stage cell population that has the ability to express metalloproteinases (MMPs).
[0124] As mentioned above, stiffness can drive the ability of cells to differentiate. The hydrogel may have an effect on the ability of cells to migrate into the organ. When necessary, the cell-containing hydrogel may be optionally Sufficient to permit migration of the cells into or away from the patch graft. Non-limiting examples of such viscoelastic properties include, but are not limited to, a viscosity of about 5 Viscoelasticity in the range of 0 to about 100 Pa or about 250 Pa, for example at least about 50 Pa, At least about 100 Pa, at least about 150 Pa, at least about 200 Pa, at most about 2 50 Pa, up to about 200 Pa, up to about 150 Pa, up to about 100 Pa, and / or or any individual value therebetween, including but not limited to, about 50 Pa, about 100 Pa, Examples of the pressure include about 150 Pa, about 200 Pa, and about 250 Pa.
[0125] Without wishing to be bound by theory, it is believed that the cells are transported from the patch graft to the target organ or tissue. As they move, they become attached to or move away from the hydrogel that coats them. The hydrogel is thought to move with the cell. Shields cells from signals in the tissue microenvironment that impart This promotes cell migration through the parenchyma. As acetylcholine is gradually broken down and removed, cells begin to differentiate or mature, becoming adult cells. Start the function.
[0126] How to generate organoids Without wishing to be bound by theory, it is believed that early stage lineage cells are It has been shown that when these are incorporated into the Organization may optionally include early lineage stages of both epithelial and mesenchymal cells.
[0127] Thus, provided herein is a method for forming organoids, the method comprising: Cultivate the mixture of epithelial and mesenchymal cells in the presence of culture medium in a vessel suitable for tissue culture. removing mature cells attached to the surface of the vessel by panning; and removing the mature cells by removing the culture medium. and recovering self-organized organoids from the cell suspension. and / or consisting essentially of organoids. The composition is disclosed herein.
[0128] In some embodiments, the procedure includes serum-free conditions and o C. In a normal culture dish To selectively and rapidly (15-30 min) remove mature cells by attachment Even under these conditions, mature cells are able to express a variety of maturation vectors that allow cell attachment. This panning process is repeated multiple times (e.g., 4 After 50 min, the cell suspension is enriched for early lineage stage cells. Transfer to adherent dishes and re-transfer into serum-free medium designed for early lineage stage cells for 37 0 C Place in an incubator overnight. This condition is suitable for the differentiation of lineage-matched epithelial and mesenchymal cells. The organoids are composed of early stage epithelial cells (ES cells) and cells, iPS cells, committed stem cells, TA cells, precursors) and early stage mesenchymal cells (vascular This can be obtained by mixing the following: blastocytes, endothelial precursors, and astrocyte precursors .
[0129] Mixtures of adult epithelial cells and mature mesenchymal cells, and mature epithelial cells and early lineage stage mesenchymal cells Chimeric mixtures of ELSMCs do not usually generate organoids, but they are useful for transplantation of biomaterials. It can be used as a mixture of cells in suspension. Mature epithelial cells (e.g., hepatocytes, bile duct cells, pancreatic islets, acinar cells, enterocytes, etc.) to mature mesenchymal cells (e.g., vascular endothelium, stellate cells, stromal cells When combined with fibroblasts (fibroblasts, myofibroblasts), the mixture promotes implantation into the target site or organ. They do not integrate successfully, but do result in persistence at the surface of the organ or tissue. Adult and stem / When a chimeric mixture containing precursors (e.g., mature hepatocytes with hemangioblasts) is used In this case, engraftment occurs because there is a source of MMPs that allows for cell engraftment and migration.
[0130] In another embodiment, isolated cells of an internal organ are cultured in a biomaterial prior to introducing the cells into a host. It can be allowed to solidify ex vivo or, alternatively, injected as a fluid material and transferred in vivo. Preferably, the cells are derived from diseased or dysfunctional tissue or It is introduced into the vicinity via injection or implantation onto / into the tissue, or by appropriate surgical procedures. The implant may be introduced using surgical techniques.
[0131] In another embodiment, a biomaterial capable of forming a hydrogel, or similar insoluble composite material, The conjugate may be hyaluronan, thiol-modified hyaluronan, or other glycosaminoglycans. The trigger for clotting may be cross-linking of matrix components or gel-binding agonists (GAGs). The crosslinking agent can be any agent that induces gelation of those components that can be gelled. Poly(ethylene glycol) (PEG) or PEG-diacrylate (PEGDA) The composition may comprise a hydrogel, or a disulfide-containing derivative thereof.
[0132] In another aspect, the present disclosure provides a method for the preparation of a first type of cell (epithelium) into one or more second types of cells. We provide a method for forming organoids by culturing the cells of the second host (mesenchymal cells) and The first type of cell is in the maturation stage to become a suitable lineage partner for the first type of cell. In some embodiments, mature cells attached to the culture dish are removed by panning. and transferring the cells that did not adhere to the low-adhesion culture dish to an appropriate medium, and This can be achieved by harvesting the organoids that self-organize in vitro. The types of cells can be epithelial stem cells, committed precursors of epithelial cells, or mature cells (e.g. The second type of cell may be of mesenchymal lineage (e.g., hemangioblasts, mesenchymal stem cells, etc.). stem cells of the endothelium), precursors of these lineages (e.g., vascular endothelial or astrocyte precursors) Alternatively, they may be a mixture of early lineage stage mesenchymal cells. For example, culture in Matrigel does not allow for patch grafting. Organoids prepared in Matrigel do not generate organoids suitable for successful engraftment. Although it is possible that engraftment may be possible, the extent of engraftment may be less than that of organoids prepared under defined conditions. Furthermore, Matrigel is not a component of the conditions used in clinical products. I can't come.
[0133] In another aspect, the present disclosure provides a method for the preparation of a biocompatible, biocompatible endothelial cell that has a neutral effect on the differentiation of donor cells. Multiple layers including a degradable backing, such as hyaluronan, that can be solidified into a hydrogel or a second layer comprising a plurality of biomaterials, epithelial cells embedded in the solidified biomaterial, and A bandage attached to the target site with a mixture of supporting mesenchymal cells, sutures or surgical adhesive The present invention provides a method for engrafting cells into an organ, the method comprising contacting a patch graft containing a cell-like structure with the organ. The lining serosal surface contains a small amount of cellular cellular markers found in soft biomaterials into which donor cells are incorporated. The coagulated tissue was prepared to achieve at least double the pressure level, 400 Pa or more. A layer of material is added. The cells within the patch graft will engraft and grow through the tissue / organ to the tissue / organ. They migrate into organs and then secrete the relevant components that are specified by the microenvironment in which they are located. The biomaterial embedded in or contained within the porous backing can mature to a somatic fate. Higher Pascal levels of erythrocytes prevent cells from migrating in the wrong direction and promote cell adhesion to the serosal surface of the graft. It is added to surfaces to minimize adhesion of cells from other organs and tissues.
[0134] Organoids According to one embodiment disclosed herein, suspension of bile duct stem cells (hereinafter, "BTSCs") is Organoid aggregates and early lineage stage mesenchymal cells (ELMCs) are This has proven to be the most successful method for incorporating cells into the implant. We report that BTSCs and ELMCs were cultured by panning to remove mature astrocyte / stromal cells. This allows for self-selection into organoids and therefore the appropriate epithelial-interstitial lineage stage of the grafts. It has been shown to be more efficient and effective in establishing leaf partners. In this disclosure, the present invention relates to a method for producing an olfactory response by culturing a first type of cell with a second type of cell. The present invention provides a method for forming ganoids, the second type of cells being stage appropriate for the first type of cells. Panning removes mature cells that are lineage partners and adhere to the culture dish, and the culture is suspended in water. The first type of cells are epithelial stem cells, or The second type of cells may be of mesenchymal lineage, mesenchymal stem cells, or committed epithelial cells. A further embodiment may be a self-organizing cell, a cell of an early lineage stage mesenchymal cell, or a cell of an early lineage stage mesenchymal cell. The present invention relates to organoids and uses thereof.
[0135] In some embodiments, either the donor cells and / or the supporting mesenchymal cells are Without wishing to be bound by theory, However, MMPs mediate the merging of donor and host cells and the formation of the Glisson capsule (or tissue or It is believed that the endothelial cells can dissolve the equivalent capsule around the organ. In some embodiments, the early stage stem cells or ELMCs express high levels of MMPs, In some embodiments, mature hepatocytes express low levels of MMPs. Mature sinusoidal endothelium (CD31+++, VEGF-receptor+, type IV collagen+ and and CD117 negative) and in combination with adult cholangiocytes, mature stellate cells and stromal cells (ICAM-1+, ASMA+, vitamin A++, type I collagen+ ), resulting in cell aggregates remaining on the organ surface and allowing for effective engraftment. In some embodiments, the engraftment of mature epithelial cells is achieved by the M cell-specific markers required for engraftment and migration. It is necessary to combine with immature mesenchymal cells that produce MPs.
[0136] According to one embodiment disclosed herein, stem / progenitor cells such as BTSCs and ELSMCs Organoids, which are suspended aggregates of cells, are the most viable cell medium for successful patch grafting. Disclosed herein are BTSC and ELSMC, which are bloodless Mature mesenchymal cells were isolated by standard panning procedures of cells attached to normal dishes under supernatant conditions. This allows the organoids to self-select, and then the remaining cells (which did not attach) are depleted. Organoids are cultured in a serum-free, defined medium on a plate. Under these conditions, the organoids grow autonomously. Self-organize.
[0137] In another aspect, the present disclosure provides a method for converting a first type of cell, an epithelial cell, into a second type of cell, a mesenchymal cell. The present invention provides a method for forming organoids by culturing a first type of cell with a second type of cell. The first type of cell is a lineage partner appropriate for the stage of maturation that adheres to a normal culture dish. Cells are removed by a panning procedure and self-organized olivaryngeal cells are isolated from the suspension in culture on low-attachment culture dishes. Harvest the ganoids. The first type of cells are epithelial stem cells, TA cells, committed epithelial The second type of cell may be a stem cell of the mesenchymal lineage, a TA cell, or a precursor cell. may be committed mesenchymal precursors.
[0138] In some embodiments, either the donor cells and / or the supporting mesenchymal cells are Without wishing to be bound by theory, However, MMPs can result in the dissolution of the cyst around the tissue or organ, resulting in the separation of donor cells and host It is believed that the present disclosure allows for the merging of cells. Early stage stem cells or ELMCs express high levels of MMPs, whereas mature hepatocytes express low levels. In some embodiments, mature hepatocytes and mature sinusoidal endothelial (CD) cells express MMPs. 31+++, VEGF-receptor+, type IV collagen+ and negative for CD117 In the case of cholangiocytes, the combination with mature stellate cells and interstitial cells (ICA M-1+, ASMA+, Vitamin A++, Type I Collagen+) and the results As a result, cell aggregates remain on the surface of the organ and cannot engraft effectively. In an embodiment, the engraftment of mature epithelial cells is achieved by inhibiting the engraftment of immature epithelial cells that produce MMPs necessary for engraftment and migration. It is necessary to combine with mesenchymal cells.
[0139] According to one embodiment disclosed herein, stem / progenitor cells such as BTSCs and ELSMCs Organoids, which are suspended aggregates of cells, are the most viable cell medium for successful patch grafting. Disclosed herein are BTSC and ELSMC, which are bloodless Mature mesenchymal cells were isolated by standard panning procedures of cells attached to normal dishes under supernatant conditions. This allows the organoids to self-select, and then the remaining cells (which did not attach) are depleted. Organoids are cultured in a serum-free, defined medium on a plate. Under these conditions, the organoids grow autonomously. Self-organize.
[0140] In another aspect, the present disclosure provides a method for converting a first type of cell, an epithelial cell, into a second type of cell, a mesenchymal cell. The present invention provides a method for forming organoids by culturing a first type of cell with a second type of cell. The first type of cell is a lineage partner appropriate for the stage of maturation that adheres to a normal culture dish. Cells are removed by a panning procedure and self-organized olivaryngeal cells are isolated from the suspension in culture on low-attachment culture dishes. Harvest the ganoids. The first type of cells are epithelial stem cells, TA cells, committed epithelial The second type of cell may be a stem cell of the mesenchymal lineage, a TA cell, or a precursor cell. may be committed mesenchymal precursors.
[0141] In some embodiments, for a patch graft strategy to be successful, donor cells and Either the cells or the supporting mesenchymal cells express multiple matrix metalloproteinases (hereafter referred to as MMPs) and in particular secreted MMPs. However, multiple isoforms of MMPs allow dissolution of the cyst around an organ or tissue, This is believed to allow rapid migration of donor cells into the host tissue. The disclosure provides that early stage epithelial stem cells and / or ELSMCs have high levels of membrane-bound and / or or express secreted MMPs, whereas mature cells (e.g., hepatocytes) express membrane-bound MMPs. Even if expressed, it is provided that the secretory MMP is expressed at a low level. Engraftment of adult cells (e.g., hepatocytes, cholangiocytes, pancreatic islets, intestinal cells, etc.) requires a mesenchymal partner MMPs, especially secretory MMPs, are needed as a cellular source if engraftment is to occur Alternatively, the implant biomaterial could be enriched with relevant isoforms of MMPs, i.e., purified The object of the present invention is to provide MMP in a form that is
[0142] According to the present disclosure, the number of cells that can be engrafted using patch grafts is quite high (>10 8 ), graft dimensions, number and size of organoids (or cell number-organoid count) (if not part of the donor cell line), whether the donor cell is a stem cell or a mature cell, and whether it is a secretory or membrane-bound These are specified by the expression of MMPs (whether of epithelial and / or mesenchymal origin). The findings are consistent with the limited number of cells (e.g., 1 0 5 -10 6 ) is quite different.
[0143] Disclosed herein is a method for producing a graft by combining cells with a target cell that is insoluble and The goal of the method is to develop a method for the localization of cells at the target site by mixing the cells with a suitable biomaterial that can keep the cells localized at the target site. In one embodiment, the isolated cells of the viscera are explanted in a biomaterial prior to introducing the cells into the host. It may be allowed to clot in vivo or, alternatively, may be injected as a fluid material and allowed to clot in vivo. In another embodiment, a biomaterial capable of forming a hydrogel, Similar insoluble complexes are composed of hyaluronan or other nonsulfated or minimally sulfated glycosaminoglycans. glycan, thiol-modified sodium hyaluronate, or plant-derived materials (e.g., alginate). The trigger for clotting is crosslinking or gelling of the matrix components. The crosslinking agent can be any agent that induces gelation of the polyethylene. Glycol diacrylate, or a disulfide-containing derivative thereof. and the insoluble complex of the biomaterial is about 0.1 to 200 Pa, preferably about 0.1 to about 1 Pa. , viscoelasticity in the range of about 1 to about 10 Pa, about 10 to 100 Pa, or about 100 to about 200 It is preferable to have.
[0144] Preferably, the cells are introduced into or near the diseased or dysfunctional tissue, by injection or other means. The compound may be introduced via surgical delivery. Without wishing to be bound by theory, the hypothetical The theory is that more rigid HA hydrogels (e.g., >500 Pa) induce cell differentiation and Reduced MMP expression with subsequent maturation and concomitant reduced migration capacity reduces engraftment To make.
[0145] backing A biocompatible, biodegradable backing that is neutral to the maturation state of the donor cells. There are a number of options. These include Seri R Surgical Silk Sca ffolds or Contour Seri-Silk (Sofregen, New The morphology of silkworm silk (such as that of silkworm moth silkworms, New York, NY), other derivatives of silkworm silk, and amniotic membrane-derived of the body, omentum, placenta, and polyglycolic acid-co-poly-L-lactic acid (PGA / PLLA). The lining may be made of synthetic fibers or materials such as morphology. Important to the effectiveness of the lining is the donor cell Therefore, most forms of The lining contains components that induce differentiation of donor cells (e.g., the formation of mature extracellular matrix). As the graft consists of a vascular graft (vascular wall), it is not useful for patch grafts.
[0146] The backing is sufficient to allow attachment of the graft to the target site by sutures or surgical adhesive. It must have sufficient tensile strength to degrade within a few months, but it is important to maintain the maturity of the donor cells. It should be made of biocompatible, biodegradable materials that contain degradation products that do not alter the Thus, the product should have minimal effect on pH or other aspects of the environment. The backing must also be able to conform to the surface of the target site, so a flexible backing is preferred. The beating facilitates the use of the graft in areas of high curvature. lk) are non-limiting examples of materials suitable for the lining. Amniotic membrane-derived substitutes are also not limited thereto. Osiris Therapeutics, Inc. (Columbia, Maryland, USA) Materials suitable for the lining include amniotic membrane-derived materials produced by the National Institute of Medical Sciences (NISA) and the National Institute of Medical Sciences (NIMS). do.
[0147] The lining may be a porous scaffold such as serisilk, or amniotic or placental membrane. Non-porous membranes such as nets, or porous or non-porous synthetic fibers, or combinations thereof If the lining is porous, a biomaterial may be used to seal it. and inject / impregnate the backing in the direction of the backing, i.e. away from the target site or through the backing. The migration of said population of cells must be inhibited. Important properties of the backing material include the above-defined As described above, the material is biocompatible, biodegradable, and neutral, and has sufficient tensile strength as described above. Additionally, the material may optionally be bioabsorbable.
[0148] The backing can be further optimized depending on the use. For example, in some embodiments, The graft, if it contains a backing designed to withstand the drying effects of air, may be It is useful for the cutaneous and subcutaneous tissues.
[0149] The hydrogel matrix disclosed herein above may be used in other portions of the patch graft. For example, a biocompatible, biodegradable backing should be porous, Hydrogels may be used to inhibit the migration of the population of cells towards the backing. The hydrogels that have been developed require higher viscoelastic properties compared to the hydrogels. For example, 1.5 to 15 times, such as 2 times or more. Non-limiting examples of suitable viscoelastic properties include, but are not limited to, However, the viscoelastic properties are preferably in the range of about 250 to about 600 Pa, e.g., at least about 250 Pa. a, at least about 300 Pa, at least about 350 Pa, at least about 400 Pa, At least about 450 Pa, at least about 500 Pa, at least about 550 Pa, at most about 60 0Pa, Maximum approx. 550Pa, Maximum approx. 500Pa, Maximum approx. 450Pa, Maximum approx. 40 0 Pa, up to about 350 Pa, up to about 200 Pa and / or any combination thereof, including but not limited to Any individual value between about 250 Pa, about 300 Pa, about 350 Pa, about 400 Pa, Pa, about 450 Pa, about 500 Pa, about 550 Pa, and about 600 Pa. Further non-limiting examples of suitable viscoelastic properties include, but are not limited to, about 600 to about 800 Pa. viscoelasticity in the range of, for example, at least about 600 Pa, at least about 650 Pa, Approximately 700 Pa, at least approximately 750 Pa, at most approximately 800 Pa, at most approximately 750 Pa, at most 700 Pa at maximum, 650 Pa at maximum, 600 Pa at maximum, and / or limited Not all values are equal, but any individual value between these: about 600 Pa, about 650 Pa, about 700 Pa a, about 750 Pa, and about 800 Pa. Still further non-limiting examples include: Includes a range of approximately 250 Pa to approximately 800 Pa.
[0150] Additionally, the hydrogels disclosed herein can be used to form a cellular matrix on the side of the support opposite the side adjacent to the cells. It may be useful as a coating to prevent adhesion to the serosal surface of the lining. The hydrogel has viscoelastic properties suitable for cell-containing hydrogels and a suitable sealing property for the lining. Non-limiting examples of suitable viscoelastic properties include: Viscoelasticity in the range of, but not limited to, about 250 to about 400 Pa or about 500 Pa, for example, At least about 250 Pa, at least about 300 Pa, at least about 350 Pa, at least About 400 Pa, at least about 450 Pa, at most about 500 Pa, at most about 450 Pa, at most 400 Pa at maximum, 350 Pa at maximum, 200 Pa at maximum, and / or limited Not all values are between these, but about 250 Pa, about 300 Pa, about 350 Pa a, about 400 Pa, about 450 Pa, and about 500 Pa.
[0151] Common grafts Generally, patch grafts are performed using the methods and components described above to transplant donor (allogeneic or autologous) tissue. Transplantation of autologous (autologous) cells into solid organs or tissues to sustain and maintain donor cells at early mature lineage stages More specifically, some or all of the donor cells can be engineered to retain the early maturation lineage. Transplantation of donor cells (allogeneic or autologous) into solid organs or tissues under conditions that will sustain and maintain the transplantation stage. In some embodiments, the patch graft is useful for transplantation of a donor. The cells are a mixture of epithelial and mesenchymal cells. In some embodiments, both donor cells are In some embodiments, the cell population is a stem / progenitor cell. In some embodiments, the epithelial cells are mature cells ( In some embodiments, the mesenchymal cells are stem / progenitor progenitor cells. The conditions of the graft biomaterial, e.g., the medium and matrix components, are adapted to the donor cell population or This allows both the primary and secondary cell populations to remain as stem / progenitor cells. In some embodiments, the medium comprises a basal medium and a soluble signal. This basal medium and soluble signals are essential for the differentiation of both donor and at least mesenchymal cell populations. In some embodiments, the extracellular matrix optionally supports the maintenance of stemness in the The matrix containing the matrix component and its stiffness level can be determined by the donor population or at least the mesenchymal stem cells. In some embodiments, the matrix supports the maintenance of stemness in both cell populations. Optionally prepared as a soft hydrogel having a viscoelasticity of about 50 Pa to about 150 Pa. In some embodiments, the patch graft comprises a hyaluronan. have sufficient mechanical strength to support the attachment and do not significantly alter the mature lineage stage of the donor cells Optionally, without further modification, the donor Protecting the donor cell-containing layer without significantly affecting the mature lineage stage of the cells In some embodiments, the backing is a mesh or scaffold, which is further impregnated with a biomaterial, such as hyaluronan; The viscoelasticity allows any cells migrating into it to fully mature and move in any direction other than toward the target site. In some embodiments, the viscoelasticity is high enough to inhibit donor cell migration. In some embodiments, the serological surface of the implant is adjacent to The implant is coated with a biomaterial to minimize adhesions from the surrounding tissue or organ. In embodiments, these biomaterials have a viscoelasticity of about 200 Pa to about 300 Pa.
[0152] The proposed backing is intended to be sufficiently elastic to withstand mechanical forces and is It can be tethered to a liver or tissue and is flexible enough to be tethered to areas of curvature. Additionally, biomaterials have the ability to sustain and maintain cell populations within a patch graft or As long as the material has sufficient viscoelastic properties to allow migration of the cell population away from the patch graft. Any biomaterial (other than hydrogel) can be used.
[0153] In another embodiment, the patch graft is useful for sustaining and maintaining a cell population. (a) to allow migration of cells into or away from the patch graft; Cells supported in culture within a hydrogel or other biomaterial with sufficient viscoelasticity (b) inhibiting the migration of cell populations toward the substrate (or a backing comprising a biocompatible, biodegradable material having sufficient viscoelasticity to provide a barrier Includes chi and to.
[0154] It is important to note that MMPs can be membrane-bound and / or secreted MMPs. and they may be provided by MMP-producing cells derived from such cells, Or it may be added to a composition of interest (eg, purified or recombinantly produced).
[0155] In another embodiment, the covering or coating has a sufficient strength to withstand mechanical forces applied to the covering or coating. Hydrogels or other biomaterials with viscoelasticity and elasticity, such forces can be applied to other Patch grafts or patches, including those applied from or by tissues and organs. A tissue cover or coating is provided. Using the cover or coating and providing a method for inhibiting or preventing adhesion formation (which is similar to other (involvement or result of mechanical forces or contact from organs and tissues), the method or other equivalent biomaterials.
[0156] In yet another embodiment, a method for engrafting cells into a target tissue is provided, comprising: contacting the patch graft with cells, the patch graft comprising (a) a population of cells; at least one population having an early lineage stage, within a patch graft or Rheological properties sufficient to allow migration of cell populations away from the patch graft (e.g. For example, single or multiple cells supported in a medium in a hydrogel or other biomaterial with viscoelastic properties (b) blocking the migration of a cell population in the direction of the substrate (or a. Biocompatible material that has sufficient rheological properties (e.g., viscoelasticity) to provide a barrier to The backing comprises a biodegradable, non-cellular, and biodegradable material, and the patch graft is adapted to sustain and support the cell population. and maintaining said at least one population having an early lineage stage differentiated to a later lineage stage. and a backing configured to inhibit the growth or further maturation of the cell. Morphologically, one population with early lineage stages is composed of membrane-bound and / or secreted matrix In another embodiment, the method comprises the steps of: In embodiments, the cells do not have this ability, but rather are capable of regulating the proliferation and proliferation of cells that are either competent in the presence of MMPs or can be competent in the presence of other sources (e.g. For example, recombinant DNA technology is included.
[0157] Grafts using cell sources of MMP Aspects of the present disclosure relate to a patch graft for sustaining and maintaining a mixed population of cells, (a) a mixed population having two or more cell types, at least one of which is a secretory Membrane-bound and / or secreted matrix metalloproteinases (M MP) in the early lineage stage, and in the medium present in the hydrogel matrix. The mixed population to be supported may optionally be placed within or on the hydrogel and / or patchgrass. Two or more particles having sufficient viscoelasticity to permit movement of the mixed mass into or out of the cavity. (b) a support having a cell orientation of the mixed population in the direction of the support; a backing comprising a biocompatible, biodegradable material having sufficient viscoelasticity to inhibit migration; Optionally, (c) a hydrogel layered on the serosal (i.e., outer) surface of the lining, This is as opposed to contacting the mixed population, where the patch graft is attached to the target site. In embodiments where the flow is occurring, it is the side opposite to the side in contact with the target site (e.g., an organ or In some embodiments, the layer comprises a hydrogel. or prevent or inhibit adhesions to or from other tissues or organs. In some embodiments, the patch graft sustains and maintains the mixed population while At least one early lineage stage cell type no longer expresses membrane-bound and / or secreted MMPs The method is configured to inhibit differentiation or further maturation to later lineage stages in which the IL-16 receptor agonist is unable to differentiate.
[0158] In some embodiments, the graft is derived from embryonic stem (ES) cells or induced pluripotent stem (iPS) cells. ) cells, this is because the cells may be the cellular source of MMPs. or alternatively, other sources, such as purified (e.g., recombinant) forms of MMPs. As long as the graft is supplemented with sucrose, it is likely to be successful.
[0159] In some embodiments, the backing is porous or non-porous. In some embodiments, the backing may be a porous and / or non-porous mesh, a scaffold, or In some embodiments, the backing comprises silk, synthetic fibers, or amniotic membrane, placenta or These include natural materials such as oysters or their derivatives, or combinations thereof. In some embodiments, the backing is a hydrogel that is used to convert it into a barrier. or other biomaterial. The injection prevents migration of the cells from the target organ or tissue. In some embodiments, the backing comprises a solid material.
[0160] In some embodiments, one or more of the hydrogels comprises hyaluronan. include.
[0161] In some embodiments, the medium is a Kubota medium or a medium that supports stem cells and The present invention includes a separate medium capable of maintaining the above-mentioned.
[0162] In some embodiments, the mixed population comprises mesenchymal and epithelial cells. In embodiments, the epithelial cells may be ectodermal, endodermal, or mesodermal. In some embodiments, the mesenchymal cells comprise early lineage stage mesenchymal cells (ELSMCs). In some embodiments, the ELSMCs are hemangioblasts, precursors of vascular endothelium, astrocyte precursors, or In some embodiments, the inflammatory bowel disease may include one or more of: In some embodiments, the epithelial cells comprise epithelial stem cells. In some embodiments, the epithelial cells comprise biliary stem cells. In some embodiments, the epithelial cells include committed (committed) cells (BTSCs). In some embodiments, the comitrized and / or mature epithelial cells. The transplanted and / or mature epithelial cells include mature parenchymal cells. In the present invention, the mature parenchymal cells are one or more of hepatocytes, bile duct cells, and pancreatic islet cells. In some embodiments, the mesenchymal and epithelial cells both comprise stem cells.
[0163] In some embodiments, the mixed population comprises autologous and / or allogeneic cells.
[0164] In some embodiments, one or more of the cell types are genetically modified.
[0165] "Layered" grafts In some embodiments, a patch graft is understood to be a multi-layered graft. For example, Provided herein is a method for producing a culture of a mammalian cell, comprising the steps of: (a) a donor cell, optionally an epithelial cell, and (b) a soft first layer of hydrogel containing mesenchymal cells; and (b) a stiff second layer of hydrogel. and (c) a third layer comprising a biocompatible, biodegradable backing. A patch graft consisting of or consisting essentially of these. In this embodiment, the second layer is embedded in, impregnated with, and bonded to the third layer, particularly when the third layer is porous. In some embodiments, the patch graft is a fourth layer of hydrogel. In some embodiments of the patch graft, the fourth layer is a serosal surface of the graft. In some embodiments of the patch graft, One layer is adapted to directly contact the target tissue or organ.
[0166] As used herein, the term "soft" refers to a material that is The term refers to a hydrogel layer that exhibits a low level of internal pressure that is quantitatively determined by the Pascal. Defined as 1 Newton per square meter. In some embodiments, the soft layer 10Pa to 300Pa, 50Pa to 250Pa, 100Pa to 250Pa a, about 50 Pa to about 200 Pa, about 150 Pa to about 200 Pa, or about 100 Pa to about In certain embodiments, the soft hydrogel layer has a viscosity of about 200 Pa. or less.
[0167] As used herein, the term "hard" refers to a hardness measured by the Pascal (Pa) measurement. This refers to a hydrogel layer that exhibits high levels of internal pressure that are quantitatively determined by the In the embodiment, the hard layer has a pressure of about 300 Pa to about 3000 Pa, about 300 Pa to about 1000 Pa. , approx. 400 Pa to approx. 750 Pa, approx. 400 Pa to approx. 550 Pa, approx. 450 Pa to approx. 600 In certain embodiments, the hard halides have a viscosity of about 500 Pa to about 600 Pa. The hydrogel layer has a viscosity of about 500 Pa or greater.
[0168] For the first layer of the layered graft, the insoluble complex of cells and biomaterials is about 0.1-2 00 Pa, preferably about 0.1 to about 1 Pa, about 1 to about 10 Pa, about 10 to 100 Pa, or in the range of about 100 to about 200, or about 50 to about 250 Pa, or about 200 Pa. The first layer of the layered graft is preferably a layer of cells and a layer of biomolecules. The insoluble complex of the material has a pressure of about 0.1 to 200 Pa, preferably about 0.1 to about 1 Pa, and more preferably about 1 to about 200 Pa. Viscoelasticity in the range of about 10 Pa, about 10 to 100 Pa, or about 100 to 200 is preferred.
[0169] In some embodiments, one or more cells in the mixture are secretory and / or In some embodiments, the stem / cell lysate that naturally secretes MMPs is a source of membrane-bound MMPs. Variables that attenuate MMP expression, including but not limited to progenitor cell populations, such as voluntarily secreted Expression of type 2 MMPs is controlled within the patch graft. Non-limiting examples of such variables include culture medium, or serum supplementation of the graft biomaterial, which may affect the differentiation of epithelial and / or mesenchymal cells. Hormones or other soluble signals that cause cell death, oxygen levels (whereas anaerobic conditions keep cells immature), (in which higher oxygen levels promote differentiation) and the stiffness of the graft material (shear and These include, but are not limited to, mechanical forces such as compression and compression can promote differentiation. These include variables that result in stem / progenitor cell maturation.
[0170] In some embodiments of the patch graft, the viscosity of the first layer is about 50 to about 250 Pa. In some embodiments of the patch graft, the viscosity of the first layer is about 200 Pa. In some embodiments of the patch graft, the viscosity of the second layer is about 250 to about 600 Pa. In some embodiments of the patch graft, the viscosity of the second layer is about 500 Pa. In some embodiments of the patch graft, the viscosity of the fourth layer is about 250 to about 500 P. In some embodiments of the patch graft, the viscosity of the fourth layer is about 400 Pa. In some embodiments of the patch graft, the viscosity of the second layer is greater than the viscosity of layer 1. In some embodiments of the patch graft, the viscosity of the second layer is greater than the viscosity of the first layer. In some embodiments of the patch graft, the second layer is about 1.5 to about 15 times larger than the first layer. Approximately twice as large as the viscosity of the layer.
[0171] In one embodiment, the patch graft is prepared by administering serum-free, defined, glycerol-free glycerol to the patient, beginning with a layer in contact with the target site. Donor cells embedded in soft (<200 Pa) hydrogels prepared in culture medium prepared with the same medium and having a higher stiffness (e.g., about 500 Pa or more); This triggers a barrier to donor cells migrating in any direction other than toward the target tissue. A second layer of hydrogel provides a neutral effect on the maturation state of donor cells and is surgically or other means to tether the implant to the target site; a third layer, which is a flexible, bioabsorbable backing; and a combination of soft hydrogels and very rigid ones. It is intermediate in stiffness between 0.01 and 0.1 mm, and has a painted or coated surface to minimize adhesion to proximal tissue. The method comprises the steps of: consisting essentially of
[0172] In some embodiments of the patch graft, the first and second layers each comprise one or In some embodiments of the patch graft, the fourth layer comprises one or more hyaluronans. or a plurality of hyaluronans.
[0173] In some embodiments of the patch graft, the epithelial cells and the mesenchymal cells are one or more In some embodiments of the patch graft, one or more aggregates are formed. The aggregates are organoids. In some embodiments of the patch graft, the epithelial cells are In some embodiments of the patch graft, the epithelial cells include bile epithelial stem cells. In some embodiments of the patch graft, the epithelial cells include committed and In some embodiments of the patch graft, committed epithelial cells are included. and / or mature epithelial cells, including mature parenchymal cells. In some embodiments, the mature parenchymal cells are one or more of hepatocytes, bile duct cells, and pancreatic islet cells. or more than one.
[0174] In some embodiments of the patch graft, the mesenchymal cells are supportive mesenchymal cells. In some embodiments of the Tigraft, the mesenchymal cells are early lineage stage mesenchymal cells (ELSMCs). In some embodiments of the patch graft, the ELSMCs comprise hemangioblasts, vascular one of the group consisting of endothelial progenitors, astrocyte progenitors, and mesenchymal stem cells (MSCs); Includes multiple.
[0175] In some embodiments of the patch graft, the epithelial and mesenchymal cells are lineage-dependent. In some embodiments of the patch graft, the epithelial cells are not mature cells. In some embodiments of the patch graft, the mesenchymal cells are ELSMCs.
[0176] In some embodiments of the patch graft, at least one of epithelial cells and mesenchymal cells is The other is derived from a donor. In some embodiments, the donor is a person requiring tissue transplantation. In some embodiments, the donor is a healthy source of cells for tissue transplantation. In some embodiments of the patch graft, at least one of epithelial cells and mesenchymal cells is The other is autologous to the intended recipient of the patch graft. In embodiments, all cells (i.e., epithelial and mesenchymal) are in tune with the intended recipient of the graft. In some embodiments, the donor of cells is autologous to the recipient. seed transplants) or for those with diseased or dysfunctional internal organs Optionally, the cells may be from a part of the internal organ that is not diseased or dysfunctional. , and / or from cells that have been genetically modified to restore function. To establish a model system to study the disease, donor cells are transplanted into the host cells, which carry the disease and are then used as experimental hosts. It may be implanted onto / into primary normal tissue.
[0177] In some embodiments of the patch graft, at least one of epithelial cells or mesenchymal cells is In some embodiments, all cells are modified. In some embodiments, the modification is a genetic modification. In some embodiments, a number of cells are modified to express the therapeutic nucleic acid or polypeptide. The method comprises the steps of: modifying one or more cells to express a wild-type allele of a nucleic acid or polypeptide; do.
[0178] In some embodiments of the patch graft, the biocompatible, biodegradable backing is bioabsorbable. In some embodiments of the patch graft, the patch graft is provided with a biocompatible, biodegradable backing. In some embodiments of the patch graft, the porous material is biocompatible, biodegradable, and The flexible backing comprises a scaffold or membrane. In some embodiments of the patch graft, The scaffold or membrane may comprise silk, amniotic membrane, synthetic fibers, or combinations thereof. In some embodiments, the biocompatible, biodegradable backing induces or induces cell differentiation. In some embodiments of the patch graft, the biocompatible The biodegradable backing comprises one or more components derived from a mature extracellular matrix. In some embodiments of the patch graft, components derived from mature extracellular matrix are The component is type I collagen.
[0179] In some embodiments of the patch graft, the patch graft comprises one or more mating In some cases, patch grafts contain multiple metalloproteinases (MMPs). In some embodiments, the MMP is a membrane-bound MMP. Membrane-bound MMPs are provided by one or more of epithelial or mesenchymal cells. In some embodiments of the patch graft, the MMP is a secreted MMP. Type MMPs are naturally produced, optionally, by one or more epithelial or mesenchymal cells. or optionally, one or more of the MMPs expressed by a recombinant expression vector for production of the MMP. It may be produced by transformation of epithelial or mesenchymal cells.
[0180] In some aspects, provided herein is a method for producing a cholangiocarcinoma comprising at least a bile duct stem cell. A soft hydrogel first layer, a hard hydrogel second layer, and biocompatible and biodegradable A third layer including a backing. It is a patch graft consisting of.
[0181] In one embodiment, the patch graft is surgically or otherwise attached to the target site. From layers of materials and cells that collectively form a "Band-Aid-like graft" that can be wound The first layer, facing the target site, is designed for cell growth and / or survival. A mixture of epithelial cells and supporting mesenchymal cells suspended in a defined, serum-free, nutrient-rich medium The first layer contained a soft hydrogel (<200 Pa) seeded with α-acetylglucosamine and the second layer was prepared in the same medium. The hydrogel contains a gel that is stiffer (i.e., at or above the Pascal level). These proteins are then ligated to form a barrier that blocks cell migration away from the target site, and the third The level does not affect or only minimally affects the differentiation level of donor cells, but the fourth layer includes a biocompatible, biodegradable backing that serves as a mechanical support for the The intermediate stiffness level between soft and hard hydrogels allows for enhanced healing of adjacent tissue cells to the graft. Paintable hydrogels (such as hyaluronan again) that serve to minimize adhesion The hydrogels are tunable with respect to biocompatibility, biodegradability, and stiffness. The material must be "tunable" in the sense that it can be adjusted. The materials used were oxygen and / or poly(ethylene glycol) diacrylate (PEGDA ), which may be triggered to form a hydrogel when exposed to Easily “adjusted” by the precise ratio of PEG and PEGDA concentrations (and / or oxygen levels) It is a thiol-modified hyaluronan that is "adjustable."
[0182] In another embodiment, the patch graft comprises multiple layers. The first layer facing the target site comprises: A minimally sulfated or non-sulfated polymeric material that can be gelled or solidified and placed on the donor tissue. A soft hydrogel that is sulfated GAG or other non-sulfated or neutral biomaterial. A second layer of hydrogel or biomaterial that is more rigid and is embedded in / on or within the backing. The backing is a biocompatible, biodegradable, bioabsorbable backing that is suitable for use in surgery or other procedures. The patch can be treated as a barrier to allow cells to migrate towards the target tissue. The serosal side of the lining is filled with hyaluronan (or other minimal sulfate) at the time of surgery. The biomaterials used in the study include sulfated or non-sulfated GAGs or other materials capable of gelling or solidifying. The Pascal level is less than that found in the soft biomaterial layer. Both are doubled and serve the purpose of minimizing adhesions from adjacent tissue. The cells are able to migrate and fully integrate into the target organ or tissue. do.
[0183] In certain embodiments, the patch graft is made of a soft hyaluronan hydrogel. It comprises a first layer of biomaterial (<200 Pa) in which are placed lineage-stage cells This layer is the donor cells that are transplanted into a serum-free, defined medium adapted to the donor cells. A more rigid layer (e.g., The stiffer layer is placed on top of the stiffer hydrogel (e.g., a more rigid hydrogel). The stiffer layer may be removed by surgery or other means. and processing the patch to allow the patch to be attached to a target site for treatment of the disease. The final layer is a biocompatible, biodegradable backing that is pre-prepared on the target tissue side. This layer is a biomaterial with a stiffness intermediate between that of the donor cells and that of the barrier. It is added to the serosal side of the graft and serves to minimize adhesions from adjacent tissues. The synthetic, biodegradable backing may be serisilk or a derivative thereof.
[0184] Methods of Use and Delivery of Patch Grafts Aspects of the present disclosure relate to compositions and methods for engrafting cells into solid organs. Efforts to transplant cells from organs to organs have typically relied on direct injection of cells via vascular routes or Lanzoni, G. et al. Stem Cells 31, 2047-2060 (2013). These transplantation methods allow a small number of cells to reach the target site. The cells are then transplanted into the body, creating the risk of potentially life-threatening embolism. When delivered by suction, cells are suspended in hyaluronan or coated with hyaluronic acid. After this, a trigger (PEGDA) was co-injected and hyaluronan was administered as described below. Ronan gels in situ in vivo. Turner R. et al. Hepatolo gy 57, 775-784 (2013). Although the number is small, Usually 10 per injection site 5 -10 7 , 10 6 -10 7 , or 10 5 -10 6 Identifying cells This strategy provides a strategy for localizing ubiquitin to specific sites, which can eliminate or eliminate ectopic cellular distribution. However, it is important to minimize the number of cells that can form and optimize the integration of cells within the site. When used, they may be highly immunogenic and require long-term immunosuppression. However, the amount of cells that can be infused may be insufficient to achieve the required clinical outcome.
[0185] These obstacles and concerns are overcome by the "patch graft" strategy described herein. In some embodiments, the "Band-Aid-like" implant is surgically or are tethered to the surface of an organ or tissue by other means, and the conditions in the graft allow the cells to fully integrate within the site. engraft, migrate throughout the organ / tissue, and subsequently mature into the relevant adult cell types Possibility of transplanting a large number of cells (>10 8 Cells) are the size of the patch, the size of the graft, A number or mixture of cells and sources of multiple forms of MMPs, ideally a cellular source of MMPs Further, in some embodiments, the use of organoids Given the ease with which organoids can be cryopreserved under defined serum-free conditions, Promote the ability to stockpile supplies.
[0186] The patch graft compositions provided herein are useful for direct implantation of cells onto tissues or solid organs. The method is safe, avoids embolism and ectopic cell distribution, and is able to deliver to the entire tissue. Optimize cell number engraftment and distribution.
[0187] Accordingly, provided herein is a method for treating a target tissue with a patch as disclosed hereinabove. contacting the graft with a cell, comprising, consisting of, or consisting essentially of the cell. This is a method to allow the cells to engraft into the target tissue.
[0188] In some embodiments of this method, the target tissue is the liver, pancreas, bile duct, thyroid, thymus, Gastrointestinal, lungs, prostate, breasts, brain, bladder, spinal cord, skin and subcutaneous tissue, uterus, kidneys, muscles, blood In some embodiments, the tissue is selected from the group consisting of vascular, cardiac, cartilage, tendon, and bone tissue. In embodiments, the target tissue is liver tissue. In some embodiments of this method, the target tissue In some embodiments of this method, the target tissue is bile duct tissue. In some embodiments of the method, the target tissue is gastrointestinal tissue. In some implementations of this method, the tissue is diseased, damaged, or impaired. In one embodiment, the target tissue is kidney tissue.
[0189] In some embodiments of this method, the target tissue is an organ. In an embodiment, the organ is a musculoskeletal system, a digestive system, a respiratory system, a urinary system, a female reproductive system, a male reproductive system, The organs are the reproductive system, the endocrine system, the circulatory system, the lymphatic system, the nervous system, or the integumentary system. In some embodiments, the organ is a liver, pancreas, bile duct, thyroid, thymus, gastrointestinal, lung, prostate, Glands, breasts, brain, bladder, spinal cord, skin and subcutaneous tissue, uterus, kidneys, muscles, blood vessels, heart, cartilage In some embodiments, the organ is selected from the group consisting of: tendons, and bones. or damaged or impaired.
[0190] Also provided herein is a method of treating a subject having a liver disease or disorder, comprising: The method includes contacting the liver of a subject with a patch graft as disclosed hereinabove. In some embodiments of this method, the method comprises, consists of, or consists essentially of Liver disease or disorders include liver fibrosis, cirrhosis, hemochromatosis, liver cancer, biliary atresia nonalcoholic fatty liver disease, hepatitis, viral hepatitis, autoimmune hepatitis, fascioliasis, Alcoholic liver disease, α1-antitrypsin deficiency, glycogen storage disease type II, transthyretin Related hereditary amyloidosis, Gilbert syndrome, primary In biliary cirrhosis, primary sclerosing cholangitis, Budd-Chiari syndrome, liver trauma, or Wilson's disease be.
[0191] In another aspect, provided herein is a method of treating a subject having a pancreatic disease or disorder. The method includes contacting the pancreas of the subject with a patch graft as disclosed hereinabove. The method includes, consists of, or consists essentially of In embodiments, the disease or disorder of the pancreas is diabetes, exocrine pancreatic insufficiency, pancreatitis, pancreatic cancer, opioid Sphincter of Diploicmia insufficiency, cystic fibrosis, pancreatic duct nonfusion, annular pancreas, pancreatic trauma, or pancreatic duct bleeding (hemosuccus pancreaticus).
[0192] In another aspect, provided herein is a method of treating a subject having a gastrointestinal disease or disorder. The method includes administering to one or more subjects an intestine a patch as disclosed hereinabove. comprising, consisting of, or consisting essentially of a graft. In some embodiments, the gastrointestinal disease or disorder is gastroenteritis, gastrointestinal cancer, ileitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, peptic ulcer, celiac disease, fibrosis, vascular dysplasia, Hirschsprung's disease, pseudomembranous colitis, or gastrointestinal trauma.
[0193] In some embodiments, provided herein are methods for treating a subject having a renal disease or disorder. The method comprises administering to one or more subjects kidneys the method as disclosed hereinabove. Comprising, consisting of, or consisting essentially of a patch graft in contact with the patch graft. In some embodiments of this method, the kidney disease or disorder is nephritis, nephrosis, renal inflammation syndrome, nephrotic syndrome, chronic kidney disease, acute kidney injury, kidney trauma, cystic kidney disease, multiple Cystic kidney disease, glomerulonephritis, IgA nephropathy, lupus nephropathy, kidney cancer, Alport syndrome, myloidosis, Goodpasture's syndrome, or Wegener's granulomatosis.
[0194] In some embodiments of the method of treatment, at least one of the epithelial cells and the mesenchymal cells In some embodiments, the donor is a subject in need of a tissue transplant. In some embodiments, the donor is a healthy source of cells for tissue transplantation. In some embodiments, at least one of the epithelial cells and the mesenchymal cells is a patch graft. In some embodiments, all cells ( i.e., the epithelium and mesenchyme) are autologous to the intended recipient of the graft. In some embodiments, the donor of the cells is other than the recipient (allograft). or may be a subject having diseased or dysfunctional internal organs (self). Optionally, cells may be derived from and / or used to restore function to a portion of an organ that is not diseased or dysfunctional. It is obtained from cells that have been genetically engineered to produce the original antigen.
[0195] In some embodiments, the patch graph used in the methods disclosed herein above The sample comprises at least a first layer of hydrogel containing epithelial cells and mesenchymal cells, a second layer of hydrogel containing epithelial cells and mesenchymal cells, and a third layer of hydrogel containing epithelial cells and mesenchymal cells. a second layer, a third layer comprising a biocompatible, biodegradable backing, and optionally a fourth layer of a hydrogel. In some embodiments, the method comprises the steps of: and allowing the cells contained within the graft to integrate into tissue. In some embodiments of the method, the first layer of hydrogel is soft. In some embodiments of the method, the second layer of hydrogel is rigid. Mesenchymal cells are supportive mesenchymal cells.
[0196] In another aspect, the present disclosure provides a method for treating a subject comprising administering to a subject, the subject being collectively connected, surgically or otherwise, to a target site. The band-aid-like composite is made up of multiple layers of material and cells that can Methods for engrafting cells into organs, including the use of patch grafts, are provided. The first layer is a defined, serum-free, nutrient-containing medium designed for cell growth and / or survival. Soft hydrogels seeded with a mixture of epithelial cells and supporting mesenchymal cells suspended in nutrient-rich medium gel (less than 200 Pa), and the second layer contains a hydrogel prepared in the same medium. However, the gel is gelled to a more rigid level (i.e., Pascal level or higher) and is not absorbed in areas other than the target area. The third level forms a barrier that blocks the migration of cells in the opposite direction to the donor cell. biocompatible, that is, it has no or minimal effect on the oxidation level and is therefore “neutral” The fourth layer contains a synthetic, biodegradable backing and a stiffness level intermediate between soft and hard hydrogels. It is a paintable material that helps minimize adhesions from adjacent tissue cells to the graft. The hydrogel is made of a biocompatible, biocompatible hydrogel (again, hyaluronan). Made from materials that are "tunable," meaning they can be adjusted for degradability and stiffness. One successful hydrogel material is a material that is resistant to oxygen and / or poly(ethylene When exposed to PEG-diacrylate (PEGDA), it forms a hydrogel. The hyaluronan and PEGDA concentrations (and / or acid Thiol-modified hyaluronan, which is easily "tunable" by the precise ratio of The cells under the conditions of the graft biomaterial are engrafted into the recipient's tissue. Produces multiple matrix metalloproteinases (MMPs) that promote cell proliferation, migration, and integration. The recipient tissue microenvironment specifies the adult fate of the transplanted cells.
[0197] In another aspect, the present disclosure provides a biocompatible, biodegradable, adhesive sheet comprising at least a first layer comprising a biocompatible, biodegradable backing; One or more hyaluronan-containing second layers containing a mixture of epithelial cells and supporting mesenchymal cells. , a patch graft comprising multiple layers, including a third layer comprising one or more hyaluronans. The present invention provides a method for engrafting cells into an organ, the method comprising contacting the cells with a The layer associated with the backing is very soft (less than 200 Pa), while the layer associated with the backing is more rigid (about 500 Pa). a or higher), and the third layer is intermediate Pascal's level and is from nearby tissues or organs. In yet another embodiment, the cells are derived from the liver, pancreas, bile duct, thymus, or gland, thymus, intestine, lung, prostate, breast, brain, spinal cord, ganglia, skin and subcutaneous tissue, uterus, bone, The virus grows in an organ selected from the group consisting of the thymus, intestine, uterus, bone, kidney, muscle, blood vessel, or heart. You may wear it.
[0198] In yet another embodiment, the cell is from a source selected from the group consisting of liver, pancreas, bile duct, thyroid, thymus, intestine, lung, prostate , breast, brain, spinal cord, ganglia, skin and subcutaneous tissue, uterus, bones, tendons, cartilage, kidneys, muscles, blood The cell may be engrafted in an organ selected from the group consisting of: blood vessels, ducts, or the heart.
[0199] Non-limiting examples of patch grafts suitable for the methods disclosed herein include patches comprising: (a) A mixed population with two or more cytotypes, of which at least At least one of the following is a secreted and / or membrane-bound and / or secreted matrix metalloproteinase It is at an early lineage stage where it can express MMPs and is capable of forming hydrogel matrices. The mixed population, supported by the medium present in the hydrogel, is optionally placed inside or outside the hydrogel and and / or a viscoelastic material sufficient to permit movement of the mixed population into or out of the patch graft. (b) a mixed population having two or more cell types, each having a specific cellular identity; The mixture is then mixed with the mixture of the cellulose, the cellulose being viscoelastic enough to inhibit or provide a barrier to the movement of the mixture. a backing comprising a biocompatible, biodegradable material, and optionally (c) a hydrogel, The serosal (i.e., outer) surface of the spleen is overlaid with that which is in contact with the mixed population. In embodiments where the patch graft is tethered to the target site, In some embodiments, the hydrogel is placed on the opposite side to the side where the hydrogel is placed (e.g., an organ or tissue). In this state, this layer is resistant to adhesions by or from other tissues or organs. In some embodiments, the patch graft maintains the mixed population. and maintaining said at least one early lineage stage cell type as membrane-bound and / or or inhibit differentiation or further maturation to later lineage stages that can no longer express secreted MMPs. It is configured to:
[0200] In some embodiments, the backing is porous or non-porous. In some embodiments, the backing comprises a porous mesh, a scaffold, or a membrane. In form, the lining may be made of silk, synthetic fibers, or aminion, placenta or In some embodiments, the backing comprises a natural material such as a mesh, or a combination thereof. The implant comprises a porous mesh infused with a hydrogel. The injection prevents migration of the cells out of the target organ or tissue. In some embodiments, the backing comprises a solid material.
[0201] In some embodiments, the patch graft comprises a hyperplastic graft layered on the serosal surface of the lining. The method further comprises the steps of: do.
[0202] In some embodiments, one or more of the hydrogels comprises hyaluronan. include.
[0203] In some embodiments, the medium is a Kubota medium or a medium that supports stem cells and The present invention includes a separate medium capable of maintaining the above-mentioned.
[0204] In some embodiments, the mixed population comprises mesenchymal and epithelial cells. In embodiments, the epithelial cells may be ectodermal, endodermal, or mesodermal. In some embodiments, the mesenchymal cells comprise early lineage stage mesenchymal cells (ELSMCs). In some embodiments, the ELSMCs are hemangioblasts, precursors of vascular endothelium, astrocyte precursors, or In some embodiments, the inflammatory bowel disease may include one or more of: In some embodiments, the epithelial cells include epithelial stem / progenitor cells. In some embodiments, the epithelial cells include committed bile duct stem cells (BTSCs). In some embodiments, the cells include committed and / or mature epithelial cells. The committed and / or mature epithelial cells include mature parenchymal cells. In embodiments, the mature parenchymal cells are one or more of hepatocytes, bile duct cells, and pancreatic islet cells. In some embodiments, the mesenchymal and epithelial cells both comprise stem cells. nothing.
[0205] In some embodiments, the mixed population comprises autologous and / or allogeneic cells.
[0206] In some embodiments, one or more of the cell types are genetically modified. EXAMPLES
[0207] The following examples are non-limiting and illustrative of procedures that may be used in various instances in carrying out the present disclosure. Additionally, all references disclosed herein below are incorporated by reference. The entirety of the above is incorporated.
[0208] Example 1: Pig model for patch graft validation animal Animals used as hosts or cell donors were obtained from NCSU (North Carolina State University). College of Veterinary Medicine in Raleigh, NC These facilities were used for surgery, necropsy, and collection of all biological fluids and tissues. All procedures were approved by the NCSU Institutional Acquisition Committee. The pigs used as cipients were Yorkshire, Large White, Landrace (female A six-way cross consisting of the sire (from pigs), Duroc, Spot, and Pietran (from boars). This highly heterogeneous genetic background is a mixture of six different breeds. The host animals are all female, approximately six weeks and It weighed about 15kg.
[0209] There were two categories: a) male pigs, approximately 6 weeks old and weighing approximately 15 kg, were used to transfer cells to females; b) Transgenic donor animals carrying the GFP transgene GFP+ donor animals were crossed with wild-type gilts and transgenic H1N1 mice by standard artificial insemination. This model was obtained by breeding 2B-GFP male pigs. CRISPR-Cas9-mediated delivery of IRES-pH2B-eGFP to the ACTB locus Transgenic animals were developed through homologous recombination repair (HDR). Figure 2 shows the ubiquitin expression of pH2B-eGFP in G FP markers localize to nucleosomes, allowing clear visualization of nuclei and chromosome dynamics. The established lines have been extensively analyzed, confirming ubiquitous and nuclear-localized expression. Furthermore, breeding shows the transmission of H2B-GFP to the next generation. The mice were healthy and the offspring showed the expected Mendelian ratio for the transmission of pH2B-eGFP. Several pregnancies were established. Male offspring were genotyped at birth and were positive for the transgene. Those that were viable were humanely euthanized for tissue collection and donor cell isolation.
[0210] For each donor and recipient animal, swine leukocyte antigen class I (SLA-I) and class II (SLA-II) loci were identified based on a PCR sequence-specific primer strategy. Using primers designed to amplify known alleles in these regions, The system is designed to detect and amplify the SLA-1, SLA-2, and SLA-3 genes. Denkoza 53 47 discriminatory SLA-I primer sets amplifying DRB1, DQB 1 and 47 discriminatory SLA-II primer sets amplifying the DQA locus. These primer sets are organized into groups that share similar sequence motifs. Developed to distinguish between alleles and detect known SLA-I and SLA-II alleles When used together, these primers Effectively providing the haplotype of each animal tested, consistent across donor and recipient animals Alternatively, an assay is provided to easily identify mismatched haplotypes.
[0211] Media and solutions All media were sterile filtered (0.22 μm filter) and kept at 4°C in the dark before use. Basal medium and fetal bovine serum (FBS) were purchased from GIBCO / Invitrogen. All growth factors were purchased from R&D Systems. All other reagents were obtained from Sigma, except as noted.
[0212] The cell wash solution consisted of 0.5 grams of serum albumin (Sigma, #A8896-5G, lipid fatty acid free), 10-9M selenium and 5ml of antibiotics (Gibco #35240-0 62, AAS)) The tissue and cells were washed during processing using 100% PBS (Ibco #11875-093). Used.
[0213] Collagenase buffer was prepared, 600U / ml for bile duct (duct) tissue (R1451 25 mg) final concentration, and for organ parenchymal tissues (liver, pancreas) 300 U / ml (12. 100 ml of collagenase supplemented with collagenase (Sigma #C5138) at a final concentration of 5 mg. The cell washing solution is composed of 100 ml of cell washing solution.
[0214] Uses Kubota's medium, a specified serum-free medium designed for endodermal stem / progenitors The cell suspension, organoids, and HA hydrogel were prepared using the medium containing copper. It is free of calcium (0.3 mM), 1 nM selenium, 0.1% bovine serum albumin, and (purified, fatty acid free, fraction V), 4.5 mM nicotinamide, 0.1 nM sulfite Lead heptahydrate, 5 μg / ml transferrin / Fe, 5 μg / ml insulin, 10 μg / ml of high density lipoprotein and highly purified fatty acid-free albumin Any basal medium (herein referred to as basal medium) containing a mixture of purified free fatty acids complexed with acetylcholine ( The preparation of the method is 57 is described in detail in This is also being carried out by PhoenixSongs Biologicals (Connecticut, USA). (Branford, Cutts.).
[0215] The soluble long-chain form of HA (Sigma Catalog #52747) is an organoid The thiol-modified cellulose was used to produce the hydrogel. HA is available from Glycosan Biosciences, a subsidiary of Biotime. These thiol-modified HA components were obtained under the ISO9001:2000 process. Produced through a proprietary bacterial fermentation process using primarily Bacillus subtilis ( www.bioppolymers.novozyme.com / ). This ingredient is Hy Produced by Novozymes under the aCare® trademark and is animal-derived 100% free of residual organic solvents and animal-derived ingredients. It is untreated, has very low protein levels and is endotoxin free. The HA hydrogel is a thiol-modified HA. Glycosil (HyStem® HA, ESI BIO-CG313) The polymer was prepared using polyethylene glycol diacrylate (PEGDA). It can be triggered to form sulfide bridges. ) in 1% phosphate buffered saline (PBS) with degassed water or, in this case, Reconstituted in Bota's medium as a 1% solution of thiolated hyaluronan. Once reconstituted, it can be incubated for several hours. It remains liquid, but may undergo some gelation when exposed to oxygen. When ycosil is treated with a crosslinking agent such as PEGDA, gelation occurs within a few minutes and More precise gelation occurs without temperature or pH changes.
[0216] The level of crosslinking dictates the level of stiffness and depends on the ratio of thiol-modified HA to PEGDA. In previous studies, stem cell populations were grown in a variety of stiffness levels of H Tested with A hydrogel, stiffness level is 200Pa 23 Antigenic only if less than were found to be maintained both quantitatively and functionally (e.g., with respect to migratory capacity) as stem cells. Using this finding, we have developed a very soft layer on the serosal side and a stiffer layer of hyaluronan hydrogel. Designing the implant with straight layers to provide a barrier against migration in directions other than the target tissue; Minimize adhesions from cells from nearby tissues. Hydrogels with different levels of stiffness The three versions of the gel are characterized in Figure 2, and the characteristics are based on direct measurements of the rheological properties. The stiffest barrier was 10X HA hydrogel (stiffness = 760 Pa). The barrier can be prepared in advance on a backing and cryopreserved if desired. Nurse cells were prepared in soft 1X HA hydrogels (stiffness = 60 Pa) and in more rigid The patch was placed on top of the 10X hydrogel (already on the backing) and tethered to the target site. After connection, a permanent BD Micro-Fine™ IV needle was inserted into the serosal side of the graft. Using the NORM-JECT 4010.200V0 plastic syringe, Coated or painted with 2X HA hydrogel (stiffness = 106 Pa).
[0217] The macroscale rheological properties of hydrogels were investigated using a stress-controlled cone-plate rheometer. A TA Instruments AR-G2, 40 mm cone diameter, 1° angle was used. The gel was vibrated at a frequency of 1 rad / s and a stress amplitude of 0.6 Pa. However, the polymerisation was actively carried out on the rheometer, and the modulus was then adjusted to check for sufficient completion of the crosslinking reaction. Once equilibrated, the hydrogel was subjected to an oscillatory frequency sweep (stress oscillation). (Pulse width: 0.6 Pa, Frequency range: 0.01-100 Hz). Three versions of the Hear used The rheological properties of luronan hydrogel are summarized in Figure 2.
[0218] The most commonly used donor cells are from transgenic H2B-GFP pigs as described above. These are similar to cell transplants in that all cells are tagged with GFP. The use of fluorescent proteins as molecular tags provides significant advantages to research. This fusion protein allowed us to track the migration and engraftment of nuclear / chromosome-specific nuclei. In the described grafts, stem cells are targeted to nucleosomes resulting in a GFP signal. express GFP entirely in the nucleus, whereas lineages restricted to adult cell types express GFP in the cytoplasm or nucleus. The level of cytoplasmic GFP was particularly high in the first week and decreased over time. Note that the engraftment / invasion / integration process is reduced by H2B-binding GFs. This is because P affects cells where it is found in the cytoplasm. This is because cells are dying. This does not mean that the high levels of MMPs and related In fact, the detected GFP+ cells were clearly viable. They are viable and proliferate, and all express a variety of adult functions (e.g., albumin, HNF 4α, AFP, insulin, glucagon, or amylase).
[0219] As described in more detail in the characterization of the grafts, the lining of mature hepatocytes (green ) and lipofuscin (dark forest green) autofluorescence is at wavelengths similar to those of GFP. Therefore, the applicant has demonstrated that the length of the GFP antibody overlaps with that of the GFP antibody. GFP+ signals are shifted to pink or rose, and secondary red fluorescent probes are used. This shifted the stem cells to the antibody with pink nuclei (nuclear blue DAPI staining and anti- The hepatocytes were recognized as small cells with a GFP+ label (fused with a rose-colored GFP+ label). Any donor cells that have matured to IFN-γ will show green autofluorescence (lipofuscin), blue (DAPI), and was recognized as having a lavender color due to the fusion of rose (GFP) (Figure 4).
[0220] Porcine extrahepatic bile duct tissue (gallbladder, common duct, and hepatic duct) was obtained from transgenic pigs. The intrahepatic and extrahepatic bile ducts are carefully maintained in tact with a sterile stainless steel mallet. The bile ducts were then cultured in 0.1% serum albumin and 1 nM sodium chloride. M Selenium (10 -9 "Cell Culture Medium" consists of sterile serum-free basal medium supplemented with antibiotics (M). The cells were then mechanically dissociated with a crossed scalpel and washed with 0.1% U.S. bovine serum albumin (BSA), 1 nM selenium, 300 U / ml type IV collagenase, Supplemented with 0.3 mg / ml deoxyribonuclease (DNAse) and antibiotics. The aggregates were enzymatically dispersed in a cell suspension in RPMI-1640. Digestion was performed at 32 °C. The digestion was performed at RT for 30–60 min with frequent mixing. Most tissues required two rounds of digestion. The cell pellets were combined and then centrifuged at 1100 rpm at 4° C. The cells were then resuspended in cell washing solution. The cell suspension was centrifuged at 30 G for 5 min at 4°C to remove red blood cells. The cell pellet was again resuspended in cell wash buffer and placed on a 40 μm nylon cell strainer. Filter through a filter (Becton Dickenson Falcon #352340) Fresh cell washing fluid was added. Cell counts were performed and viability was assessed using trypan blue. Cell viabilities greater than 90–95% were routinely observed.
[0221] In previous studies, applicants have demonstrated that essential paracrine regulation is required for hepatocytes and biliary stem cells. The antigenic profiles of mesenchymal cell populations provide the signals and other signals required for mature parenchymal cells. The mesenchymal cells that partner with BTSCs do not contain MHC antigens and are Low lateral scatter and hemangioblasts (CD117+, CD133+, VEGF receptor+ and CD 31 negative), and endothelial precursors (CD133+, VEGF receptor+, and CD31+). , and astrocyte precursors (CD146+, ICAM1+, VCAM+, α-smooth muscle cells). These three subpopulations are identifiable as vitamin A+, vitamin B+, and vitamin A-negative. The two subpopulations are collectively referred to as early lineage stage mesenchymal cells (ELSMCs). Somatic hepatocytes express mature sinusoidal endothelial cells (CD31+++, type IV collagen+, VEGF receptor +, and CD117 negative) and mature astrocytes and interstitial cells (ICAM-1+, Associated with adult cholangiocytes associated with ASMA+, vitamin A++, and type I collagen+ can be.
[0222] The cell suspension was cultured in serum-free Kubota medium in a Multiwell Flatbottom culture medium. In addition to the Cell Culture Plate (Corning #353043) The medium was serum-free and incubated at 37°C for approximately one hour to promote the attachment of mature mesenchymal cells. Even so, mature mesenchymal cells attached to the dish within 10-15 min. Cells remaining in suspension The cells were transferred to another dish and incubated again for up to one hour. After depletion of mature mesenchymal cells, the remaining floating cells were ng per well of ultra-low attachment dishes (Corning #3471) in serum-free Kubota medium. Approximately 2×10 5 100 x 100 cells and incubate overnight at 37 °C in a CO2 incubator. Organoids consisting of bile duct stem cells (BTSCs) and ELMSCs formed overnight ( These organoid cultures were specifically designed to be cultured with a soluble form of HA (Sigma). When supplemented (0.1%), they survived for several weeks on Kubota's medium and were subsequently Each gram of newborn pig bile duct tissue may yield approximately 1.5X10 7 Thin Approximately 3-6x10 cells were obtained per well of a 6-well ultra-low attachment plate. 5 Using cells from The cells were incubated in serum-free Kubota medium for 1 h at 4°C for 1 h. The average number of cells was 6,000–20,000. Generate small organoids (approximately 50–100 cells / organoid / well). At least 100,000 organoids (>10 7 Cells) were used. Depending on the size of the implant, the applicant may choose to limit the number of organoids in the implant to 3cm x 4.5cm. The 10 mm tissue was embedded in approximately 1 ml of soft hyaluronan hydrogel on a 30-μm 3D retina.8 Organoi (i.e., about 10 9 We were able to increase the number of cells by more than 100,000 cells.
[0223] The isolated stem cell organoids were cultured in a medium containing antifreeze factor, dextran, and DMSO (Washington University Press). Biolife, Seattle, TN; https: / / www.stemcell.c om / products / cryostor-cs10.html) The cells were cryopreserved in CS10, a freezing buffer. The viability of the cells was evaluated by adding 0.1% HA (Si Further improvement was achieved by supplementing with CryoMed™ C The cells were frozen and stored using a controlled-rate freezer. Viability was over 90%, and post-thaw cells attached, proliferated ex vivo and in vivo, and The expected mature cells were able to be generated in vitro and in vivo.
[0224] Isolating the cells and assembling the graft is characterized in a schematic diagram in Figure 1 and detailed in Figure 2. The grafts were formed using a backing (Table 1), on which soft hyaluronan was placed. The stem cell organoids embedded in the nan hydrogel were placed in the The explants were prepared in a 30-well plate and maintained overnight in a culture dish in an incubator. The explants were then incubated for the duration of the experiment. The organoids were stable at the target site. Cryopreservation of the organoids was easily achieved, but the soft hydrogels This was not the case for organoids in gels. This is due to the soft hydrogel structure of the organoids. This meant that the gel embedding had to be done just prior to surgery.
[0225] surgery Anesthesia was performed with a combination of ketamine / xylazine (2–3 mg / kg each) injected intravenously. g body weight) or 20 mg / kg ketamine and 2 mg / kg xylazine injected intramuscularly The anaesthetic is induced by administering a gaseous anaesthetic to the patient in oxygen via a closed-loop gaseous anaesthetic unit. was maintained with isoflurane.
[0226] The animals were placed in dorsal recumbency and the abdomen was incised from the xyphoid to the pubis. The skin was prepared aseptically with alternating iodized scrubs and alcohol solutions. After entering the room, skin preparation is repeated using sterile technique prior to application of a sterile surgical drape. The area was then covered with topical iodine solution. The surgeon used proper aseptic technique. Beginning at the mid-abdominal area and extending caudally for 8–12 cm, the skin, subcutaneous tissue, and linea alba are An incision was made. The left hepatic segment was exposed and a 3x4.5cm patch graft was placed on the ventral surface of the liver. This was done by applying 10X HA (approximately 760 Pa) to the organophosphate ion exchange membrane (PET) that was placed on a backing containing 10X HA. The patch contains 1X HA (approximately 60 Pa) embedded with cellulose acetate, and is in direct contact with the surface of the liver capsule. The patch graft was placed with 4-6 simple interrupted sutures of 4-0 polypropylene. The exposed surface of the graft was then sutured to the liver using 2 ml of 2X HA hydrochloride. The graft was treated with a gel (approximately 106 Pa), and its stiffness level was adjusted by painting or coating the serosal side of the graft. The fluid is sufficient to provide a protective layer of the tissue and further minimize adhesions from adjacent tissue. After placement of the surgical graft, the linea alba was closed with a simple running suture using 0-PDS. The linea alba was blocked with an intramuscular injection of 2 mg / kg 0.5% bupivacaine. The subcutaneous tissue and skin were then stained with 2-0 PDS and 3-0 Monocryl, respectively. The wound was closed with continued sutures. Tissue adhesive was placed on the skin surface.
[0227] The transplantation of the graft from the transgenic pig to the recipient is allogeneic and therefore immunosuppressive. Immunosuppression was required. The immunosuppression protocol used was established by others. All pigs were administered the immunosuppressant drug tacrolimus (0.5 mg / kg) for 24 hours prior to surgery. The rats were orally administered 100 mg / kg of DMSO and 500 mg of mycophenolic acid twice daily. These were given continuously throughout the entire period of the study. When mixed with the animals' favorite food, It can be easily given.
[0228] All animals were euthanized with ketamine / xylazine and isofluorane (isoflu orane anesthesia followed by a lethal dose of intravenous sodium pentobarbital Mice were humanely euthanized at the indicated time points by intravenous injection. Upon confirmation of death, the carcasses were carefully dissected. After dissection, target organs were removed and placed on chilled Kubota medium for transport to the laboratory. In addition to the liver, lungs, heart, kidneys, and spleen were harvested and fixed in 10% neutral formalin. It was determined.
[0229] Characterization of the grafts At least 48 hours after fixation, tissue samples were placed in labeling cassettes in 70% ethanol and incubated for 1 h at 37 °C for 2 h. Approximately 10 hours in an ica ASP300S tissue processor at 60 degrees on a long cycle After overnight processing was completed, the samples were mounted on a Leica EG1160 embedded station. The mold was filled with wax and the specimen was placed in the correct orientation to obtain the desired cut. The cassette allows the block and tissue sample to be collected as a single unit from the mold. The block was then cooled down before being removed. Sections were cut at 5 microns using a tome, the sections were floated in a water bath and placed on slides. Slides were air-dried overnight before staining. Sections were stained with hematoxylin and eosin (H &E;Reagents #7211 and #7111) or Masson's trichrome (Masso n's Trichrome Stain:Blue Collagen Kit# 8 7019) by Richard Allan Scientific Histology Staining was performed using the following manufacturer's recommended protocol. The col is programmed into a Leica Autostainer XL.
[0230] Tissues were embedded, frozen in OCT, and snap frozen at −20°C for cryosectioning. Frozen sections were stained with IHC according to the protocol described above. Thaw at room temperature for 1 hour, then resuspend in 10% buffered formaldehyde, acetaldehyde, or glycerol according to antibody specifications. After fixation, the sections were fixed in 1% phosphate-buffered saline (PBS) or methanol. The sections were washed three times with PBS (PBS), followed by blocking with 2.5% horse serum in PBS for 1 hour at room temperature. Primary antibodies diluted in 10% goat serum in PBS were added and incubated overnight at 4°C. The next morning, sections were rinsed three times with PBS and incubated with 2.5% horse serum in PBS. The sections were incubated with the primary antibody for 2 hours at room temperature. Zeiss CLSM 710 Spectrum Images were taken using a confocal laser scanning microscope (Carl Zeiss Microscopy). The antibodies are listed in Table 3.
[0231] For the images in Figure 5, sections (3 μm) were hematoxylin-200 (H2O2) and lysed according to standard protocols. For immunohistochemistry, endogenous peroxisome proliferator-activated receptor (ACE) was stained with fluorescein-eosin and Sirius red. The enzyme activity was assayed by incubation with methanolic hydrogen peroxide (2.5%) for 30 min. Proteinase K (code S302) was used as indicated by the vendor. 0, Dako, Glostrup, Denmark) for 10 min at room temperature. The antigen was removed. The sections were then incubated with the primary antibody (pan-Cytokeratin, Da ko, code: Z0622, dilution: 1:100; Sox9, Millipore, code The samples were incubated overnight at 4°C with 1:200 PBS (AB5535, dilution: 1:200). Rinse twice with PBS for 5 min and incubate with secondary biotinylated antibody (LSAB+ System-HRP, (Code K0690, Dako, Glostrup, Denmark) and then strain Putavidin-HRP (LSAB+ System-HRP, code K0690, Dak The plates were incubated with 100 µL of ... Aminobenzidine (Dako, Glostrup, Denmark) was used as a substrate. Sections were counterstained with hematoxylin (PMID: 29248458). Nonspecific protein binding was blocked with 5% normal goat serum. The cells were incubated overnight at 4°C with primary antibody (chicken anti-GFP, Abcam, Cortez-La). Code: ab13970, dilution=1:200; rabbit anti-HNF4α, Abcam, code: 9 2378, dilution: 1:50; rabbit anti-albumin, ab2406, dilution = 1:500) The specimens were washed and incubated with a labeled isotype-specific secondary antibody (anti-chicken AlexaFl uor-546, anti-mouse AlexaFluor-488, anti-rabbit AlexaFluo r-488, Invitrogen, Life Technologies Ltd, P aisley, UK) for 1 h and 4,6-diamidino-2-phenylindole Counterstained with DAPI to visualize cell nuclei (PMID: 26610370) For all immunoreactions, negative controls (primary antibody was replaced with preimmune serum) were included. Sections were then transferred to a Jenoptik Prog Res C10 Plus Vid Equipped with eocam (Jena, Germany), Leica Microsystems DM 4500 B light and fluorescence microscope (Leica Microsystems, Weltzlar, Germany). Immunofluorescence staining was also performed using confocal microscope. The slides were analyzed using a spot microscope (Leica TCS-SP2). The samples were then further processed in a blinded system (IAS-Delta Sistemi, Rome, Italy). The immunofluorescence staining was performed using a digital scanner ( Aperio Scanscope FL System, Aperio Techno Scanned by ImageSco Processed by pe.
[0232] Considering the high autofluorescence of liver cells (lipofuscin) and the fluorescence of the serisil lining, Frozen sections were problematic. Applicant has been working on the preparation of paraffin sections and the use of GFP (Novus Rabbit polyclonal antibody against IgG (Biologcoils, NE600-308) We have had great success with staining for GFP using rabbit anti-GFP antibodies, donkey anti-rabbit IgG H&L (Alexa Fluor 568;ab175470, Invitro gen) secondary antibody, whereas donkey anti-goat IgG Alexa Fluor488 antibody was used to exclude nonspecific staining of liver autofluorescence. Autofluorescence was reduced by quenching with dyes including trypan blue. Pan blue was used in tissue / cells at 0.4% in PBS. This reduced background staining. The bandwidth is significantly reduced.
[0233] Use Trizol (Invitrogen) to extract total RNA from organoids or transplants. Extracted from a piece. Primescript 1st strand cDNA synthesis kit The first strand cDNA synthesized using the ELISA kit (Takara) was used as a template for PCR amplification. The ABI PRISM 7900HT sequence detection system (Applied Faststart Universal Probe with Biosystems The mRNA levels were determined using the Master (Roche Diagnostics). Quantitative analysis was performed. Primers were from the Universal Probe Library. Assay Design Center(Roche Applied Science The primer sequences are listed in Table 4. The primers were incubated at 50°C for 2 min. The mixture was annealed at 95°C for 10 min for 1 h, then annealed at 95°C (15 s) and 60°C (1 min) for 40 min. The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was Commonly used as controls and standards.
[0234] RNA was purified from cells using the Qiagen RNeasy Kit and delivered to Agile RNA integrity (RIN) analysis was performed using the nt 2000 Bioanalyzer. The cDNA library was generated using Illumina TruSeq Stranded mR The DNA was generated using a NA preparation kit and analyzed on the Illumina HiSeq 2500 platform. Two samples were sequenced per lane, and all samples (one frame) were sequenced. A total of eight lanes were occupied by 100 µL of lysate (low-column cells). Quality control analysis was completed using FastQ. Mapping column reads to the human genome (hg19) using default parameters Transcript quantification was performed by RSEM analysis and DES. Gene expression was normalized and differentially expressed genes were identified using eq. MapSp Licce2 was also used to detect candidate fusion transcripts. Fusion Call ls) were based on the depth and complexity of reads across candidate fusion junctions. Compare gene expression profiles using correlation analysis and hierarchical clustering in R Hierarchical clustering was performed using the variance-stabilizing transformation provided in the DESeq package. Pathway enrichment analysis was performed according to the Ingenuity Pathway Analysis. The differential gene expression analysis was performed using at least one A minimum mean normalized number of >50 was only performed for genes in each category.
[0235] Statistical differences between samples were calculated using two-tailed Student's t-test, and the results were averaged. Results are expressed as mean ± standard deviation (SD). P values less than 0.05 were considered statistically significant. It was.
[0236] result Previous studies of injected transplants have shown that engraftment requires the use of epithelial cells and lineage-stage appropriate mesenchymal cells. It was found that co-transplantation of a partner is necessary. For liver and bile duct stem cells, These mesenchymal cells are hemangioblasts (CD117+, CD133+, VEGFr+, CD3 1 negative) and their direct progeny, vascular endothelial precursors (CD133+, VEGFr+, CD 31+, von Willebrand factor) as well as astrocyte precursors (CD146+, IC AM-1+, smooth muscle alpha actin+ (ASMA), vitamin A negative). These are collectively referred to as early lineage stage mesenchymal cells (ELSMCs). Applicants also The isolated porcine mesenchymal stem cells (MSCs) were prepared from the liver of newborn pigs. Partially successful.
[0237] In previous studies, applicants have used multi-parametric flow cytometry to By determining the ratio of epithelial and mesenchymal lineage stage partners in cell suspensions, Isolation of matching epithelial and mesenchymal cell stages was achieved and then immunoselected cells were used to implant the graft. In these studies, applicants repeated the panning procedure and Afterwards, the remaining cell suspension was cultured in low-attachment dishes and serum-free Kubota medium for 6 to 8 hours. We found that it was more efficient to deplete the cell suspension of mature mesenchymal cells. Organoids self-organized with each aggregate containing approximately 50-100 cells. Markers The analysis showed the combination of BTSC with ELSMC (Figure 1). As stated above, they were either used immediately or under pre-determined, defined conditions. The cells were cryopreserved under cryopreservation conditions and thawed according to the need for grafts. The noids were characterized using immunofluorescence (IF), qRT-PCR and RNA-seq. to express classical traits of BTSC (Fig. 1) and ELSMC (data not shown). BTSCs in organoids do not express mature hepatic or pancreatic genes. However, low levels of pluripotency genes (e.g., OCT4, SOX2) and endodermal stem cell genes were detected. Genes (e.g., EpCAM, SOX 9, SOX17, PDX1, LGR5, CXCR4 , MAFA, NGN3, and NIS. The results of the IHC assay confirmed the findings from IF and IHC of the pre-transplant cells (Figure 1D). The more primitive cells (e.g., those expressing pluripotency genes) are likely to be present within the organoids. Distributed to late mature lineage stages in the periphery and periphery (e.g., EpCAM or albumin We demonstrated that the expression of IFN-γ in cells expressing IFN-γ was significantly increased in mice (Figure 1C).
[0238] Results from patch grafts were compared using a previously established method consisting of injection of cells and Gel hyaluronan with polyethylene glycol diacrylate (PEGDA) within minutes The results were compared with those of implanted grafts in pig liver parenchyma. The injected grafts resulted in essentially 100% engraftment with minimal (if any) migration. and integration into host tissues (data not shown) occurred slowly over several weeks. The findings were similar to those previously observed in hepatic stem cell-injected grafts. 17 Liver lobe Implantation of the graft into the mesentery adjacent to the duct / portal branch of the posterior hepatic duct is feasible in large ducts. However, smaller ones were blocked by the swelling effect of the HA hydrogel and also caused cholestasis. The success with the patch graft has led to further advances in the implanted graft strategy. I decided to abandon the effort.
[0239] Stem cell graft compositions achieve levels of stiffness assessed by rheological assays To achieve this, we developed a hyaluronan (HA) hyaluronan complex with a precise concentration of HA relative to PEGDA. The procedure entailed the use of three separate layers of soft HA gel (Figure 2C). (approximately 100 Pa) and placed against the liver / pancreas surface. stem cell phenotype 23 and was proven to be essential for engraftment in these studies. This layer is a rigid ( 10X; approximately 700 Pa) was placed on top of the HA layer. The patch was then attached by suturing or surgical adhesive. The serosal surface of the implant was painted or coated during surgery. Soft enough (stiffness = approx. 200P) to further minimize adhesion from nearby tissues. a) 2X HA hydrogel.
[0240] The patch graft is placed on the liver surface, i.e., on the surface of the Glisson's capsule or pancreatic capsule, and sutured. The horns were attached to the horns by means of adhesive or surgical glue (Figure 2F). This allows the graft to withstand significant mechanical forces in areas with minimal curvature (e.g., near the diaphragm). For pancreatic grafts, the graft was placed between the duodenum and the pancreas. It was wedged in place.
[0241] The only variant of patch grafting that has been tried and abandoned is sharp surgical removal of the capsule. The bleeding was due to altered host hemostasis associated with liver failure, or due to donor cell Even in normal hosts where the serum has been adversely affected, future use is not overly hindered. Without these efforts to modify the organ capsule, patch grafts would be a surgical procedure. It proved to be easy.
[0242] Much of the evidence has been focused on clinical use in abdominal surgery. All except Serisilk caused problems and warranted further investigation (Tables 1 and 2). This problem included the vulnerability of the drug (e.g., Seprafil m, Retroglyde), induction of necrosis or fibrosis and significant levels of adhesions (e.g. (e.g., Surgisis, Vetrix), as well as fibrous sponge versions of Serisilk or abdominal lining supplemented with carboxymethylcellulose ("berry jelly") Among those tested, the SERI Surgical Silencer nine 24-26 (Allergan, Inc. Irvine, Calif.) It provides the best combination of support and minimal adhesions, and this effect is enhanced by Se after attachment to the target site. This was further enhanced by applying 2X HA to the serosal surface of the riSilk. The product is purified fibroin from Bombyx moss silk and was developed by David Kaplan ( Developed by the University of Tufts, Boston, Massachusetts The applicant considered this to be rigid, but this characteristic was not observed in surgical procedures and in the liver. We found that the stiffness is useful for placement on surfaces / rigid organs. However, the stiffness of the membrane makes it difficult to apply to areas where flexibility is required. This demonstrated that the lining was neutral with respect to maturation effects on the graft, making it acceptable for patch grafts. In the 3-week grafts, the silk was wrapped by a collagen band. The results suggest a mild foreign body reaction. Evaluation of other potential linings, such as synthetic fibers, is ongoing. It is in the middle.
[0243] Evidence of remodeling at 1 week after surgery was determined by collagen and other extracellular matrix components. The results were verified by trichrome staining (Figures 3 and 7) or Safranin O, which contains a dye that stains Images of the grafts stained with trichrome (Figure 3A-B) were compared with those of the same site. The tissue was stained with hematoxylin / eosin (Figure 3C-D). Reconstruction of the Glisson capsule and lobule Remodeling occurred in parallel with hyaluronan absorption by 3 weeks. The zone containing the remodeled area was The size was astonishing (Figures 3-5, 7).
[0244] Donor cells obtained from transgenic GFP+ pigs were GFP expressing through IHC assay. In the pancreas, donor cells were identified by green fluorescence. However, in the liver, autofluorescence of hepatocyte lipofuscin peaks at wavelengths that overlap with those of GFP. Therefore, donor cells in the liver were identified with an antibody against GFP (rabbit anti-GFP). FP antibody; Novus, NB600-308) and a red fluorescent probe (donkey anti-rabbit 55 5, Invitrogen) to bind to the secondary antibody, giving the donor cells a pink nucleus (red fluorescent The host cells had their blue nuclei (DAPI stained). However, no GFP expression was observed (Figure 4).
[0245] Liver lobules of mature hepatocytes were forest green from autofluorescence (lipofuscin) (Figure 4B) Donor GFP+ cells that matured into hepatocyte aggregates were stained with a red fluorescent probe, D, from GFP. Pink due to a fusion of blue from API and dark green autofluorescence from lipofuscin The hepatocytes are lavender in color and contain nuclei (Figure 4C). Hepatocytes may be host-derived or donor-derived. However, bright red cells were observed, possibly due to vitamin A in mature astrocytes (Fig. 4C). Clustered by host mesenchymal cells (vascular endothelium, astrocytes) with yellow / green autofluorescence IHC data for vascular endothelium and astrocytes are not shown.
[0246] Within a week, patch grafts of BTSC / ELSMC organoids formed organ encapsulation and This resulted in the re-formation of adjacent lobules and subsequent merging of host and donor cells. (Figures 3-5, 7). Finger-like extensions of donor cells expand into the hepatic lobule of the host tissue, In parallel, host cells expanded into the HA of the graft (Fig. 4). In the case of the pancreas, the graft was The tube was wedged between the pancreas and the duodenum, and by one week after surgery, the pancreatic and duodenal submucosal bullae were Engraftment of donor cells occurred in both the liver (or pancreas) and the donor gland (Figure 6). Cell integration within the area was complete by 2 weeks, when the hyaluronan layer was mostly absorbed. , a lineage restricted to the adult liver parenchymal fate of both cholangiocytes and hepatocytes (Figure 5) or pancreatic fate The genotype was consistent (Figure 6).
[0247] By 3 weeks, the hyaluronan layer was completely absorbed, leaving only the lining. This is due to the organ encapsulation and The histological structure of the tissues near the capsule (Figures 3, 5, and 6), or the pancreatic capsule and pancreatic histological structure This correlated with the reappearance of islet cells (Figure 6). In the pancreas, mature cells are differentiated into islet cells (beta cells). were identified by functional markers, including insulin and acinar cell amylase.
[0248] Engraftment efficiency for both the liver and pancreas approached 100% by 1 week. All identified donor cells were located in the liver or can grow in the pancreas, ignoring evidence of ectopic cell distribution in other organs (e.g., lung). for it has been found that there is little or no
[0249] The migration rate of donor cells in BTSC / ELSMC grafts through the liver and pancreas was measured over a period of one week. Significantly, donor cells were brought to most areas of the organ (liver or pancreas) by the end of the study. Results were favorable, with clear, uniformly distributed cells throughout the tissue (liver / pancreas) by 2-3 weeks. (Figures 3-6).
[0250] Dissolution of the Glisson's capsule (or pancreatic capsule) and adjacent hepatic lobule (or pancreatic tissue) and Correlating with remodeling and significant engraftment was the ability to dissolve extracellular matrix components and induce cell migration. The expression of several MMPs, which are known to be associated with cell proliferation, was increased in the stem / prostate. Data from RNA-seq studies and IHC assays of MMPs expressed by precursor versus adult cells Summary. BTSCs are classified into secreted (e.g., MMP2, MMP7) and membrane-bound forms. High levels of multiple MMPs consisting of both mitochondrial and mitochondrial forms (e.g., MMP14 and MMP15) ELSMCs, the precursors of vascular endothelial and astrocyte cells, also contribute multiple MMPs. Ta.
[0251] Findings from RNA-seq data suggest that MMPs are essential for the proteins encoded by the genes. This was confirmed by IHC assay (Figure 7). The IHC assay showed that the We confirmed the presence of secreted MMPs (e.g., MMP1, MMP2, MMP7, and MMP9) in the The protein expression of MMP1 was significantly increased in BTSC / ELSMC organoids and explants. However, existing databanks of RNA-seq findings do not contain any MMP1 is not included due to the lack of annotated species for porcine MMP1. The recognition of expression is based on an IHC assay.
[0252] Variables that induce differentiation of donor cells suppress the expression of MMPs, especially the secretory forms. In parallel, there was a loss of engraftment and migration potential (data not shown). The supernatant was then incubated with various soluble regulatory signals (growth factors) known to affect donor cell differentiation. molecules, cytokines, hormones), in hydrogels or linings (especially those containing type I collagen) The extracellular matrix components of the HA hydrogel (i.e., Pa level If ELSMC differentiation proceeds preferentially toward the stroma, the graft In the case of vascular endothelium, the grafts retained viable cells and tissue, but It remained superficial to the organ encystment (data not shown).
[0253] BTSC / ELSMC organoids are the most successful arrangement of cells for transplantation In the past, cells were identified by flow cytometry using characteristic surface antigens. were immunoselected from the suspension and then found in cell suspensions from freshly isolated tissues. Epithelial-mesenchymal partners were co-transplanted by mixing them according to the ratio 17 . Here, we self-selected them into organoids after panning removal of mature mesenchymal cells. This allows for the proper epithelial-mesenchymal phenotype development with lineage-stage paracrine signaling associated with the graft. More efficient in establishing a host and generating organoids under defined (serum-free) conditions It has been found that these are simple and effective and that they are easily and safely cryopreserved.
[0254] The primary design of the implant is to incorporate cells into the implant, making it insoluble and allowing cells to remain localized at the target site. For the graft, the ideal biomaterial would be one that is compatible with all stem cells. Non-sulfated or minimally sulfated glycosamides such as hyaluronan (HA) found in the walls of cells It has been demonstrated that the receptor for HA is a classical stem cell phenotype. Maintenance of cells as stem / progenitors is related to the expression of secreted and membrane-bound MMPs that are effective for engraftment. The current situation has been optimized.
[0255] Evidence of the engraftment process was particularly evident within areas of remodeling that occurred at the interface of the graft and host tissue. To verify the findings of remodeling, we used dyes that stain for extracellular matrix components. Stain with hematoxylin / eosin, trichrome stain and safranin O. Adjacent sections were analyzed in parallel (Figures 3 and 7). By 3 weeks after surgery, these assays confirmed the re-formation of the capsule and adjacent tissue. The histology of the organ capsule and normal tissue was reconstituted after removal. The reconstituted zone was especially prominent in the hand. The size was astonishingly large one week after surgery (Figs. 3 and 7), and multiple forms of MMP were involved. As shown (Figure 7).
[0256] There are many sources and forms of HA, the most useful of which is the Chio established by Restwich (University of Utah, Salt Lake City, Utah) This is a novel PEGDA-triggered polymerase that can be used to develop precise biochemical and mechanical properties. These properties of HA give it perfect elasticity and allow it to be easily absorbed by blood, lymph, and other tissues. Allows all soluble signals in the lymph nodes or interstitial fluid to access the graft, promoting engraftment and migration. Minimize donor cell maturation until HA and PEGDA concentrations are sufficient. The ability to alter rheological factors with temperature can direct cell migration and minimize adhesion. The soft HA hydrogel mimics the properties of stem cell niches. The gel was permissive for the expression of the stem / progenitor cell-associated repertoire of MMPs. The mechanical properties of HA, which have long been studied in the function of skeletal tissues, are also important in managing transplantation strategies. is 23 .
[0257] Patch grafts containing stem / progenitors are characterized by the fact that within a few days the graft “dissolves” into the tissue, and then The donor and host cells merge and distribute throughout most areas of the organ within one to two weeks. The subsequent maturation of donor cells and restoration of organ encapsulation were accompanied by the remarkable phenomenon of HA This occurred in parallel with the removal of tissue from the graft.
[0258] The engraftment and integration process is calcium-dependent, degrading extracellular matrix components. It correlated with the expression of several MMPs, a family of zinc-containing endopeptidases. Using RNA sequencing studies, we identified high levels of secreted (e.g., MMP2, MMP7) as well as The pathway of stem / progenitor-associated MMPs, consisting of membrane-bound forms (e.g., MMP14, MMP15) The IHC assay identified secreted MMPs (e.g., MMP1, MMP2, MMP3, MMP4, MMP5, MMP6, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP18, MMP19, MMP20, MMP21, MMP22, MMP23, MMP24, MMP25, MMP26, MMP27, MMP28, MMP29, MMP30, MMP31, MMP32, MMP33, MMP34, MMP35, MMP36, MMP37, MMP38, MMP39, MMP40, MMP41, MMP42, MMP43, MMP44, MMP45, MMP46, MMP47, MMP48, MMP49, MMP4 MP7) protein levels showed that it was abundantly expressed in areas of remodeling (Fig. 7 ). Conditions for differentiation of donor cells (soluble growth factors, cytokines, serum, matrix components) , mechanical force) specifically reduces secretory MMPs and, in parallel, inhibits the engraftment process. Ta.
[0259] Implants, particularly HA biomaterials, have been shown to promote cell proliferation in vitro and in vivo, and to promote stem cell proliferation in vivo. The grafts maintain their sexual characteristics because they lack known signals that can trigger fate decisions. Depending on whether the explants were placed in the liver or pancreas, donors matured to different adult fates. The findings of the cellular context provide a logical basis for the local microenvironment of the host tissue as a basis for the relevant factors in the maturation process. This is suggested as a possible solution.
[0260] The number of viable cells was significant (>10 8 ) and the dimensions of the graft, cell number, and fraction These findings are specified by a repertoire of secreted and membrane-bound MMPs. Limited numbers of cells (e.g., 10 5 -10 6 ) in contrast to
[0261] Patch grafting is a safe strategy for transplanting large numbers of cells into solid organs, including visceral organs and may be useful in treating patients, especially if engraftment occurs sufficiently in the disease state. However, if the tissue is fibrotic or affected by cirrhosis, abnormal There is concern that engraftment may occur. Therefore, patching of the method aspects is discussed herein. An example is provided for determining the effectiveness of a raft.
[0262] Example 2: Treatment of liver disease. This example illustrates the use of a patch graft to treat a subject with a liver disease or disorder. The donor cells are selected from the group consisting of hepatic and pancreatic progenitor cells, as described herein. The organoids are prepared from bile duct stem cells (BTSCs), which are the primary organelles of the blood. Hemangioblasts and their early lineage stage progeny, which are endothelial and astrocyte precursors BTSC / EL SMC organoids are placed on a soft tissue support that is tethered to the target site in the subject's liver. Embedded in luronan hydrogel (<200 Pa).
[0263] After application of the patch graft, the subject is monitored for improvement in liver function. Commonly used tests for this purpose include alanine transaminase (ALT), asparagine AST, alkaline phosphatase (ALP), albumin These tests include, but are not limited to, ALT and AST. The test measures an enzyme released by the liver in response to injury or disease. Albumin and bilirubin tests, which measure how well the liver makes the protein albumin. It measures how well your blood works and how well it disposes of bilirubin, a waste product of the blood. It is expected that improvement in liver function will be detected after approximately 36 weeks. Improvement will occur following application of the graft. Improved values of one or more liver function tests compared to previous values, and / or a diagnosis of liver disease or The present invention is determined by detecting an improvement or amelioration of one or more symptoms of the disorder.
[0264] Example 3: Treatment of pancreatic disease. This example describes the use of a patch graft to treat a subject with a pancreatic disease or disorder. An exemplary method is described. Donor cells are cholangioblastoma (BCH) stem cells, as described herein. SC (sc) organoids are prepared and the organoids contain endothelial progenitors and astrocytes. Early lineage stage mesenchyme, consisting of precursor hemangioblasts and their early lineage stage progeny The BTSC / ELSMC organoids were aggregated with the target cells (ELSMC). A soft hyaluronan hydrogel (< It is embedded in a 200 Pa.
[0265] After application of the patch graft, the subject is monitored for improvement in pancreatic function. Commonly used tests include blood tests for levels of the pancreatic enzymes amylase and lipase; Direct pancreatic function tests after administration of lectin or cholecystokinin, fecal elastase tests The study included CT scans with contrast, abdominal ultrasound, and endoscopic retrograde cholangiopancreatography (ERCP). These include, but are not limited to, endoscopy, ultrasound endoscopy, and magnetic resonance cholangiopancreatography. It is expected that improvements in pancreatic function will be detected after approximately 2 to 36 weeks. Improved values of one or more pancreatic function tests compared to values before application of the explant, and / or or by detecting an improvement or remission of one or more symptoms of a disease or disorder of the pancreas. It is decided that.
[0266] Example 4: Treatment of kidney disease. This example uses a patch graft to treat a subject with a kidney disease or disorder. An exemplary method is described. Donor cells are cholangioblastoma (BCH) stem cells, as described herein. SC (sc) organoids are prepared and the organoids contain endothelial progenitors and astrocytes. Early lineage stage mesenchyme, consisting of precursor hemangioblasts and their early lineage stage progeny The BTSC / ELSMC organoids were aggregated with the target cells (ELSMC). A soft hyaluronan hydrogel (<2 mm) was placed on a lining tethered to the renal target site. 00 Pa).
[0267] After application of the patch graft, the subject is monitored for improvement in kidney function. Commonly used tests for assessing renal function include clinical tests known in the art. Relevant endpoints include, but are not limited to, renal function after about 2 weeks to about 36 weeks. Improvements are expected to be detected in one or more of the following measures compared to values before application of the graft: improved values of multiple renal function tests and / or improved diagnosis of one or more renal diseases or disorders is determined by detecting improvement or remission of multiple symptoms.
[0268] Example 5: Treatment of gastrointestinal disorders. This example illustrates the use of a patch graft to treat a subject with a gastrointestinal disease or disorder. An exemplary method is described. Donor cells are cholangioblastoma (BCH) stem cells, as described herein. SC (sc) organoids are prepared and the organoids contain endothelial progenitors and astrocytes. Early lineage stage mesenchyme, consisting of precursor hemangioblasts and their early lineage stage progeny The BTSC / ELSMC organoids were aggregated with the target cells (ELSMC). A soft hyaluronan hydrogel (<20 μg / ml) was placed on a lining that was tethered to the intestinal target site. The sample is embedded in a 350 nm laser (0 Pa).
[0269] After application of the patch graft, the subject is monitored for improvement in bowel function. Commonly used tests for this purpose include clinically relevant measures of bowel function known in the art. The endpoints include, but are not limited to, improvement in bowel function after about 2 weeks to about 36 weeks. The improvement is expected to be detected by one or more measures of the improvement compared to values prior to application of the implant. Improved bowel function test values and / or one or more symptoms of a gastrointestinal disease or disorder. The treatment is determined by detecting improvement or remission of symptoms. Attachments to the statement Tables 1-4 Patch Graft 2018 [Table 1] [Table 2] [Table 3] JPEG2024161469000005.jpg94144JPEG2024161469000006.jpg27144 [Table 4] JPEG2024161469000008.jpg21146
Claims
1. 1. A method for engrafting cells in a target tissue, comprising contacting said target tissue with a patch graft, (a) a mixed population having two or more cell types, at least one of which is at an early lineage stage capable of expressing membrane-bound and / or secreted matrix metalloproteinases (MMPs), said mixed population supported in a medium in a first hydrogel having a viscoelasticity sufficient to permit movement of said mixed population towards and into a target tissue, said first hydrogel having a viscoelasticity of 0.1-200 Pa; (b) the backing comprising a biocompatible, biodegradable material having sufficient viscoelasticity to inhibit movement of the mixed population away from the target tissue and through the backing or barrier.
2. The method of claim 1 , further comprising allowing the cells contained within the patch graft to integrate into the tissue.
3. 2. The method of claim 1, wherein the target tissue is selected from the group consisting of liver, pancreas, bile duct, thyroid, thymus, gastrointestinal, lung, prostate, breast, brain, bladder, spinal cord, skin, uterus, kidney, muscle, vascular, cardiac, cartilage, tendon, and bone tissue.
4. The method of claim 3 , wherein the target tissue is liver tissue.
5. The method of claim 3 , wherein the target tissue is pancreatic tissue.
6. The method of claim 3 , wherein the target tissue is bile duct tissue.
7. The method of claim 3 , wherein the target tissue is a gastrointestinal tissue.
8. The method of claim 3 , wherein the target tissue is renal tissue.
9. The method of claim 3 , wherein the target tissue is an organ.
10. 10. The method of claim 9, wherein the organ is an organ of the musculoskeletal system, the digestive system, the respiratory system, the urinary system, the female reproductive system, the male reproductive system, the endocrine system, the circulatory system, the lymphatic system, the nervous system, or the integumentary system.
11. 10. The method of claim 9, wherein the organ is selected from the group consisting of liver, pancreas, bile duct, thyroid, thymus, intestine, lung, prostate, breast, brain, bladder, spinal cord, skin, uterus, kidney, muscle, blood vessel, heart, cartilage, tendon, and bone.
12. A patch graft for use in a method for engrafting cells in a target tissue, comprising contacting the patch graft with the target tissue, the patch graft comprising: (a) a population of cells, the population including one having an early lineage stage, the population including a single or multiple types of cells supported in a medium of a first hydrogel or other biomaterial, the first hydrogel having sufficient rheological properties (e.g., viscoelasticity) to permit movement of the cells of the population into or away from the patch graft, the first hydrogel having a viscoelasticity of 0.1-200 Pa; (b) the backing comprises a biocompatible, biodegradable material having rheological properties (e.g., viscoelasticity) sufficient to inhibit (or provide a barrier to) migration of cells of the population in the direction of the backing; The patch graft is configured to sustain and maintain the populations of cells while inhibiting the one population having an early lineage stage from differentiating or further maturing to a later lineage stage.
13. The patch graft of claim 12, wherein said one population having an early lineage stage has the ability to express membrane-bound and / or secreted matrix metalloproteinases (MMPs).
14. 1. A patch graft for use in a method of treating a subject having a liver disease or disorder, the method comprising contacting the patch graft with the liver of the subject, (a) a mixed population having two or more cell types, at least one of which is at an early lineage stage capable of expressing membrane-bound and / or secreted matrix metalloproteinases (MMPs), the mixed population supported in medium in a first hydrogel having a viscoelasticity sufficient to permit movement of the mixed population towards and into a target tissue, the first hydrogel having a viscoelasticity of 0.1-200 Pa; (b) the backing comprises a biocompatible, biodegradable material having sufficient viscoelasticity to inhibit migration of the mixed population through the backing or barrier in a direction away from the target tissue; A patch graft that allows the cells contained within the patch graft to integrate into the liver, thereby restoring some degree of liver function.
15. The patch graft of claim 14, wherein the liver disease or disorder is liver fibrosis, liver cirrhosis, hemochromatosis, liver cancer, biliary atresia, nonalcoholic fatty liver disease, hepatitis, viral hepatitis, autoimmune hepatitis, fascioliasis, alcoholic liver disease, alpha 1-antitrypsin deficiency, glycogen storage disease type II, transthyretin-associated hereditary amyloidosis, Gilbert's syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, Budd-Chiari syndrome, liver trauma, or Wilson's disease.
16. 1. A patch graft for use in a method of treating a subject having a pancreatic disease or disorder, the method comprising contacting the patch graft with the pancreas of the subject, (a) a mixed population having two or more cell types, at least one of which is at an early lineage stage capable of expressing membrane-bound and / or secreted matrix metalloproteinases (MMPs), the mixed population supported in medium in a first hydrogel having a viscoelasticity sufficient to permit movement of the mixed population towards and into a target tissue, the first hydrogel having a viscoelasticity of 0.1-200 Pa; (b) the backing comprises a biocompatible, biodegradable material having sufficient viscoelasticity to inhibit migration of the mixed population through the backing or barrier in a direction away from the target tissue; A patch graft that allows the cells contained within the patch graft to integrate into the pancreas, thereby restoring some degree of pancreatic function.
17. 17. The patch graft of claim 16, wherein the disease or disorder of the pancreas is diabetes mellitus, exocrine pancreatic insufficiency, pancreatitis, pancreatic cancer, sphincter of Oddi insufficiency, cystic fibrosis, pancreatic ductal nonunion, annular pancreas, pancreatic trauma, or hemosuccius pancreaticus.
18. 1. A patch graft for use in a method of treating a subject having a gastrointestinal disease or disorder, the method comprising contacting the patch graft with one or more of the subject's intestines, the patch graft comprising: (a) a mixed population having two or more cell types, at least one of which is at an early lineage stage capable of expressing membrane-bound and / or secreted matrix metalloproteinases (MMPs), the mixed population supported in medium in a first hydrogel having a viscoelasticity sufficient to permit movement of the mixed population towards and into a target tissue, the first hydrogel having a viscoelasticity of 0.1-200 Pa; (b) the backing comprises a biocompatible, biodegradable material having sufficient viscoelasticity to inhibit migration of the mixed population through the backing or barrier in a direction away from the target tissue; A patch graft that allows the cells contained within the patch graft to integrate into the intestine, thereby restoring some degree of intestinal function.
19. 19. The patch graft of claim 18, wherein the gastrointestinal disease or disorder is gastroenteritis, gastrointestinal cancer, ileitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, peptic ulcer, celiac disease, fibrosis, angiodysplasia, Hirschsprung's disease, pseudomembranous colitis, or gastrointestinal trauma.
20. 1. A patch graft for use in a method of treating a subject having a renal disease or disorder, the method comprising contacting one or more of the subject's kidneys with the patch graft, comprising: (a) a mixed population having two or more cell types, at least one of which is at an early lineage stage capable of expressing membrane-bound and / or secreted matrix metalloproteinases (MMPs), the mixed population supported in medium in a first hydrogel having a viscoelasticity sufficient to permit movement of the mixed population towards and into a target tissue, the first hydrogel having a viscoelasticity of 0.1-200 Pa; (b) the backing comprises a biocompatible, biodegradable material having sufficient viscoelasticity to inhibit migration of the mixed population through the backing or barrier in a direction away from the target tissue; A patch graft that allows the cells contained within the patch graft to integrate into the kidney, thereby restoring some degree of renal function.
21. The patch graft of claim 20, wherein the kidney disease or disorder is nephritis, nephrosis, nephritic syndrome, nephrotic syndrome, chronic kidney disease, acute kidney injury, kidney trauma, cystic kidney disease, polycystic kidney disease, glomerulonephritis, IgA nephropathy, lupus nephropathy, kidney cancer, Alport syndrome, amyloidosis, Goodpasture's syndrome, or Wegener's granulomatosis.
Citation Information
Patent Citations
Medical cell preparation derived from placenta
JP2004210713A
Methods for transplanting cells from actual tissue
JP2013526297A
